#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine
#Text=Obsessive–compulsive symptoms (OCS) in patients with schizophrenia are a common co-occurring condition, often associated with additional impairments.
1-1	0-7	Reduced	_	
1-2	8-16	activity	_	
1-3	17-20	and	_	
1-4	21-33	connectivity	_	
1-5	34-36	of	_	
1-6	37-41	left	_	
1-7	42-50	amygdala	_	
1-8	51-53	in	_	
1-9	54-62	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-10	63-67	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-11	68-81	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-12	82-89	treated	_	
1-13	90-94	with	_	
1-14	95-104	clozapine	_	
1-15	105-107	or	_	
1-16	108-118	olanzapine	_	
1-17	119-139	Obsessive–compulsive	_	
1-18	140-148	symptoms	_	
1-19	149-150	(	_	
1-20	150-153	OCS	_	
1-21	153-154	)	_	
1-22	155-157	in	_	
1-23	158-166	patients	_	
1-24	167-171	with	_	
1-25	172-185	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-26	186-189	are	_	
1-27	190-191	a	_	
1-28	192-198	common	_	
1-29	199-211	co-occurring	_	
1-30	212-221	condition	_	
1-31	221-222	,	_	
1-32	223-228	often	_	
1-33	229-239	associated	_	
1-34	240-244	with	_	
1-35	245-255	additional	_	
1-36	256-267	impairments	_	
1-37	267-268	.	_	

#Text=A subgroup of these patients develops OCS during treatment with second-generation antipsychotics (SGAs), most importantly clozapine and olanzapine.
2-1	269-270	A	_	
2-2	271-279	subgroup	_	
2-3	280-282	of	_	
2-4	283-288	these	_	
2-5	289-297	patients	_	
2-6	298-306	develops	_	
2-7	307-310	OCS	_	
2-8	311-317	during	_	
2-9	318-327	treatment	_	
2-10	328-332	with	_	
2-11	333-350	second-generation	_	
2-12	351-365	antipsychotics	_	
2-13	366-367	(	_	
2-14	367-371	SGAs	_	
2-15	371-372	)	_	
2-16	372-373	,	_	
2-17	374-378	most	_	
2-18	379-390	importantly	_	
2-19	391-400	clozapine	_	
2-20	401-404	and	_	
2-21	405-415	olanzapine	_	
2-22	415-416	.	_	

#Text=So far, little is known about possible neural mechanism of these SGAs, which seem to aggravate or induce OCS.
3-1	417-419	So	_	
3-2	420-423	far	_	
3-3	423-424	,	_	
3-4	425-431	little	_	
3-5	432-434	is	_	
3-6	435-440	known	_	
3-7	441-446	about	_	
3-8	447-455	possible	_	
3-9	456-462	neural	_	
3-10	463-472	mechanism	_	
3-11	473-475	of	_	
3-12	476-481	these	_	
3-13	482-486	SGAs	_	
3-14	486-487	,	_	
3-15	488-493	which	_	
3-16	494-498	seem	_	
3-17	499-501	to	_	
3-18	502-511	aggravate	_	
3-19	512-514	or	_	
3-20	515-521	induce	_	
3-21	522-525	OCS	_	
3-22	525-526	.	_	

#Text=To investigate the role of SGA treatment on neural activation and connectivity during emotional processing, patients were stratified according to their monotherapy into two groups (group I: clozapine or olanzapine, n = 20; group II: amisulpride or aripiprazole, n = 20).
4-1	527-529	To	_	
4-2	530-541	investigate	_	
4-3	542-545	the	_	
4-4	546-550	role	_	
4-5	551-553	of	_	
4-6	554-557	SGA	_	
4-7	558-567	treatment	_	
4-8	568-570	on	_	
4-9	571-577	neural	_	
4-10	578-588	activation	_	
4-11	589-592	and	_	
4-12	593-605	connectivity	_	
4-13	606-612	during	_	
4-14	613-622	emotional	_	
4-15	623-633	processing	_	
4-16	633-634	,	_	
4-17	635-643	patients	_	
4-18	644-648	were	_	
4-19	649-659	stratified	_	
4-20	660-669	according	_	
4-21	670-672	to	_	
4-22	673-678	their	_	
4-23	679-690	monotherapy	_	
4-24	691-695	into	_	
4-25	696-699	two	_	
4-26	700-706	groups	_	
4-27	707-708	(	_	
4-28	708-713	group	_	
4-29	714-715	I	_	
4-30	715-716	:	_	
4-31	717-726	clozapine	_	
4-32	727-729	or	_	
4-33	730-740	olanzapine	_	
4-34	740-741	,	_	
4-35	742-743	n	_	
4-36	744-745	=	_	
4-37	746-748	20	_	
4-38	748-749	;	_	
4-39	750-755	group	_	
4-40	756-758	II	_	
4-41	758-759	:	_	
4-42	760-771	amisulpride	_	
4-43	772-774	or	_	
4-44	775-787	aripiprazole	_	
4-45	787-788	,	_	
4-46	789-790	n	_	
4-47	791-792	=	_	
4-48	793-795	20	_	
4-49	795-796	)	_	
4-50	796-797	.	_	

#Text=We used an fMRI approach, applying an implicit emotion recognition task.
5-1	798-800	We	_	
5-2	801-805	used	_	
5-3	806-808	an	_	
5-4	809-813	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
5-5	814-822	approach	_	
5-6	822-823	,	_	
5-7	824-832	applying	_	
5-8	833-835	an	_	
5-9	836-844	implicit	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-10	845-852	emotion	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-11	853-864	recognition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-12	865-869	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[2]	
5-13	869-870	.	_	

#Text=Group comparisons showed significantly higher frequency and severity of comorbid OCS in group I than group II.
6-1	871-876	Group	_	
6-2	877-888	comparisons	_	
6-3	889-895	showed	_	
6-4	896-909	significantly	_	
6-5	910-916	higher	_	
6-6	917-926	frequency	_	
6-7	927-930	and	_	
6-8	931-939	severity	_	
6-9	940-942	of	_	
6-10	943-951	comorbid	_	
6-11	952-955	OCS	_	
6-12	956-958	in	_	
6-13	959-964	group	_	
6-14	965-966	I	_	
6-15	967-971	than	_	
6-16	972-977	group	_	
6-17	978-980	II	_	
6-18	980-981	.	_	

#Text=Task specific activation was attenuated in group I in the left amygdala.
7-1	982-986	Task	_	
7-2	987-995	specific	_	
7-3	996-1006	activation	_	
7-4	1007-1010	was	_	
7-5	1011-1021	attenuated	_	
7-6	1022-1024	in	_	
7-7	1025-1030	group	_	
7-8	1031-1032	I	_	
7-9	1033-1035	in	_	
7-10	1036-1039	the	_	
7-11	1040-1044	left	_	
7-12	1045-1053	amygdala	_	
7-13	1053-1054	.	_	

#Text=Furthermore, functional connectivity from left amygdala to right ventral striatum was reduced in group I.
8-1	1055-1066	Furthermore	_	
8-2	1066-1067	,	_	
8-3	1068-1078	functional	_	
8-4	1079-1091	connectivity	_	
8-5	1092-1096	from	_	
8-6	1097-1101	left	_	
8-7	1102-1110	amygdala	_	
8-8	1111-1113	to	_	
8-9	1114-1119	right	_	
8-10	1120-1127	ventral	_	
8-11	1128-1136	striatum	_	
8-12	1137-1140	was	_	
8-13	1141-1148	reduced	_	
8-14	1149-1151	in	_	
8-15	1152-1157	group	_	
8-16	1158-1159	I	_	
8-17	1159-1160	.	_	

#Text=Reduced amygdala activation was associated with OCS severity.
9-1	1161-1168	Reduced	_	
9-2	1169-1177	amygdala	_	
9-3	1178-1188	activation	_	
9-4	1189-1192	was	_	
9-5	1193-1203	associated	_	
9-6	1204-1208	with	_	
9-7	1209-1212	OCS	_	
9-8	1213-1221	severity	_	
9-9	1221-1222	.	_	

#Text=Recent literature suggests an involvement of an amygdala–cortico–striatal network in the pathogenesis of obsessive–compulsive disorder.
10-1	1223-1229	Recent	_	
10-2	1230-1240	literature	_	
10-3	1241-1249	suggests	_	
10-4	1250-1252	an	_	
10-5	1253-1264	involvement	_	
10-6	1265-1267	of	_	
10-7	1268-1270	an	_	
10-8	1271-1296	amygdala–cortico–striatal	_	
10-9	1297-1304	network	_	
10-10	1305-1307	in	_	
10-11	1308-1311	the	_	
10-12	1312-1324	pathogenesis	_	
10-13	1325-1327	of	_	
10-14	1328-1348	obsessive–compulsive	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder[3]	
10-15	1349-1357	disorder	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder[3]	
10-16	1357-1358	.	_	

#Text=The observed differential activation and connectivity pattern of the amygdala might thus indicate a neural mechanism for the development of SGA-associated OCS in patients with schizophrenia.
11-1	1359-1362	The	_	
11-2	1363-1371	observed	_	
11-3	1372-1384	differential	_	
11-4	1385-1395	activation	_	
11-5	1396-1399	and	_	
11-6	1400-1412	connectivity	_	
11-7	1413-1420	pattern	_	
11-8	1421-1423	of	_	
11-9	1424-1427	the	_	
11-10	1428-1436	amygdala	_	
11-11	1437-1442	might	_	
11-12	1443-1447	thus	_	
11-13	1448-1456	indicate	_	
11-14	1457-1458	a	_	
11-15	1459-1465	neural	_	
11-16	1466-1475	mechanism	_	
11-17	1476-1479	for	_	
11-18	1480-1483	the	_	
11-19	1484-1495	development	_	
11-20	1496-1498	of	_	
11-21	1499-1513	SGA-associated	_	
11-22	1514-1517	OCS	_	
11-23	1518-1520	in	_	
11-24	1521-1529	patients	_	
11-25	1530-1534	with	_	
11-26	1535-1548	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
11-27	1548-1549	.	_	

#Text=Further neurobiological research and interventional studies are needed for causal inferences.
#Text=1.
12-1	1550-1557	Further	_	
12-2	1558-1573	neurobiological	_	
12-3	1574-1582	research	_	
12-4	1583-1586	and	_	
12-5	1587-1601	interventional	_	
12-6	1602-1609	studies	_	
12-7	1610-1613	are	_	
12-8	1614-1620	needed	_	
12-9	1621-1624	for	_	
12-10	1625-1631	causal	_	
12-11	1632-1642	inferences	_	
12-12	1642-1643	.	_	
12-13	1644-1645	1	_	
12-14	1645-1646	.	_	

#Text=Introduction
#Text=Psychiatric comorbidities are common among patients with schizophrenia.
13-1	1647-1659	Introduction	_	
13-2	1660-1671	Psychiatric	_	
13-3	1672-1685	comorbidities	_	
13-4	1686-1689	are	_	
13-5	1690-1696	common	_	
13-6	1697-1702	among	_	
13-7	1703-1711	patients	_	
13-8	1712-1716	with	_	
13-9	1717-1730	schizophrenia	_	
13-10	1730-1731	.	_	

#Text=One of the foremost comorbid conditions are obsessive–compulsive symptoms (OCS), reported in 30% of cases, with about 13% fulfilling the criteria of an obsessive–compulsive disorder (OCD).
14-1	1732-1735	One	_	
14-2	1736-1738	of	_	
14-3	1739-1742	the	_	
14-4	1743-1751	foremost	_	
14-5	1752-1760	comorbid	_	
14-6	1761-1771	conditions	_	
14-7	1772-1775	are	_	
14-8	1776-1796	obsessive–compulsive	_	
14-9	1797-1805	symptoms	_	
14-10	1806-1807	(	_	
14-11	1807-1810	OCS	_	
14-12	1810-1811	)	_	
14-13	1811-1812	,	_	
14-14	1813-1821	reported	_	
14-15	1822-1824	in	_	
14-16	1825-1828	30%	_	
14-17	1829-1831	of	_	
14-18	1832-1837	cases	_	
14-19	1837-1838	,	_	
14-20	1839-1843	with	_	
14-21	1844-1849	about	_	
14-22	1850-1853	13%	_	
14-23	1854-1864	fulfilling	_	
14-24	1865-1868	the	_	
14-25	1869-1877	criteria	_	
14-26	1878-1880	of	_	
14-27	1881-1883	an	_	
14-28	1884-1904	obsessive–compulsive	_	
14-29	1905-1913	disorder	_	
14-30	1914-1915	(	_	
14-31	1915-1918	OCD	_	
14-32	1918-1919	)	_	
14-33	1919-1920	.	_	

#Text=Co-occurring OCS results in a lower quality of life, more severe depressive symptoms, higher rates of suicidality and an unfavorable prognosis.
15-1	1921-1933	Co-occurring	_	
15-2	1934-1937	OCS	_	
15-3	1938-1945	results	_	
15-4	1946-1948	in	_	
15-5	1949-1950	a	_	
15-6	1951-1956	lower	_	
15-7	1957-1964	quality	_	
15-8	1965-1967	of	_	
15-9	1968-1972	life	_	
15-10	1972-1973	,	_	
15-11	1974-1978	more	_	
15-12	1979-1985	severe	_	
15-13	1986-1996	depressive	_	
15-14	1997-2005	symptoms	_	
15-15	2005-2006	,	_	
15-16	2007-2013	higher	_	
15-17	2014-2019	rates	_	
15-18	2020-2022	of	_	
15-19	2023-2034	suicidality	_	
15-20	2035-2038	and	_	
15-21	2039-2041	an	_	
15-22	2042-2053	unfavorable	_	
15-23	2054-2063	prognosis	_	
15-24	2063-2064	.	_	

#Text=The clinical presentation of OCS in schizophrenia is diverse with onset prior to, simultaneously with or subsequent to the onset of psychosis.
16-1	2065-2068	The	_	
16-2	2069-2077	clinical	_	
16-3	2078-2090	presentation	_	
16-4	2091-2093	of	_	
16-5	2094-2097	OCS	_	
16-6	2098-2100	in	_	
16-7	2101-2114	schizophrenia	_	
16-8	2115-2117	is	_	
16-9	2118-2125	diverse	_	
16-10	2126-2130	with	_	
16-11	2131-2136	onset	_	
16-12	2137-2142	prior	_	
16-13	2143-2145	to	_	
16-14	2145-2146	,	_	
16-15	2147-2161	simultaneously	_	
16-16	2162-2166	with	_	
16-17	2167-2169	or	_	
16-18	2170-2180	subsequent	_	
16-19	2181-2183	to	_	
16-20	2184-2187	the	_	
16-21	2188-2193	onset	_	
16-22	2194-2196	of	_	
16-23	2197-2206	psychosis	_	
16-24	2206-2207	.	_	

#Text=This heterogeneity suggests multiple interacting pathways.
17-1	2208-2212	This	_	
17-2	2213-2226	heterogeneity	_	
17-3	2227-2235	suggests	_	
17-4	2236-2244	multiple	_	
17-5	2245-2256	interacting	_	
17-6	2257-2265	pathways	_	
17-7	2265-2266	.	_	

#Text=For the subgroup of patients, who develop OCS subsequent to their first psychotic episode and initiation of antipsychotic treatment, increasing evidence strongly suggests a “pro-obsessive” effect of certain second-generation antipsychotics (SGAs), especially clozapine and olanzapine.
18-1	2267-2270	For	_	
18-2	2271-2274	the	_	
18-3	2275-2283	subgroup	_	
18-4	2284-2286	of	_	
18-5	2287-2295	patients	_	
18-6	2295-2296	,	_	
18-7	2297-2300	who	_	
18-8	2301-2308	develop	_	
18-9	2309-2312	OCS	_	
18-10	2313-2323	subsequent	_	
18-11	2324-2326	to	_	
18-12	2327-2332	their	_	
18-13	2333-2338	first	_	
18-14	2339-2348	psychotic	_	
18-15	2349-2356	episode	_	
18-16	2357-2360	and	_	
18-17	2361-2371	initiation	_	
18-18	2372-2374	of	_	
18-19	2375-2388	antipsychotic	_	
18-20	2389-2398	treatment	_	
18-21	2398-2399	,	_	
18-22	2400-2410	increasing	_	
18-23	2411-2419	evidence	_	
18-24	2420-2428	strongly	_	
18-25	2429-2437	suggests	_	
18-26	2438-2439	a	_	
18-27	2440-2441	“	_	
18-28	2441-2454	pro-obsessive	_	
18-29	2454-2455	”	_	
18-30	2456-2462	effect	_	
18-31	2463-2465	of	_	
18-32	2466-2473	certain	_	
18-33	2474-2491	second-generation	_	
18-34	2492-2506	antipsychotics	_	
18-35	2507-2508	(	_	
18-36	2508-2512	SGAs	_	
18-37	2512-2513	)	_	
18-38	2513-2514	,	_	
18-39	2515-2525	especially	_	
18-40	2526-2535	clozapine	_	
18-41	2536-2539	and	_	
18-42	2540-2550	olanzapine	_	
18-43	2550-2551	.	_	

#Text=Clozapine, and similarly olanzapine, exerts its effects via a relatively low affinity to dopamine D2 receptors combined with strong antagonism at 5-HT1C, 5-HT2A and 5HT2C receptors.
19-1	2552-2561	Clozapine	_	
19-2	2561-2562	,	_	
19-3	2563-2566	and	_	
19-4	2567-2576	similarly	_	
19-5	2577-2587	olanzapine	_	
19-6	2587-2588	,	_	
19-7	2589-2595	exerts	_	
19-8	2596-2599	its	_	
19-9	2600-2607	effects	_	
19-10	2608-2611	via	_	
19-11	2612-2613	a	_	
19-12	2614-2624	relatively	_	
19-13	2625-2628	low	_	
19-14	2629-2637	affinity	_	
19-15	2638-2640	to	_	
19-16	2641-2649	dopamine	_	
19-17	2650-2652	D2	_	
19-18	2653-2662	receptors	_	
19-19	2663-2671	combined	_	
19-20	2672-2676	with	_	
19-21	2677-2683	strong	_	
19-22	2684-2694	antagonism	_	
19-23	2695-2697	at	_	
19-24	2698-2699	5	_	
19-25	2699-2700	-	_	
19-26	2700-2704	HT1C	_	
19-27	2704-2705	,	_	
19-28	2706-2707	5	_	
19-29	2707-2708	-	_	
19-30	2708-2712	HT2A	_	
19-31	2713-2716	and	_	
19-32	2717-2722	5HT2C	_	
19-33	2723-2732	receptors	_	
19-34	2732-2733	.	_	

#Text=In contrast, predominantly dopaminergic SGAs such as amisulpride or the partial dopaminergic/serotonergic agonist aripiprazole are two substances that rather seem to have a beneficial or at least neutral effect on OCS.
20-1	2734-2736	In	_	
20-2	2737-2745	contrast	_	
20-3	2745-2746	,	_	
20-4	2747-2760	predominantly	_	
20-5	2761-2773	dopaminergic	_	
20-6	2774-2778	SGAs	_	
20-7	2779-2783	such	_	
20-8	2784-2786	as	_	
20-9	2787-2798	amisulpride	_	
20-10	2799-2801	or	_	
20-11	2802-2805	the	_	
20-12	2806-2813	partial	_	
20-13	2814-2826	dopaminergic	_	
20-14	2826-2827	/	_	
20-15	2827-2839	serotonergic	_	
20-16	2840-2847	agonist	_	
20-17	2848-2860	aripiprazole	_	
20-18	2861-2864	are	_	
20-19	2865-2868	two	_	
20-20	2869-2879	substances	_	
20-21	2880-2884	that	_	
20-22	2885-2891	rather	_	
20-23	2892-2896	seem	_	
20-24	2897-2899	to	_	
20-25	2900-2904	have	_	
20-26	2905-2906	a	_	
20-27	2907-2917	beneficial	_	
20-28	2918-2920	or	_	
20-29	2921-2923	at	_	
20-30	2924-2929	least	_	
20-31	2930-2937	neutral	_	
20-32	2938-2944	effect	_	
20-33	2945-2947	on	_	
20-34	2948-2951	OCS	_	
20-35	2951-2952	.	_	

#Text=Hence, differences in receptor binding profiles of clozapine/olanzapine vs. amisulpride/aripiprazole might explain diverging effects on co-occurring OCS.
21-1	2953-2958	Hence	_	
21-2	2958-2959	,	_	
21-3	2960-2971	differences	_	
21-4	2972-2974	in	_	
21-5	2975-2983	receptor	_	
21-6	2984-2991	binding	_	
21-7	2992-3000	profiles	_	
21-8	3001-3003	of	_	
21-9	3004-3013	clozapine	_	
21-10	3013-3014	/	_	
21-11	3014-3024	olanzapine	_	
21-12	3025-3027	vs	_	
21-13	3027-3028	.	_	
21-14	3029-3040	amisulpride	_	
21-15	3040-3041	/	_	
21-16	3041-3053	aripiprazole	_	
21-17	3054-3059	might	_	
21-18	3060-3067	explain	_	
21-19	3068-3077	diverging	_	
21-20	3078-3085	effects	_	
21-21	3086-3088	on	_	
21-22	3089-3101	co-occurring	_	
21-23	3102-3105	OCS	_	
21-24	3105-3106	.	_	

#Text=The assumption that SGAs aggravate OCS via an antiserotonergic mechanism also seems plausible, because treatment with selective serotonin reuptake inhibitors (SSRIs) has been proven effective in the treatment of OCD.
22-1	3107-3110	The	_	
22-2	3111-3121	assumption	_	
22-3	3122-3126	that	_	
22-4	3127-3131	SGAs	_	
22-5	3132-3141	aggravate	_	
22-6	3142-3145	OCS	_	
22-7	3146-3149	via	_	
22-8	3150-3152	an	_	
22-9	3153-3169	antiserotonergic	_	
22-10	3170-3179	mechanism	_	
22-11	3180-3184	also	_	
22-12	3185-3190	seems	_	
22-13	3191-3200	plausible	_	
22-14	3200-3201	,	_	
22-15	3202-3209	because	_	
22-16	3210-3219	treatment	_	
22-17	3220-3224	with	_	
22-18	3225-3234	selective	_	
22-19	3235-3244	serotonin	_	
22-20	3245-3253	reuptake	_	
22-21	3254-3264	inhibitors	_	
22-22	3265-3266	(	_	
22-23	3266-3271	SSRIs	_	
22-24	3271-3272	)	_	
22-25	3273-3276	has	_	
22-26	3277-3281	been	_	
22-27	3282-3288	proven	_	
22-28	3289-3298	effective	_	
22-29	3299-3301	in	_	
22-30	3302-3305	the	_	
22-31	3306-3315	treatment	_	
22-32	3316-3318	of	_	
22-33	3319-3322	OCD	_	
22-34	3322-3323	.	_	

#Text=Furthermore, CBT treatment of OCD exerts a serotonergic normalization and several clinical trials revealed positive effects of serotonergic antidepressants for comorbid OCD in schizophrenia.
23-1	3324-3335	Furthermore	_	
23-2	3335-3336	,	_	
23-3	3337-3340	CBT	_	
23-4	3341-3350	treatment	_	
23-5	3351-3353	of	_	
23-6	3354-3357	OCD	_	
23-7	3358-3364	exerts	_	
23-8	3365-3366	a	_	
23-9	3367-3379	serotonergic	_	
23-10	3380-3393	normalization	_	
23-11	3394-3397	and	_	
23-12	3398-3405	several	_	
23-13	3406-3414	clinical	_	
23-14	3415-3421	trials	_	
23-15	3422-3430	revealed	_	
23-16	3431-3439	positive	_	
23-17	3440-3447	effects	_	
23-18	3448-3450	of	_	
23-19	3451-3463	serotonergic	_	
23-20	3464-3479	antidepressants	_	
23-21	3480-3483	for	_	
23-22	3484-3492	comorbid	_	
23-23	3493-3496	OCD	_	
23-24	3497-3499	in	_	
23-25	3500-3513	schizophrenia	_	
23-26	3513-3514	.	_	

#Text=The neural mechanisms of how antipsychotics change brain functioning are poorly understood.
24-1	3515-3518	The	_	
24-2	3519-3525	neural	_	
24-3	3526-3536	mechanisms	_	
24-4	3537-3539	of	_	
24-5	3540-3543	how	_	
24-6	3544-3558	antipsychotics	_	
24-7	3559-3565	change	_	
24-8	3566-3571	brain	_	
24-9	3572-3583	functioning	_	
24-10	3584-3587	are	_	
24-11	3588-3594	poorly	_	
24-12	3595-3605	understood	_	
24-13	3605-3606	.	_	

#Text=Röder et al. reviewed literature on antipsychotic influence on the blood-oxygenation-level-dependent (BOLD)-signal and suggested that functional magnetic resonance imaging (fMRI) can be a useful approach to provide information about differential drug effects.
25-1	3607-3612	Röder	_	
25-2	3613-3615	et	_	
25-3	3616-3618	al	_	
25-4	3618-3619	.	_	
25-5	3620-3628	reviewed	_	
25-6	3629-3639	literature	_	
25-7	3640-3642	on	_	
25-8	3643-3656	antipsychotic	_	
25-9	3657-3666	influence	_	
25-10	3667-3669	on	_	
25-11	3670-3673	the	_	
25-12	3674-3707	blood-oxygenation-level-dependent	_	
25-13	3708-3709	(	_	
25-14	3709-3713	BOLD	_	
25-15	3713-3714	)	_	
25-16	3714-3715	-	_	
25-17	3715-3721	signal	_	
25-18	3722-3725	and	_	
25-19	3726-3735	suggested	_	
25-20	3736-3740	that	_	
25-21	3741-3751	functional	_	
25-22	3752-3760	magnetic	_	
25-23	3761-3770	resonance	_	
25-24	3771-3778	imaging	_	
25-25	3779-3780	(	_	
25-26	3780-3784	fMRI	_	
25-27	3784-3785	)	_	
25-28	3786-3789	can	_	
25-29	3790-3792	be	_	
25-30	3793-3794	a	_	
25-31	3795-3801	useful	_	
25-32	3802-3810	approach	_	
25-33	3811-3813	to	_	
25-34	3814-3821	provide	_	
25-35	3822-3833	information	_	
25-36	3834-3839	about	_	
25-37	3840-3852	differential	_	
25-38	3853-3857	drug	_	
25-39	3858-3865	effects	_	
25-40	3865-3866	.	_	

#Text=In a prior study, we investigated differential effects of SGAs on OCS in schizophrenia by comparing patients treated with clozapine or olanzapine to a group treated with aripiprazole or amisulpride.
26-1	3867-3869	In	_	
26-2	3870-3871	a	_	
26-3	3872-3877	prior	_	
26-4	3878-3883	study	_	
26-5	3883-3884	,	_	
26-6	3885-3887	we	_	
26-7	3888-3900	investigated	_	
26-8	3901-3913	differential	_	
26-9	3914-3921	effects	_	
26-10	3922-3924	of	_	
26-11	3925-3929	SGAs	_	
26-12	3930-3932	on	_	
26-13	3933-3936	OCS	_	
26-14	3937-3939	in	_	
26-15	3940-3953	schizophrenia	_	
26-16	3954-3956	by	_	
26-17	3957-3966	comparing	_	
26-18	3967-3975	patients	_	
26-19	3976-3983	treated	_	
26-20	3984-3988	with	_	
26-21	3989-3998	clozapine	_	
26-22	3999-4001	or	_	
26-23	4002-4012	olanzapine	_	
26-24	4013-4015	to	_	
26-25	4016-4017	a	_	
26-26	4018-4023	group	_	
26-27	4024-4031	treated	_	
26-28	4032-4036	with	_	
26-29	4037-4049	aripiprazole	_	
26-30	4050-4052	or	_	
26-31	4053-4064	amisulpride	_	
26-32	4064-4065	.	_	

#Text=FMRI analyses showed aberrant orbitofrontal cortex (OFC) activation during a flanker task in the clozapine/olanzapine group.
27-1	4066-4070	FMRI	_	
27-2	4071-4079	analyses	_	
27-3	4080-4086	showed	_	
27-4	4087-4095	aberrant	_	
27-5	4096-4109	orbitofrontal	_	
27-6	4110-4116	cortex	_	
27-7	4117-4118	(	_	
27-8	4118-4121	OFC	_	
27-9	4121-4122	)	_	
27-10	4123-4133	activation	_	
27-11	4134-4140	during	_	
27-12	4141-4142	a	_	
27-13	4143-4150	flanker	_	
27-14	4151-4155	task	_	
27-15	4156-4158	in	_	
27-16	4159-4162	the	_	
27-17	4163-4172	clozapine	_	
27-18	4172-4173	/	_	
27-19	4173-4183	olanzapine	_	
27-20	4184-4189	group	_	
27-21	4189-4190	.	_	

#Text=OFC activation mediated the association between SGA treatment and co-occurring OCS.
28-1	4191-4194	OFC	_	
28-2	4195-4205	activation	_	
28-3	4206-4214	mediated	_	
28-4	4215-4218	the	_	
28-5	4219-4230	association	_	
28-6	4231-4238	between	_	
28-7	4239-4242	SGA	_	
28-8	4243-4252	treatment	_	
28-9	4253-4256	and	_	
28-10	4257-4269	co-occurring	_	
28-11	4270-4273	OCS	_	
28-12	4273-4274	.	_	

#Text=To the best of our knowledge, four other fMRI studies investigated neural correlates of OCS in schizophrenia, but did not specifically focus on OCD-related brain regions, nor did they account for possible underlying pharmacodynamic mechanisms.
29-1	4275-4277	To	_	
29-2	4278-4281	the	_	
29-3	4282-4286	best	_	
29-4	4287-4289	of	_	
29-5	4290-4293	our	_	
29-6	4294-4303	knowledge	_	
29-7	4303-4304	,	_	
29-8	4305-4309	four	_	
29-9	4310-4315	other	_	
29-10	4316-4320	fMRI	_	
29-11	4321-4328	studies	_	
29-12	4329-4341	investigated	_	
29-13	4342-4348	neural	_	
29-14	4349-4359	correlates	_	
29-15	4360-4362	of	_	
29-16	4363-4366	OCS	_	
29-17	4367-4369	in	_	
29-18	4370-4383	schizophrenia	_	
29-19	4383-4384	,	_	
29-20	4385-4388	but	_	
29-21	4389-4392	did	_	
29-22	4393-4396	not	_	
29-23	4397-4409	specifically	_	
29-24	4410-4415	focus	_	
29-25	4416-4418	on	_	
29-26	4419-4430	OCD-related	_	
29-27	4431-4436	brain	_	
29-28	4437-4444	regions	_	
29-29	4444-4445	,	_	
29-30	4446-4449	nor	_	
29-31	4450-4453	did	_	
29-32	4454-4458	they	_	
29-33	4459-4466	account	_	
29-34	4467-4470	for	_	
29-35	4471-4479	possible	_	
29-36	4480-4490	underlying	_	
29-37	4491-4506	pharmacodynamic	_	
29-38	4507-4517	mechanisms	_	
29-39	4517-4518	.	_	

#Text=Apart from the fronto-striato-thalamocortical (CSTC) circuitry, which is known to be involved in OCD pathogenesis, recent findings proposed to extend research to limbic regions, and highlighted the role of the amygdala,.
30-1	4519-4524	Apart	_	
30-2	4525-4529	from	_	
30-3	4530-4533	the	_	
30-4	4534-4564	fronto-striato-thalamocortical	_	
30-5	4565-4566	(	_	
30-6	4566-4570	CSTC	_	
30-7	4570-4571	)	_	
30-8	4572-4581	circuitry	_	
30-9	4581-4582	,	_	
30-10	4583-4588	which	_	
30-11	4589-4591	is	_	
30-12	4592-4597	known	_	
30-13	4598-4600	to	_	
30-14	4601-4603	be	_	
30-15	4604-4612	involved	_	
30-16	4613-4615	in	_	
30-17	4616-4619	OCD	_	
30-18	4620-4632	pathogenesis	_	
30-19	4632-4633	,	_	
30-20	4634-4640	recent	_	
30-21	4641-4649	findings	_	
30-22	4650-4658	proposed	_	
30-23	4659-4661	to	_	
30-24	4662-4668	extend	_	
30-25	4669-4677	research	_	
30-26	4678-4680	to	_	
30-27	4681-4687	limbic	_	
30-28	4688-4695	regions	_	
30-29	4695-4696	,	_	
30-30	4697-4700	and	_	
30-31	4701-4712	highlighted	_	
30-32	4713-4716	the	_	
30-33	4717-4721	role	_	
30-34	4722-4724	of	_	
30-35	4725-4728	the	_	
30-36	4729-4737	amygdala	_	
30-37	4737-4738	,	_	
30-38	4738-4739	.	_	

#Text=In their review, Wood and Ahmari discussed the potential role of a corticolimbic-ventral striatum network, extending the traditional OCD model with an important aspect, namely affective dysregulation.
31-1	4740-4742	In	_	
31-2	4743-4748	their	_	
31-3	4749-4755	review	_	
31-4	4755-4756	,	_	
31-5	4757-4761	Wood	_	
31-6	4762-4765	and	_	
31-7	4766-4772	Ahmari	_	
31-8	4773-4782	discussed	_	
31-9	4783-4786	the	_	
31-10	4787-4796	potential	_	
31-11	4797-4801	role	_	
31-12	4802-4804	of	_	
31-13	4805-4806	a	_	
31-14	4807-4828	corticolimbic-ventral	_	
31-15	4829-4837	striatum	_	
31-16	4838-4845	network	_	
31-17	4845-4846	,	_	
31-18	4847-4856	extending	_	
31-19	4857-4860	the	_	
31-20	4861-4872	traditional	_	
31-21	4873-4876	OCD	_	
31-22	4877-4882	model	_	
31-23	4883-4887	with	_	
31-24	4888-4890	an	_	
31-25	4891-4900	important	_	
31-26	4901-4907	aspect	_	
31-27	4907-4908	,	_	
31-28	4909-4915	namely	_	
31-29	4916-4925	affective	_	
31-30	4926-4939	dysregulation	_	
31-31	4939-4940	.	_	

#Text=This circuit connecting frontal and limbic brain regions, specifically the amygdala with the ventral striatum plays a particularly important role in the emotional appraisal of situations and the generation of emotional responses and reward-based behaviors.
32-1	4941-4945	This	_	
32-2	4946-4953	circuit	_	
32-3	4954-4964	connecting	_	
32-4	4965-4972	frontal	_	
32-5	4973-4976	and	_	
32-6	4977-4983	limbic	_	
32-7	4984-4989	brain	_	
32-8	4990-4997	regions	_	
32-9	4997-4998	,	_	
32-10	4999-5011	specifically	_	
32-11	5012-5015	the	_	
32-12	5016-5024	amygdala	_	
32-13	5025-5029	with	_	
32-14	5030-5033	the	_	
32-15	5034-5041	ventral	_	
32-16	5042-5050	striatum	_	
32-17	5051-5056	plays	_	
32-18	5057-5058	a	_	
32-19	5059-5071	particularly	_	
32-20	5072-5081	important	_	
32-21	5082-5086	role	_	
32-22	5087-5089	in	_	
32-23	5090-5093	the	_	
32-24	5094-5103	emotional	_	
32-25	5104-5113	appraisal	_	
32-26	5114-5116	of	_	
32-27	5117-5127	situations	_	
32-28	5128-5131	and	_	
32-29	5132-5135	the	_	
32-30	5136-5146	generation	_	
32-31	5147-5149	of	_	
32-32	5150-5159	emotional	_	
32-33	5160-5169	responses	_	
32-34	5170-5173	and	_	
32-35	5174-5186	reward-based	_	
32-36	5187-5196	behaviors	_	
32-37	5196-5197	.	_	

#Text=The circuit has been found altered in OCD explaining increased anxiety and repetitive behaviors.
33-1	5198-5201	The	_	
33-2	5202-5209	circuit	_	
33-3	5210-5213	has	_	
33-4	5214-5218	been	_	
33-5	5219-5224	found	_	
33-6	5225-5232	altered	_	
33-7	5233-5235	in	_	
33-8	5236-5239	OCD	_	
33-9	5240-5250	explaining	_	
33-10	5251-5260	increased	_	
33-11	5261-5268	anxiety	_	
33-12	5269-5272	and	_	
33-13	5273-5283	repetitive	_	
33-14	5284-5293	behaviors	_	
33-15	5293-5294	.	_	

#Text=Accordingly, a number of fMRI studies reported increased amygdala activation and enhanced amygdala-prefrontal connectivity during emotion recognition tasks, whereas others showed attenuated amygdala responsivity to emotional stimuli in OCD patients relative to healthy controls.
34-1	5295-5306	Accordingly	_	
34-2	5306-5307	,	_	
34-3	5308-5309	a	_	
34-4	5310-5316	number	_	
34-5	5317-5319	of	_	
34-6	5320-5324	fMRI	_	
34-7	5325-5332	studies	_	
34-8	5333-5341	reported	_	
34-9	5342-5351	increased	_	
34-10	5352-5360	amygdala	_	
34-11	5361-5371	activation	_	
34-12	5372-5375	and	_	
34-13	5376-5384	enhanced	_	
34-14	5385-5404	amygdala-prefrontal	_	
34-15	5405-5417	connectivity	_	
34-16	5418-5424	during	_	
34-17	5425-5432	emotion	_	
34-18	5433-5444	recognition	_	
34-19	5445-5450	tasks	_	
34-20	5450-5451	,	_	
34-21	5452-5459	whereas	_	
34-22	5460-5466	others	_	
34-23	5467-5473	showed	_	
34-24	5474-5484	attenuated	_	
34-25	5485-5493	amygdala	_	
34-26	5494-5506	responsivity	_	
34-27	5507-5509	to	_	
34-28	5510-5519	emotional	_	
34-29	5520-5527	stimuli	_	
34-30	5528-5530	in	_	
34-31	5531-5534	OCD	_	
34-32	5535-5543	patients	_	
34-33	5544-5552	relative	_	
34-34	5553-5555	to	_	
34-35	5556-5563	healthy	_	
34-36	5564-5572	controls	_	
34-37	5572-5573	.	_	

#Text=Differences in amygdala activity and corticolimbic connectivity during emotion processing have also been found in patients with schizophrenia.
35-1	5574-5585	Differences	_	
35-2	5586-5588	in	_	
35-3	5589-5597	amygdala	_	
35-4	5598-5606	activity	_	
35-5	5607-5610	and	_	
35-6	5611-5624	corticolimbic	_	
35-7	5625-5637	connectivity	_	
35-8	5638-5644	during	_	
35-9	5645-5652	emotion	_	
35-10	5653-5663	processing	_	
35-11	5664-5668	have	_	
35-12	5669-5673	also	_	
35-13	5674-5678	been	_	
35-14	5679-5684	found	_	
35-15	5685-5687	in	_	
35-16	5688-5696	patients	_	
35-17	5697-5701	with	_	
35-18	5702-5715	schizophrenia	_	
35-19	5715-5716	.	_	

#Text=Meta-analytic findings suggest hypoactivation of the amygdala in response to emotional facial expressions compared to healthy controls, whereas more recent studies reported hyperactivation in response to neutral facial expressions.
36-1	5717-5730	Meta-analytic	_	
36-2	5731-5739	findings	_	
36-3	5740-5747	suggest	_	
36-4	5748-5762	hypoactivation	_	
36-5	5763-5765	of	_	
36-6	5766-5769	the	_	
36-7	5770-5778	amygdala	_	
36-8	5779-5781	in	_	
36-9	5782-5790	response	_	
36-10	5791-5793	to	_	
36-11	5794-5803	emotional	_	
36-12	5804-5810	facial	_	
36-13	5811-5822	expressions	_	
36-14	5823-5831	compared	_	
36-15	5832-5834	to	_	
36-16	5835-5842	healthy	_	
36-17	5843-5851	controls	_	
36-18	5851-5852	,	_	
36-19	5853-5860	whereas	_	
36-20	5861-5865	more	_	
36-21	5866-5872	recent	_	
36-22	5873-5880	studies	_	
36-23	5881-5889	reported	_	
36-24	5890-5905	hyperactivation	_	
36-25	5906-5908	in	_	
36-26	5909-5917	response	_	
36-27	5918-5920	to	_	
36-28	5921-5928	neutral	_	
36-29	5929-5935	facial	_	
36-30	5936-5947	expressions	_	
36-31	5947-5948	.	_	

#Text=Hence, aberrant amygdala activation and connectivity to regions of the corticolimbic-ventral striatum network during emotion processing might indicate a neural correlate of both OCD and schizophrenia and might play a role in the co-occurrence of the two disorders.
37-1	5949-5954	Hence	_	
37-2	5954-5955	,	_	
37-3	5956-5964	aberrant	_	
37-4	5965-5973	amygdala	_	
37-5	5974-5984	activation	_	
37-6	5985-5988	and	_	
37-7	5989-6001	connectivity	_	
37-8	6002-6004	to	_	
37-9	6005-6012	regions	_	
37-10	6013-6015	of	_	
37-11	6016-6019	the	_	
37-12	6020-6041	corticolimbic-ventral	_	
37-13	6042-6050	striatum	_	
37-14	6051-6058	network	_	
37-15	6059-6065	during	_	
37-16	6066-6073	emotion	_	
37-17	6074-6084	processing	_	
37-18	6085-6090	might	_	
37-19	6091-6099	indicate	_	
37-20	6100-6101	a	_	
37-21	6102-6108	neural	_	
37-22	6109-6118	correlate	_	
37-23	6119-6121	of	_	
37-24	6122-6126	both	_	
37-25	6127-6130	OCD	_	
37-26	6131-6134	and	_	
37-27	6135-6148	schizophrenia	_	
37-28	6149-6152	and	_	
37-29	6153-6158	might	_	
37-30	6159-6163	play	_	
37-31	6164-6165	a	_	
37-32	6166-6170	role	_	
37-33	6171-6173	in	_	
37-34	6174-6177	the	_	
37-35	6178-6191	co-occurrence	_	
37-36	6192-6194	of	_	
37-37	6195-6198	the	_	
37-38	6199-6202	two	_	
37-39	6203-6212	disorders	_	
37-40	6212-6213	.	_	

#Text=However, additive effects and modulations due to therapeutic interventions seem possible.
38-1	6214-6221	However	_	
38-2	6221-6222	,	_	
38-3	6223-6231	additive	_	
38-4	6232-6239	effects	_	
38-5	6240-6243	and	_	
38-6	6244-6255	modulations	_	
38-7	6256-6259	due	_	
38-8	6260-6262	to	_	
38-9	6263-6274	therapeutic	_	
38-10	6275-6288	interventions	_	
38-11	6289-6293	seem	_	
38-12	6294-6302	possible	_	
38-13	6302-6303	.	_	

#Text=Accordingly, pharmacological treatment affects brain activation involved in emotional processing.
39-1	6304-6315	Accordingly	_	
39-2	6315-6316	,	_	
39-3	6317-6332	pharmacological	_	
39-4	6333-6342	treatment	_	
39-5	6343-6350	affects	_	
39-6	6351-6356	brain	_	
39-7	6357-6367	activation	_	
39-8	6368-6376	involved	_	
39-9	6377-6379	in	_	
39-10	6380-6389	emotional	_	
39-11	6390-6400	processing	_	
39-12	6400-6401	.	_	

#Text=Effects of antipsychotic agents should be considered when investigating OCS-related aberrations in brain activation in schizophrenia.
40-1	6402-6409	Effects	_	
40-2	6410-6412	of	_	
40-3	6413-6426	antipsychotic	_	
40-4	6427-6433	agents	_	
40-5	6434-6440	should	_	
40-6	6441-6443	be	_	
40-7	6444-6454	considered	_	
40-8	6455-6459	when	_	
40-9	6460-6473	investigating	_	
40-10	6474-6485	OCS-related	_	
40-11	6486-6497	aberrations	_	
40-12	6498-6500	in	_	
40-13	6501-6506	brain	_	
40-14	6507-6517	activation	_	
40-15	6518-6520	in	_	
40-16	6521-6534	schizophrenia	_	
40-17	6534-6535	.	_	

#Text=The aim of the present study was to investigate whether SGAs with different pharmacodynamic profiles differentially affect functioning of brain regions known to be involved in emotional processing.
41-1	6536-6539	The	_	
41-2	6540-6543	aim	_	
41-3	6544-6546	of	_	
41-4	6547-6550	the	_	
41-5	6551-6558	present	_	
41-6	6559-6564	study	_	
41-7	6565-6568	was	_	
41-8	6569-6571	to	_	
41-9	6572-6583	investigate	_	
41-10	6584-6591	whether	_	
41-11	6592-6596	SGAs	_	
41-12	6597-6601	with	_	
41-13	6602-6611	different	_	
41-14	6612-6627	pharmacodynamic	_	
41-15	6628-6636	profiles	_	
41-16	6637-6651	differentially	_	
41-17	6652-6658	affect	_	
41-18	6659-6670	functioning	_	
41-19	6671-6673	of	_	
41-20	6674-6679	brain	_	
41-21	6680-6687	regions	_	
41-22	6688-6693	known	_	
41-23	6694-6696	to	_	
41-24	6697-6699	be	_	
41-25	6700-6708	involved	_	
41-26	6709-6711	in	_	
41-27	6712-6721	emotional	_	
41-28	6722-6732	processing	_	
41-29	6732-6733	.	_	

#Text=We assumed to find differences in brain activation and connectivity especially of the amygdala between SGA groups.
42-1	6734-6736	We	_	
42-2	6737-6744	assumed	_	
42-3	6745-6747	to	_	
42-4	6748-6752	find	_	
42-5	6753-6764	differences	_	
42-6	6765-6767	in	_	
42-7	6768-6773	brain	_	
42-8	6774-6784	activation	_	
42-9	6785-6788	and	_	
42-10	6789-6801	connectivity	_	
42-11	6802-6812	especially	_	
42-12	6813-6815	of	_	
42-13	6816-6819	the	_	
42-14	6820-6828	amygdala	_	
42-15	6829-6836	between	_	
42-16	6837-6840	SGA	_	
42-17	6841-6847	groups	_	
42-18	6847-6848	.	_	

#Text=On a secondary level, we intended to investigate associations between task-specific activation and the severity of OCS.
43-1	6849-6851	On	_	
43-2	6852-6853	a	_	
43-3	6854-6863	secondary	_	
43-4	6864-6869	level	_	
43-5	6869-6870	,	_	
43-6	6871-6873	we	_	
43-7	6874-6882	intended	_	
43-8	6883-6885	to	_	
43-9	6886-6897	investigate	_	
43-10	6898-6910	associations	_	
43-11	6911-6918	between	_	
43-12	6919-6932	task-specific	_	
43-13	6933-6943	activation	_	
43-14	6944-6947	and	_	
43-15	6948-6951	the	_	
43-16	6952-6960	severity	_	
43-17	6961-6963	of	_	
43-18	6964-6967	OCS	_	
43-19	6967-6968	.	_	

#Text=Method
#Text=Study design and participants
#Text=This neuroimaging approach was part of a multimodal assessment.
44-1	6969-6975	Method	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
44-2	6976-6981	Study	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
44-3	6982-6988	design	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
44-4	6989-6992	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
44-5	6993-7005	participants	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
44-6	7006-7010	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-7	7011-7023	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-8	7024-7032	approach	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-9	7033-7036	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-10	7037-7041	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-11	7042-7044	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-12	7045-7046	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-13	7047-7057	multimodal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-14	7058-7068	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-15	7068-7069	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Patients were divided into two groups, those with an inherent antiserotonergic profile (group I: olanzapine and clozapine) and those with a primarily dopaminergic treatment profile (group II: amisulpride and aripiprazole).
45-1	7070-7078	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-2	7079-7083	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-3	7084-7091	divided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-4	7092-7096	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-5	7097-7100	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-6	7101-7107	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-7	7107-7108	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-8	7109-7114	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-9	7115-7119	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-10	7120-7122	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-11	7123-7131	inherent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-12	7132-7148	antiserotonergic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-13	7149-7156	profile	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-14	7157-7158	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-15	7158-7163	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-16	7164-7165	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-17	7165-7166	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-18	7167-7177	olanzapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-19	7178-7181	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-20	7182-7191	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-21	7191-7192	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-22	7193-7196	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-23	7197-7202	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-24	7203-7207	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-25	7208-7209	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-26	7210-7219	primarily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-27	7220-7232	dopaminergic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-28	7233-7242	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-29	7243-7250	profile	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-30	7251-7252	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-31	7252-7257	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-32	7258-7260	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-33	7260-7261	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-34	7262-7273	amisulpride	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-35	7274-7277	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-36	7278-7290	aripiprazole	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-37	7290-7291	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
45-38	7291-7292	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=As described earlier, participants were aged 18–60 years, diagnosed with a schizophrenia spectrum disorder according to DSM-IV-TR, received stable monotherapy with clozapine, olanzapine, amisulpride or aripiprazole and showed stable psychopathology over a period of at least 2 weeks with constant severity scores in psychosocial functioning (PSP) and the Positive and Negative Syndrome Scale (PANSS).
46-1	7293-7295	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-2	7296-7305	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-3	7306-7313	earlier	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-4	7313-7314	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-5	7315-7327	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-6	7328-7332	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-7	7333-7337	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-8	7338-7340	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-9	7340-7341	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-10	7341-7343	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-11	7343-7344	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-12	7344-7349	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-13	7349-7350	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-14	7351-7360	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-15	7361-7365	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-16	7366-7367	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-17	7368-7381	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
46-18	7382-7390	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-19	7391-7399	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-20	7400-7409	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-21	7410-7412	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-22	7413-7422	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-23	7422-7423	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-24	7424-7432	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-25	7433-7439	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-26	7440-7451	monotherapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-27	7452-7456	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-28	7457-7466	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-29	7466-7467	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-30	7468-7478	olanzapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-31	7478-7479	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-32	7480-7491	amisulpride	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-33	7492-7494	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-34	7495-7507	aripiprazole	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-35	7508-7511	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-36	7512-7518	showed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-37	7519-7525	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-38	7526-7541	psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-39	7542-7546	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-40	7547-7548	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-41	7549-7555	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-42	7556-7558	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-43	7559-7561	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-44	7562-7567	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-45	7568-7569	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-46	7569-7570	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-47	7570-7575	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
46-48	7576-7580	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-49	7581-7589	constant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-50	7590-7598	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-51	7599-7605	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-52	7606-7608	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-53	7609-7621	psychosocial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-54	7622-7633	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-55	7634-7635	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-56	7635-7638	PSP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-57	7638-7639	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-58	7640-7643	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-59	7644-7647	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
46-60	7648-7656	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-61	7657-7660	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-62	7661-7669	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-63	7670-7678	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-64	7679-7684	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-65	7685-7686	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-66	7686-7691	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-67	7691-7692	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[8]	
46-68	7692-7693	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Exclusion criteria included a history of alcohol or drug addiction or current treatment with antidepressants (except for reboxetine and bupropion—substances without marked serotonergic effects).
47-1	7694-7703	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-2	7704-7712	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-3	7713-7721	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-4	7722-7723	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-5	7724-7731	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-6	7732-7734	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-7	7735-7742	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]	
47-8	7743-7745	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-9	7746-7750	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[10]	
47-10	7751-7760	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[10]	
47-11	7761-7763	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-12	7764-7771	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-13	7772-7781	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-14	7782-7786	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-15	7787-7802	antidepressants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-16	7803-7804	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-17	7804-7810	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-18	7811-7814	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-19	7815-7825	reboxetine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-20	7826-7829	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-21	7830-7850	bupropion—substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-22	7851-7858	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-23	7859-7865	marked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-24	7866-7878	serotonergic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-25	7879-7886	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-26	7886-7887	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
47-27	7887-7888	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Benzodiazepine intake was no exclusion criteria, but only one patient was prescribed clonazepam on demand.
48-1	7889-7903	Benzodiazepine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-2	7904-7910	intake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-3	7911-7914	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-4	7915-7917	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-5	7918-7927	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-6	7928-7936	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-7	7936-7937	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-8	7938-7941	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-9	7942-7946	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-10	7947-7950	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-11	7951-7958	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-12	7959-7962	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-13	7963-7973	prescribed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-14	7974-7984	clonazepam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-15	7985-7987	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-16	7988-7994	demand	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-17	7994-7995	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=The investigation was approved by the ethical committee of the University of Heidelberg (no. 2008-235N-MA) and performed in agreement with the guidelines of good clinical practice.
49-1	7996-7999	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-2	8000-8013	investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-3	8014-8017	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-4	8018-8026	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-5	8027-8029	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-6	8030-8033	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-7	8034-8041	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-8	8042-8051	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-9	8052-8054	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-10	8055-8058	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-11	8059-8069	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-12	8070-8072	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-13	8073-8083	Heidelberg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-14	8084-8085	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-15	8085-8087	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-16	8087-8088	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-17	8089-8093	2008	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-18	8093-8094	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-19	8094-8101	235N-MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-20	8101-8102	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-21	8103-8106	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-22	8107-8116	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-23	8117-8119	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-24	8120-8129	agreement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-25	8130-8134	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-26	8135-8138	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-27	8139-8149	guidelines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-28	8150-8152	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-29	8153-8157	good	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-30	8158-8166	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-31	8167-8175	practice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-32	8175-8176	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=All participants provided written informed consent prior to study inclusion.
50-1	8177-8180	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-2	8181-8193	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-3	8194-8202	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-4	8203-8210	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-5	8211-8219	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-6	8220-8227	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-7	8228-8233	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-8	8234-8236	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-9	8237-8242	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-10	8243-8252	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-11	8252-8253	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Clinical assessment
#Text=Sociodemographic and clinical variables were assessed using questionnaires and structured clinical interviews by a trained and certified rater (FS).
51-1	8254-8262	Clinical	_	
51-2	8263-8273	assessment	_	
51-3	8274-8290	Sociodemographic	_	
51-4	8291-8294	and	_	
51-5	8295-8303	clinical	_	
51-6	8304-8313	variables	_	
51-7	8314-8318	were	_	
51-8	8319-8327	assessed	_	
51-9	8328-8333	using	_	
51-10	8334-8348	questionnaires	_	
51-11	8349-8352	and	_	
51-12	8353-8363	structured	_	
51-13	8364-8372	clinical	_	
51-14	8373-8383	interviews	_	
51-15	8384-8386	by	_	
51-16	8387-8388	a	_	
51-17	8389-8396	trained	_	
51-18	8397-8400	and	_	
51-19	8401-8410	certified	_	
51-20	8411-8416	rater	_	
51-21	8417-8418	(	_	
51-22	8418-8420	FS	_	
51-23	8420-8421	)	_	
51-24	8421-8422	.	_	

#Text=The Yale–Brown Obsessive–Compulsive Scale (YBOCS) was applied to assess OCS severity, which has been validated in schizophrenia populations.
52-1	8423-8426	The	_	
52-2	8427-8437	Yale–Brown	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[12]	
52-3	8438-8458	Obsessive–Compulsive	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[12]	
52-4	8459-8464	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[12]	
52-5	8465-8466	(	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[12]	
52-6	8466-8471	YBOCS	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[12]	
52-7	8471-8472	)	_	
52-8	8473-8476	was	_	
52-9	8477-8484	applied	_	
52-10	8485-8487	to	_	
52-11	8488-8494	assess	_	
52-12	8495-8498	OCS	_	
52-13	8499-8507	severity	_	
52-14	8507-8508	,	_	
52-15	8509-8514	which	_	
52-16	8515-8518	has	_	
52-17	8519-8523	been	_	
52-18	8524-8533	validated	_	
52-19	8534-8536	in	_	
52-20	8537-8550	schizophrenia	_	
52-21	8551-8562	populations	_	
52-22	8562-8563	.	_	

#Text=The YBOCS allows the rating of compulsions and obsessions on 5-point Likert scales (0–4), yielding subtotal scores ranging from 0 to 20.
53-1	8564-8567	The	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[13]	
53-2	8568-8573	YBOCS	http://maven.renci.org/NeuroBridge/neurobridge#Yale–BrownObsessive–CompulsiveScale[13]	
53-3	8574-8580	allows	_	
53-4	8581-8584	the	_	
53-5	8585-8591	rating	_	
53-6	8592-8594	of	_	
53-7	8595-8606	compulsions	_	
53-8	8607-8610	and	_	
53-9	8611-8621	obsessions	_	
53-10	8622-8624	on	_	
53-11	8625-8626	5	_	
53-12	8626-8627	-	_	
53-13	8627-8632	point	_	
53-14	8633-8639	Likert	_	
53-15	8640-8646	scales	_	
53-16	8647-8648	(	_	
53-17	8648-8649	0	_	
53-18	8649-8650	–	_	
53-19	8650-8651	4	_	
53-20	8651-8652	)	_	
53-21	8652-8653	,	_	
53-22	8654-8662	yielding	_	
53-23	8663-8671	subtotal	_	
53-24	8672-8678	scores	_	
53-25	8679-8686	ranging	_	
53-26	8687-8691	from	_	
53-27	8692-8693	0	_	
53-28	8694-8696	to	_	
53-29	8697-8699	20	_	
53-30	8699-8700	.	_	

#Text=According to the interpretation guidelines of the original authors, total scores of ≤ 7 are likely to be subclinical, whereas scores of ≥ 8 are likely to represent at least a mild case of OCD.
54-1	8701-8710	According	_	
54-2	8711-8713	to	_	
54-3	8714-8717	the	_	
54-4	8718-8732	interpretation	_	
54-5	8733-8743	guidelines	_	
54-6	8744-8746	of	_	
54-7	8747-8750	the	_	
54-8	8751-8759	original	_	
54-9	8760-8767	authors	_	
54-10	8767-8768	,	_	
54-11	8769-8774	total	_	
54-12	8775-8781	scores	_	
54-13	8782-8784	of	_	
54-14	8785-8786	≤	_	
54-15	8787-8788	7	_	
54-16	8789-8792	are	_	
54-17	8793-8799	likely	_	
54-18	8800-8802	to	_	
54-19	8803-8805	be	_	
54-20	8806-8817	subclinical	_	
54-21	8817-8818	,	_	
54-22	8819-8826	whereas	_	
54-23	8827-8833	scores	_	
54-24	8834-8836	of	_	
54-25	8837-8838	≥	_	
54-26	8839-8840	8	_	
54-27	8841-8844	are	_	
54-28	8845-8851	likely	_	
54-29	8852-8854	to	_	
54-30	8855-8864	represent	_	
54-31	8865-8867	at	_	
54-32	8868-8873	least	_	
54-33	8874-8875	a	_	
54-34	8876-8880	mild	_	
54-35	8881-8885	case	_	
54-36	8886-8888	of	_	
54-37	8889-8892	OCD	_	
54-38	8892-8893	.	_	

#Text=In addition, the Hamburger Zwangsinventar (HZI) was applied as a self-rating questionnaire to measure the presence of obsessions and different types of compulsions.
55-1	8894-8896	In	_	
55-2	8897-8905	addition	_	
55-3	8905-8906	,	_	
55-4	8907-8910	the	_	
55-5	8911-8920	Hamburger	http://www.case.edu/ProvCaRe/provcare#Scale[14]	
55-6	8921-8935	Zwangsinventar	http://www.case.edu/ProvCaRe/provcare#Scale[14]	
55-7	8936-8937	(	http://www.case.edu/ProvCaRe/provcare#Scale[14]	
55-8	8937-8940	HZI	http://www.case.edu/ProvCaRe/provcare#Scale[14]	
55-9	8940-8941	)	http://www.case.edu/ProvCaRe/provcare#Scale[14]	
55-10	8942-8945	was	_	
55-11	8946-8953	applied	_	
55-12	8954-8956	as	_	
55-13	8957-8958	a	_	
55-14	8959-8970	self-rating	_	
55-15	8971-8984	questionnaire	_	
55-16	8985-8987	to	_	
55-17	8988-8995	measure	_	
55-18	8996-8999	the	_	
55-19	9000-9008	presence	_	
55-20	9009-9011	of	_	
55-21	9012-9022	obsessions	_	
55-22	9023-9026	and	_	
55-23	9027-9036	different	_	
55-24	9037-9042	types	_	
55-25	9043-9045	of	_	
55-26	9046-9057	compulsions	_	
55-27	9057-9058	.	_	

#Text=The severity of psychotic symptoms was rated with the PANSS positive, negative and general psychopathology subscale.
56-1	9059-9062	The	_	
56-2	9063-9071	severity	_	
56-3	9072-9074	of	_	
56-4	9075-9084	psychotic	_	
56-5	9085-9093	symptoms	_	
56-6	9094-9097	was	_	
56-7	9098-9103	rated	_	
56-8	9104-9108	with	_	
56-9	9109-9112	the	_	
56-10	9113-9118	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
56-11	9119-9127	positive	_	
56-12	9127-9128	,	_	
56-13	9129-9137	negative	_	
56-14	9138-9141	and	_	
56-15	9142-9149	general	_	
56-16	9150-9165	psychopathology	_	
56-17	9166-9174	subscale	_	
56-18	9174-9175	.	_	

#Text=Subdomains of negative symptoms were further explored with the five subscales of the Scale for the Assessment of Negative Symptoms (SANS).
57-1	9176-9186	Subdomains	_	
57-2	9187-9189	of	_	
57-3	9190-9198	negative	_	
57-4	9199-9207	symptoms	_	
57-5	9208-9212	were	_	
57-6	9213-9220	further	_	
57-7	9221-9229	explored	_	
57-8	9230-9234	with	_	
57-9	9235-9238	the	_	
57-10	9239-9243	five	_	
57-11	9244-9253	subscales	_	
57-12	9254-9256	of	_	
57-13	9257-9260	the	_	
57-14	9261-9266	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-15	9267-9270	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-16	9271-9274	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-17	9275-9285	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-18	9286-9288	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-19	9289-9297	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-20	9298-9306	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-21	9307-9308	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-22	9308-9312	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-23	9312-9313	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[15]	
57-24	9313-9314	.	_	

#Text=Comorbid depressive symptoms were rated with the Calgary Depression Scale for Schizophrenia (CDSS).
58-1	9315-9323	Comorbid	_	
58-2	9324-9334	depressive	_	
58-3	9335-9343	symptoms	_	
58-4	9344-9348	were	_	
58-5	9349-9354	rated	_	
58-6	9355-9359	with	_	
58-7	9360-9363	the	_	
58-8	9364-9371	Calgary	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-9	9372-9382	Depression	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-10	9383-9388	Scale	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-11	9389-9392	for	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-12	9393-9406	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-13	9407-9408	(	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-14	9408-9412	CDSS	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-15	9412-9413	)	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale[16]	
58-16	9413-9414	.	_	

#Text=General and social functioning was assessed with the Personal and Social Performance Scale (PSP).
59-1	9415-9422	General	_	
59-2	9423-9426	and	_	
59-3	9427-9433	social	_	
59-4	9434-9445	functioning	_	
59-5	9446-9449	was	_	
59-6	9450-9458	assessed	_	
59-7	9459-9463	with	_	
59-8	9464-9467	the	_	
59-9	9468-9476	Personal	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-10	9477-9480	and	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-11	9481-9487	Social	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-12	9488-9499	Performance	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-13	9500-9505	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-14	9506-9507	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-15	9507-9510	PSP	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-16	9510-9511	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale[17]	
59-17	9511-9512	.	_	

#Text=Functional MRI
#Text=To elicit amygdala response, we used the classical implicit emotion recognition face-matching paradigm of Hariri et al..
60-1	9513-9523	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[18]	
60-2	9524-9527	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[18]	
60-3	9528-9530	To	_	
60-4	9531-9537	elicit	_	
60-5	9538-9546	amygdala	_	
60-6	9547-9555	response	_	
60-7	9555-9556	,	_	
60-8	9557-9559	we	_	
60-9	9560-9564	used	_	
60-10	9565-9568	the	_	
60-11	9569-9578	classical	_	
60-12	9579-9587	implicit	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
60-13	9588-9595	emotion	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
60-14	9596-9607	recognition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
60-15	9608-9621	face-matching	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
60-16	9622-9630	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
60-17	9631-9633	of	_	
60-18	9634-9640	Hariri	_	
60-19	9641-9643	et	_	
60-20	9644-9646	al	_	
60-21	9646-9647	.	_	
60-22	9647-9648	.	_	

#Text=In this task, participants see three items on a screen: either faces showing emotional states such as anger or fear in the experimental condition or geometrical figures in the control condition.
61-1	9649-9651	In	_	
61-2	9652-9656	this	_	
61-3	9657-9661	task	_	
61-4	9661-9662	,	_	
61-5	9663-9675	participants	_	
61-6	9676-9679	see	_	
61-7	9680-9685	three	_	
61-8	9686-9691	items	_	
61-9	9692-9694	on	_	
61-10	9695-9696	a	_	
61-11	9697-9703	screen	_	
61-12	9703-9704	:	_	
61-13	9705-9711	either	_	
61-14	9712-9717	faces	_	
61-15	9718-9725	showing	_	
61-16	9726-9735	emotional	_	
61-17	9736-9742	states	_	
61-18	9743-9747	such	_	
61-19	9748-9750	as	_	
61-20	9751-9756	anger	_	
61-21	9757-9759	or	_	
61-22	9760-9764	fear	_	
61-23	9765-9767	in	_	
61-24	9768-9771	the	_	
61-25	9772-9784	experimental	_	
61-26	9785-9794	condition	_	
61-27	9795-9797	or	_	
61-28	9798-9809	geometrical	_	
61-29	9810-9817	figures	_	
61-30	9818-9820	in	_	
61-31	9821-9824	the	_	
61-32	9825-9832	control	_	
61-33	9833-9842	condition	_	
61-34	9842-9843	.	_	

#Text=A reference item is shown at the top and two items for comparison left and right below the target item.
62-1	9844-9845	A	_	
62-2	9846-9855	reference	_	
62-3	9856-9860	item	_	
62-4	9861-9863	is	_	
62-5	9864-9869	shown	_	
62-6	9870-9872	at	_	
62-7	9873-9876	the	_	
62-8	9877-9880	top	_	
62-9	9881-9884	and	_	
62-10	9885-9888	two	_	
62-11	9889-9894	items	_	
62-12	9895-9898	for	_	
62-13	9899-9909	comparison	_	
62-14	9910-9914	left	_	
62-15	9915-9918	and	_	
62-16	9919-9924	right	_	
62-17	9925-9930	below	_	
62-18	9931-9934	the	_	
62-19	9935-9941	target	_	
62-20	9942-9946	item	_	
62-21	9946-9947	.	_	

#Text=The task is to indicate which of the two comparison items is identical to the target item.
63-1	9948-9951	The	_	
63-2	9952-9956	task	_	
63-3	9957-9959	is	_	
63-4	9960-9962	to	_	
63-5	9963-9971	indicate	_	
63-6	9972-9977	which	_	
63-7	9978-9980	of	_	
63-8	9981-9984	the	_	
63-9	9985-9988	two	_	
63-10	9989-9999	comparison	_	
63-11	10000-10005	items	_	
63-12	10006-10008	is	_	
63-13	10009-10018	identical	_	
63-14	10019-10021	to	_	
63-15	10022-10025	the	_	
63-16	10026-10032	target	_	
63-17	10033-10037	item	_	
63-18	10037-10038	.	_	

#Text=Each face and object was presented for 5 s in an A–B block design.
64-1	10039-10043	Each	_	
64-2	10044-10048	face	_	
64-3	10049-10052	and	_	
64-4	10053-10059	object	_	
64-5	10060-10063	was	_	
64-6	10064-10073	presented	_	
64-7	10074-10077	for	_	
64-8	10078-10079	5	_	
64-9	10079-10080	 	_	
64-10	10080-10081	s	_	
64-11	10082-10084	in	_	
64-12	10085-10087	an	_	
64-13	10088-10091	A–B	_	
64-14	10092-10097	block	_	
64-15	10098-10104	design	_	
64-16	10104-10105	.	_	

#Text=Each block lasted around 30 s with a total experimental duration of 4.5 min.
65-1	10106-10110	Each	_	
65-2	10111-10116	block	_	
65-3	10117-10123	lasted	_	
65-4	10124-10130	around	_	
65-5	10131-10133	30	_	
65-6	10133-10134	 	_	
65-7	10134-10135	s	_	
65-8	10136-10140	with	_	
65-9	10141-10142	a	_	
65-10	10143-10148	total	_	
65-11	10149-10161	experimental	_	
65-12	10162-10170	duration	_	
65-13	10171-10173	of	_	
65-14	10174-10177	4.5	_	
65-15	10177-10178	 	_	
65-16	10178-10181	min	_	
65-17	10181-10182	.	_	

#Text=The task was presented with presentation (neurobehavioral systems) and responses were given via button press (current design).
66-1	10183-10186	The	_	
66-2	10187-10191	task	_	
66-3	10192-10195	was	_	
66-4	10196-10205	presented	_	
66-5	10206-10210	with	_	
66-6	10211-10223	presentation	_	
66-7	10224-10225	(	_	
66-8	10225-10240	neurobehavioral	_	
66-9	10241-10248	systems	_	
66-10	10248-10249	)	_	
66-11	10250-10253	and	_	
66-12	10254-10263	responses	_	
66-13	10264-10268	were	_	
66-14	10269-10274	given	_	
66-15	10275-10278	via	_	
66-16	10279-10285	button	_	
66-17	10286-10291	press	_	
66-18	10292-10293	(	_	
66-19	10293-10300	current	_	
66-20	10301-10307	design	_	
66-21	10307-10308	)	_	
66-22	10308-10309	.	_	

#Text=Data acquisition and analyses
#Text=Sociodemographic characteristics and clinical variables at baseline were compared between groups using parametric Student t test and χ2 test.
67-1	10310-10314	Data	_	
67-2	10315-10326	acquisition	_	
67-3	10327-10330	and	_	
67-4	10331-10339	analyses	_	
67-5	10340-10356	Sociodemographic	_	
67-6	10357-10372	characteristics	_	
67-7	10373-10376	and	_	
67-8	10377-10385	clinical	_	
67-9	10386-10395	variables	_	
67-10	10396-10398	at	_	
67-11	10399-10407	baseline	_	
67-12	10408-10412	were	_	
67-13	10413-10421	compared	_	
67-14	10422-10429	between	_	
67-15	10430-10436	groups	_	
67-16	10437-10442	using	_	
67-17	10443-10453	parametric	_	
67-18	10454-10461	Student	_	
67-19	10462-10463	t	_	
67-20	10464-10468	test	_	
67-21	10469-10472	and	_	
67-22	10473-10475	χ2	_	
67-23	10476-10480	test	_	
67-24	10480-10481	.	_	

#Text=In case the assumption of normal distribution was violated, non-parametric Mann–Whitney U test was applied.
68-1	10482-10484	In	_	
68-2	10485-10489	case	_	
68-3	10490-10493	the	_	
68-4	10494-10504	assumption	_	
68-5	10505-10507	of	_	
68-6	10508-10514	normal	_	
68-7	10515-10527	distribution	_	
68-8	10528-10531	was	_	
68-9	10532-10540	violated	_	
68-10	10540-10541	,	_	
68-11	10542-10556	non-parametric	_	
68-12	10557-10569	Mann–Whitney	_	
68-13	10570-10571	U	_	
68-14	10572-10576	test	_	
68-15	10577-10580	was	_	
68-16	10581-10588	applied	_	
68-17	10588-10589	.	_	

#Text=Effect-sizes were calculated for between-group differences using Cohens’ d for normally distributed and Rosenthals’ r for non-normally distributed data.
69-1	10590-10602	Effect-sizes	_	
69-2	10603-10607	were	_	
69-3	10608-10618	calculated	_	
69-4	10619-10622	for	_	
69-5	10623-10636	between-group	_	
69-6	10637-10648	differences	_	
69-7	10649-10654	using	_	
69-8	10655-10661	Cohens	_	
69-9	10661-10662	’	_	
69-10	10663-10664	d	_	
69-11	10665-10668	for	_	
69-12	10669-10677	normally	_	
69-13	10678-10689	distributed	_	
69-14	10690-10693	and	_	
69-15	10694-10704	Rosenthals	_	
69-16	10704-10705	’	_	
69-17	10706-10707	r	_	
69-18	10708-10711	for	_	
69-19	10712-10724	non-normally	_	
69-20	10725-10736	distributed	_	
69-21	10737-10741	data	_	
69-22	10741-10742	.	_	

#Text=Statistical analyses were performed using the Statistical package for Social Sciences (SPSS version 24.0, Chicago, IL, US), assuming a two-sided significance levels of α < 0.05.
70-1	10743-10754	Statistical	_	
70-2	10755-10763	analyses	_	
70-3	10764-10768	were	_	
70-4	10769-10778	performed	_	
70-5	10779-10784	using	_	
70-6	10785-10788	the	_	
70-7	10789-10800	Statistical	_	
70-8	10801-10808	package	_	
70-9	10809-10812	for	_	
70-10	10813-10819	Social	_	
70-11	10820-10828	Sciences	_	
70-12	10829-10830	(	_	
70-13	10830-10834	SPSS	_	
70-14	10835-10842	version	_	
70-15	10843-10847	24.0	_	
70-16	10847-10848	,	_	
70-17	10849-10856	Chicago	_	
70-18	10856-10857	,	_	
70-19	10858-10860	IL	_	
70-20	10860-10861	,	_	
70-21	10862-10864	US	_	
70-22	10864-10865	)	_	
70-23	10865-10866	,	_	
70-24	10867-10875	assuming	_	
70-25	10876-10877	a	_	
70-26	10878-10887	two-sided	_	
70-27	10888-10900	significance	_	
70-28	10901-10907	levels	_	
70-29	10908-10910	of	_	
70-30	10911-10912	α	_	
70-31	10913-10914	<	_	
70-32	10915-10919	0.05	_	
70-33	10919-10920	.	_	

#Text=Functional imaging data was acquired with a 3 T Siemens Tim TRIO (Siemens Erlangen).
71-1	10921-10931	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[20]	
71-2	10932-10939	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[20]	
71-3	10940-10944	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[20]	
71-4	10945-10948	was	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[20]	
71-5	10949-10957	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[20]	
71-6	10958-10962	with	_	
71-7	10963-10964	a	_	
71-8	10965-10966	3	_	
71-9	10966-10967	 	_	
71-10	10967-10968	T	_	
71-11	10969-10976	Siemens	_	
71-12	10977-10980	Tim	_	
71-13	10981-10985	TRIO	_	
71-14	10986-10987	(	_	
71-15	10987-10994	Siemens	_	
71-16	10995-11003	Erlangen	_	
71-17	11003-11004	)	_	
71-18	11004-11005	.	_	

#Text=An echo-planar imaging (EPI) sequence was used with the following parameters: 28 axial slices, field of view 19.2 cm, matrix 64 × 64, voxel size 3 × 3 × 5 mm3, repetition time 2000 ms, echo time 30 ms.
72-1	11006-11008	An	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-2	11009-11020	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-3	11021-11028	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-4	11029-11030	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-5	11030-11033	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-6	11033-11034	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-7	11035-11043	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
72-8	11044-11047	was	_	
72-9	11048-11052	used	_	
72-10	11053-11057	with	_	
72-11	11058-11061	the	_	
72-12	11062-11071	following	_	
72-13	11072-11082	parameters	_	
72-14	11082-11083	:	_	
72-15	11084-11086	28	_	
72-16	11087-11092	axial	_	
72-17	11093-11099	slices	_	
72-18	11099-11100	,	_	
72-19	11101-11106	field	_	
72-20	11107-11109	of	_	
72-21	11110-11114	view	_	
72-22	11115-11119	19.2	_	
72-23	11119-11120	 	_	
72-24	11120-11122	cm	_	
72-25	11122-11123	,	_	
72-26	11124-11130	matrix	_	
72-27	11131-11133	64	_	
72-28	11134-11135	×	_	
72-29	11136-11138	64	_	
72-30	11138-11139	,	_	
72-31	11140-11145	voxel	_	
72-32	11146-11150	size	_	
72-33	11151-11152	3	_	
72-34	11153-11154	×	_	
72-35	11155-11156	3	_	
72-36	11157-11158	×	_	
72-37	11159-11160	5	_	
72-38	11161-11164	mm3	_	
72-39	11164-11165	,	_	
72-40	11166-11176	repetition	_	
72-41	11177-11181	time	_	
72-42	11182-11186	2000	_	
72-43	11186-11187	 	_	
72-44	11187-11189	ms	_	
72-45	11189-11190	,	_	
72-46	11191-11195	echo	_	
72-47	11196-11200	time	_	
72-48	11201-11203	30	_	
72-49	11203-11204	 	_	
72-50	11204-11206	ms	_	
72-51	11206-11207	.	_	

#Text=Scans were acquired in descending order. 134 scans were acquired for the face-matching task.
73-1	11208-11213	Scans	_	
73-2	11214-11218	were	_	
73-3	11219-11227	acquired	_	
73-4	11228-11230	in	_	
73-5	11231-11241	descending	_	
73-6	11242-11247	order	_	
73-7	11247-11248	.	_	
73-8	11249-11252	134	_	
73-9	11253-11258	scans	_	
73-10	11259-11263	were	_	
73-11	11264-11272	acquired	_	
73-12	11273-11276	for	_	
73-13	11277-11280	the	_	
73-14	11281-11294	face-matching	_	
73-15	11295-11299	task	_	
73-16	11299-11300	.	_	

#Text=The first four volumes were discarded to account for saturation effects.
74-1	11301-11304	The	_	
74-2	11305-11310	first	_	
74-3	11311-11315	four	_	
74-4	11316-11323	volumes	_	
74-5	11324-11328	were	_	
74-6	11329-11338	discarded	_	
74-7	11339-11341	to	_	
74-8	11342-11349	account	_	
74-9	11350-11353	for	_	
74-10	11354-11364	saturation	_	
74-11	11365-11372	effects	_	
74-12	11372-11373	.	_	

#Text=Functional imaging data was analyzed using SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/).
75-1	11374-11384	Functional	_	
75-2	11385-11392	imaging	_	
75-3	11393-11397	data	_	
75-4	11398-11401	was	_	
75-5	11402-11410	analyzed	_	
75-6	11411-11416	using	_	
75-7	11417-11421	SPM8	_	
75-8	11422-11423	(	_	
75-9	11423-11427	http	_	
75-10	11427-11428	:	_	
75-11	11428-11429	/	_	
75-12	11429-11430	/	_	
75-13	11430-11451	www.fil.ion.ucl.ac.uk	_	
75-14	11451-11452	/	_	
75-15	11452-11455	spm	_	
75-16	11455-11456	/	_	
75-17	11456-11464	software	_	
75-18	11464-11465	/	_	
75-19	11465-11469	spm8	_	
75-20	11469-11470	/	_	
75-21	11470-11471	)	_	
75-22	11471-11472	.	_	

#Text=Pre-processing involved realignment, slice time correction, normalization to the standard MNI-EPI-template (Montreal Neurological Institute [MNI] EPI template) with resampling to an isotropic 3 × 3 × 3 mm voxel size and smoothing with a 9 mm full-width at half-maximum Gaussian filter.
76-1	11473-11487	Pre-processing	_	
76-2	11488-11496	involved	_	
76-3	11497-11508	realignment	_	
76-4	11508-11509	,	_	
76-5	11510-11515	slice	_	
76-6	11516-11520	time	_	
76-7	11521-11531	correction	_	
76-8	11531-11532	,	_	
76-9	11533-11546	normalization	_	
76-10	11547-11549	to	_	
76-11	11550-11553	the	_	
76-12	11554-11562	standard	_	
76-13	11563-11579	MNI-EPI-template	_	
76-14	11580-11581	(	_	
76-15	11581-11589	Montreal	_	
76-16	11590-11602	Neurological	_	
76-17	11603-11612	Institute	_	
76-18	11613-11614	[	_	
76-19	11614-11617	MNI	_	
76-20	11617-11618	]	_	
76-21	11619-11622	EPI	_	
76-22	11623-11631	template	_	
76-23	11631-11632	)	_	
76-24	11633-11637	with	_	
76-25	11638-11648	resampling	_	
76-26	11649-11651	to	_	
76-27	11652-11654	an	_	
76-28	11655-11664	isotropic	_	
76-29	11665-11666	3	_	
76-30	11667-11668	×	_	
76-31	11669-11670	3	_	
76-32	11671-11672	×	_	
76-33	11673-11674	3	_	
76-34	11674-11675	 	_	
76-35	11675-11677	mm	_	
76-36	11678-11683	voxel	_	
76-37	11684-11688	size	_	
76-38	11689-11692	and	_	
76-39	11693-11702	smoothing	_	
76-40	11703-11707	with	_	
76-41	11708-11709	a	_	
76-42	11710-11711	9	_	
76-43	11711-11712	 	_	
76-44	11712-11714	mm	_	
76-45	11715-11725	full-width	_	
76-46	11726-11728	at	_	
76-47	11729-11741	half-maximum	_	
76-48	11742-11750	Gaussian	_	
76-49	11751-11757	filter	_	
76-50	11757-11758	.	_	

#Text=To estimate individual neural activity, the general linear model (GLM) was applied to the BOLD-signal change.
77-1	11759-11761	To	_	
77-2	11762-11770	estimate	_	
77-3	11771-11781	individual	_	
77-4	11782-11788	neural	_	
77-5	11789-11797	activity	_	
77-6	11797-11798	,	_	
77-7	11799-11802	the	_	
77-8	11803-11810	general	_	
77-9	11811-11817	linear	_	
77-10	11818-11823	model	_	
77-11	11824-11825	(	_	
77-12	11825-11828	GLM	_	
77-13	11828-11829	)	_	
77-14	11830-11833	was	_	
77-15	11834-11841	applied	_	
77-16	11842-11844	to	_	
77-17	11845-11848	the	_	
77-18	11849-11860	BOLD-signal	_	
77-19	11861-11867	change	_	
77-20	11867-11868	.	_	

#Text=BOLD changes for each condition (faces, geometrical shapes) were modeled as a convolution of the canonical hemodynamic response function with a box-car function of the corresponding condition.
78-1	11869-11873	BOLD	_	
78-2	11874-11881	changes	_	
78-3	11882-11885	for	_	
78-4	11886-11890	each	_	
78-5	11891-11900	condition	_	
78-6	11901-11902	(	_	
78-7	11902-11907	faces	_	
78-8	11907-11908	,	_	
78-9	11909-11920	geometrical	_	
78-10	11921-11927	shapes	_	
78-11	11927-11928	)	_	
78-12	11929-11933	were	_	
78-13	11934-11941	modeled	_	
78-14	11942-11944	as	_	
78-15	11945-11946	a	_	
78-16	11947-11958	convolution	_	
78-17	11959-11961	of	_	
78-18	11962-11965	the	_	
78-19	11966-11975	canonical	_	
78-20	11976-11987	hemodynamic	_	
78-21	11988-11996	response	_	
78-22	11997-12005	function	_	
78-23	12006-12010	with	_	
78-24	12011-12012	a	_	
78-25	12013-12020	box-car	_	
78-26	12021-12029	function	_	
78-27	12030-12032	of	_	
78-28	12033-12036	the	_	
78-29	12037-12050	corresponding	_	
78-30	12051-12060	condition	_	
78-31	12060-12061	.	_	

#Text=Additionally, head movement was taken into account by means of six regressors (three translations, three rotations) obtained from realignment.
79-1	12062-12074	Additionally	_	
79-2	12074-12075	,	_	
79-3	12076-12080	head	_	
79-4	12081-12089	movement	_	
79-5	12090-12093	was	_	
79-6	12094-12099	taken	_	
79-7	12100-12104	into	_	
79-8	12105-12112	account	_	
79-9	12113-12115	by	_	
79-10	12116-12121	means	_	
79-11	12122-12124	of	_	
79-12	12125-12128	six	_	
79-13	12129-12139	regressors	_	
79-14	12140-12141	(	_	
79-15	12141-12146	three	_	
79-16	12147-12159	translations	_	
79-17	12159-12160	,	_	
79-18	12161-12166	three	_	
79-19	12167-12176	rotations	_	
79-20	12176-12177	)	_	
79-21	12178-12186	obtained	_	
79-22	12187-12191	from	_	
79-23	12192-12203	realignment	_	
79-24	12203-12204	.	_	

#Text=For functional connectivity analyses with the left amygdala (seed region), eigenvariate time series were extracted from this region, and used as an additional regressor in the second GLM analysis.
80-1	12205-12208	For	_	
80-2	12209-12219	functional	_	
80-3	12220-12232	connectivity	_	
80-4	12233-12241	analyses	_	
80-5	12242-12246	with	_	
80-6	12247-12250	the	_	
80-7	12251-12255	left	_	
80-8	12256-12264	amygdala	_	
80-9	12265-12266	(	_	
80-10	12266-12270	seed	_	
80-11	12271-12277	region	_	
80-12	12277-12278	)	_	
80-13	12278-12279	,	_	
80-14	12280-12292	eigenvariate	_	
80-15	12293-12297	time	_	
80-16	12298-12304	series	_	
80-17	12305-12309	were	_	
80-18	12310-12319	extracted	_	
80-19	12320-12324	from	_	
80-20	12325-12329	this	_	
80-21	12330-12336	region	_	
80-22	12336-12337	,	_	
80-23	12338-12341	and	_	
80-24	12342-12346	used	_	
80-25	12347-12349	as	_	
80-26	12350-12352	an	_	
80-27	12353-12363	additional	_	
80-28	12364-12373	regressor	_	
80-29	12374-12376	in	_	
80-30	12377-12380	the	_	
80-31	12381-12387	second	_	
80-32	12388-12391	GLM	_	
80-33	12392-12400	analysis	_	
80-34	12400-12401	.	_	

#Text=Further, eigenvariate time series from white matter and cerebrospinal fluid were extracted and used as covariates.
81-1	12402-12409	Further	_	
81-2	12409-12410	,	_	
81-3	12411-12423	eigenvariate	_	
81-4	12424-12428	time	_	
81-5	12429-12435	series	_	
81-6	12436-12440	from	_	
81-7	12441-12446	white	_	
81-8	12447-12453	matter	_	
81-9	12454-12457	and	_	
81-10	12458-12471	cerebrospinal	_	
81-11	12472-12477	fluid	_	
81-12	12478-12482	were	_	
81-13	12483-12492	extracted	_	
81-14	12493-12496	and	_	
81-15	12497-12501	used	_	
81-16	12502-12504	as	_	
81-17	12505-12515	covariates	_	
81-18	12515-12516	.	_	

#Text=To avoid confounding effects of task activation, amygdala’s eigenvariates were calculated after task activations were regressed out of the data in the first GLM.
82-1	12517-12519	To	_	
82-2	12520-12525	avoid	_	
82-3	12526-12537	confounding	_	
82-4	12538-12545	effects	_	
82-5	12546-12548	of	_	
82-6	12549-12553	task	_	
82-7	12554-12564	activation	_	
82-8	12564-12565	,	_	
82-9	12566-12574	amygdala	_	
82-10	12574-12575	’	_	
82-11	12575-12576	s	_	
82-12	12577-12590	eigenvariates	_	
82-13	12591-12595	were	_	
82-14	12596-12606	calculated	_	
82-15	12607-12612	after	_	
82-16	12613-12617	task	_	
82-17	12618-12629	activations	_	
82-18	12630-12634	were	_	
82-19	12635-12644	regressed	_	
82-20	12645-12648	out	_	
82-21	12649-12651	of	_	
82-22	12652-12655	the	_	
82-23	12656-12660	data	_	
82-24	12661-12663	in	_	
82-25	12664-12667	the	_	
82-26	12668-12673	first	_	
82-27	12674-12677	GLM	_	
82-28	12677-12678	.	_	

#Text=For activity analyses of the contrast faces > geometrical figures, second-level group statistics were conducted by one-sample and two-sample t tests, and regression analyses.
83-1	12679-12682	For	_	
83-2	12683-12691	activity	_	
83-3	12692-12700	analyses	_	
83-4	12701-12703	of	_	
83-5	12704-12707	the	_	
83-6	12708-12716	contrast	_	
83-7	12717-12722	faces	_	
83-8	12723-12724	>	_	
83-9	12725-12736	geometrical	_	
83-10	12737-12744	figures	_	
83-11	12744-12745	,	_	
83-12	12746-12758	second-level	_	
83-13	12759-12764	group	_	
83-14	12765-12775	statistics	_	
83-15	12776-12780	were	_	
83-16	12781-12790	conducted	_	
83-17	12791-12793	by	_	
83-18	12794-12804	one-sample	_	
83-19	12805-12808	and	_	
83-20	12809-12819	two-sample	_	
83-21	12820-12821	t	_	
83-22	12822-12827	tests	_	
83-23	12827-12828	,	_	
83-24	12829-12832	and	_	
83-25	12833-12843	regression	_	
83-26	12844-12852	analyses	_	
83-27	12852-12853	.	_	

#Text=Second-level connectivity analyses were achieved with two-sample t test.
84-1	12854-12866	Second-level	_	
84-2	12867-12879	connectivity	_	
84-3	12880-12888	analyses	_	
84-4	12889-12893	were	_	
84-5	12894-12902	achieved	_	
84-6	12903-12907	with	_	
84-7	12908-12918	two-sample	_	
84-8	12919-12920	t	_	
84-9	12921-12925	test	_	
84-10	12925-12926	.	_	

#Text=Significance threshold at the voxel level was set to p < 0.05 FWE corrected, k = 10 for whole brain analyses.
85-1	12927-12939	Significance	_	
85-2	12940-12949	threshold	_	
85-3	12950-12952	at	_	
85-4	12953-12956	the	_	
85-5	12957-12962	voxel	_	
85-6	12963-12968	level	_	
85-7	12969-12972	was	_	
85-8	12973-12976	set	_	
85-9	12977-12979	to	_	
85-10	12980-12981	p	_	
85-11	12982-12983	<	_	
85-12	12984-12988	0.05	_	
85-13	12989-12992	FWE	_	
85-14	12993-13002	corrected	_	
85-15	13002-13003	,	_	
85-16	13004-13005	k	_	
85-17	13006-13007	=	_	
85-18	13008-13010	10	_	
85-19	13011-13014	for	_	
85-20	13015-13020	whole	_	
85-21	13021-13026	brain	_	
85-22	13027-13035	analyses	_	
85-23	13035-13036	.	_	

#Text=In addition, region of interest (ROI) analyses for activity differences were conducted for left and right amygdala.
86-1	13037-13039	In	_	
86-2	13040-13048	addition	_	
86-3	13048-13049	,	_	
86-4	13050-13056	region	_	
86-5	13057-13059	of	_	
86-6	13060-13068	interest	_	
86-7	13069-13070	(	_	
86-8	13070-13073	ROI	_	
86-9	13073-13074	)	_	
86-10	13075-13083	analyses	_	
86-11	13084-13087	for	_	
86-12	13088-13096	activity	_	
86-13	13097-13108	differences	_	
86-14	13109-13113	were	_	
86-15	13114-13123	conducted	_	
86-16	13124-13127	for	_	
86-17	13128-13132	left	_	
86-18	13133-13136	and	_	
86-19	13137-13142	right	_	
86-20	13143-13151	amygdala	_	
86-21	13151-13152	.	_	

#Text=Furthermore, to investigate differences between groups in connectivity of the amygdala with the corticolimbic-ventral striatal circuitry, we applied ROIs for left and right ventral striatum.
87-1	13153-13164	Furthermore	_	
87-2	13164-13165	,	_	
87-3	13166-13168	to	_	
87-4	13169-13180	investigate	_	
87-5	13181-13192	differences	_	
87-6	13193-13200	between	_	
87-7	13201-13207	groups	_	
87-8	13208-13210	in	_	
87-9	13211-13223	connectivity	_	
87-10	13224-13226	of	_	
87-11	13227-13230	the	_	
87-12	13231-13239	amygdala	_	
87-13	13240-13244	with	_	
87-14	13245-13248	the	_	
87-15	13249-13270	corticolimbic-ventral	_	
87-16	13271-13279	striatal	_	
87-17	13280-13289	circuitry	_	
87-18	13289-13290	,	_	
87-19	13291-13293	we	_	
87-20	13294-13301	applied	_	
87-21	13302-13306	ROIs	_	
87-22	13307-13310	for	_	
87-23	13311-13315	left	_	
87-24	13316-13319	and	_	
87-25	13320-13325	right	_	
87-26	13326-13333	ventral	_	
87-27	13334-13342	striatum	_	
87-28	13342-13343	.	_	

#Text=Masks were taken from the Wake Forest University (WFU)-Pickatlas.
88-1	13344-13349	Masks	_	
88-2	13350-13354	were	_	
88-3	13355-13360	taken	_	
88-4	13361-13365	from	_	
88-5	13366-13369	the	_	
88-6	13370-13374	Wake	_	
88-7	13375-13381	Forest	_	
88-8	13382-13392	University	_	
88-9	13393-13394	(	_	
88-10	13394-13397	WFU	_	
88-11	13397-13398	)	_	
88-12	13398-13399	-	_	
88-13	13399-13408	Pickatlas	_	
88-14	13408-13409	.	_	

#Text=The ROI of the left amygdala was also taken for eigenvariate extraction for functional connectivity.
89-1	13410-13413	The	_	
89-2	13414-13417	ROI	_	
89-3	13418-13420	of	_	
89-4	13421-13424	the	_	
89-5	13425-13429	left	_	
89-6	13430-13438	amygdala	_	
89-7	13439-13442	was	_	
89-8	13443-13447	also	_	
89-9	13448-13453	taken	_	
89-10	13454-13457	for	_	
89-11	13458-13470	eigenvariate	_	
89-12	13471-13481	extraction	_	
89-13	13482-13485	for	_	
89-14	13486-13496	functional	_	
89-15	13497-13509	connectivity	_	
89-16	13509-13510	.	_	

#Text=Significance threshold for the ROI analyses at the voxel level was set to p < 0.05, small volume corrected (svc), k = 10.
90-1	13511-13523	Significance	_	
90-2	13524-13533	threshold	_	
90-3	13534-13537	for	_	
90-4	13538-13541	the	_	
90-5	13542-13545	ROI	_	
90-6	13546-13554	analyses	_	
90-7	13555-13557	at	_	
90-8	13558-13561	the	_	
90-9	13562-13567	voxel	_	
90-10	13568-13573	level	_	
90-11	13574-13577	was	_	
90-12	13578-13581	set	_	
90-13	13582-13584	to	_	
90-14	13585-13586	p	_	
90-15	13587-13588	<	_	
90-16	13589-13593	0.05	_	
90-17	13593-13594	,	_	
90-18	13595-13600	small	_	
90-19	13601-13607	volume	_	
90-20	13608-13617	corrected	_	
90-21	13618-13619	(	_	
90-22	13619-13622	svc	_	
90-23	13622-13623	)	_	
90-24	13623-13624	,	_	
90-25	13625-13626	k	_	
90-26	13627-13628	=	_	
90-27	13629-13631	10	_	
90-28	13631-13632	.	_	

#Text=Results
#Text=Sociodemographic characteristics and clinical assessment
#Text=Comparisons between group I [n = 20; olanzapine (n = 7) + clozapine (n = 13)] and group II [n = 20; amisulpride (n = 8) + aripiprazole (n = 12)] are presented in Table1.
91-1	13633-13640	Results	_	
91-2	13641-13657	Sociodemographic	_	
91-3	13658-13673	characteristics	_	
91-4	13674-13677	and	_	
91-5	13678-13686	clinical	_	
91-6	13687-13697	assessment	_	
91-7	13698-13709	Comparisons	_	
91-8	13710-13717	between	_	
91-9	13718-13723	group	_	
91-10	13724-13725	I	_	
91-11	13726-13727	[	_	
91-12	13727-13728	n	_	
91-13	13729-13730	=	_	
91-14	13731-13733	20	_	
91-15	13733-13734	;	_	
91-16	13735-13745	olanzapine	_	
91-17	13746-13747	(	_	
91-18	13747-13748	n	_	
91-19	13749-13750	=	_	
91-20	13751-13752	7	_	
91-21	13752-13753	)	_	
91-22	13754-13755	+	_	
91-23	13756-13765	clozapine	_	
91-24	13766-13767	(	_	
91-25	13767-13768	n	_	
91-26	13769-13770	=	_	
91-27	13771-13773	13	_	
91-28	13773-13774	)	_	
91-29	13774-13775	]	_	
91-30	13776-13779	and	_	
91-31	13780-13785	group	_	
91-32	13786-13788	II	_	
91-33	13789-13790	[	_	
91-34	13790-13791	n	_	
91-35	13792-13793	=	_	
91-36	13794-13796	20	_	
91-37	13796-13797	;	_	
91-38	13798-13809	amisulpride	_	
91-39	13810-13811	(	_	
91-40	13811-13812	n	_	
91-41	13813-13814	=	_	
91-42	13815-13816	8	_	
91-43	13816-13817	)	_	
91-44	13818-13819	+	_	
91-45	13820-13832	aripiprazole	_	
91-46	13833-13834	(	_	
91-47	13834-13835	n	_	
91-48	13836-13837	=	_	
91-49	13838-13840	12	_	
91-50	13840-13841	)	_	
91-51	13841-13842	]	_	
91-52	13843-13846	are	_	
91-53	13847-13856	presented	_	
91-54	13857-13859	in	_	
91-55	13860-13866	Table1	_	
91-56	13866-13867	.	_	

#Text=Analyses showed no significant differences between group I and group II in terms of age, gender, premorbid estimated verbal IQ, or education.
92-1	13868-13876	Analyses	_	
92-2	13877-13883	showed	_	
92-3	13884-13886	no	_	
92-4	13887-13898	significant	_	
92-5	13899-13910	differences	_	
92-6	13911-13918	between	_	
92-7	13919-13924	group	_	
92-8	13925-13926	I	_	
92-9	13927-13930	and	_	
92-10	13931-13936	group	_	
92-11	13937-13939	II	_	
92-12	13940-13942	in	_	
92-13	13943-13948	terms	_	
92-14	13949-13951	of	_	
92-15	13952-13955	age	_	
92-16	13955-13956	,	_	
92-17	13957-13963	gender	_	
92-18	13963-13964	,	_	
92-19	13965-13974	premorbid	_	
92-20	13975-13984	estimated	_	
92-21	13985-13991	verbal	_	
92-22	13992-13994	IQ	_	
92-23	13994-13995	,	_	
92-24	13996-13998	or	_	
92-25	13999-14008	education	_	
92-26	14008-14009	.	_	

#Text=No significant differences (χ2 = 3.683 p = 0.159) were observed with respect to concomitant treatment with antidepressants (reboxetine and bupropion).
93-1	14010-14012	No	_	
93-2	14013-14024	significant	_	
93-3	14025-14036	differences	_	
93-4	14037-14038	(	_	
93-5	14038-14040	χ2	_	
93-6	14041-14042	=	_	
93-7	14043-14048	3.683	_	
93-8	14049-14050	p	_	
93-9	14051-14052	=	_	
93-10	14053-14058	0.159	_	
93-11	14058-14059	)	_	
93-12	14060-14064	were	_	
93-13	14065-14073	observed	_	
93-14	14074-14078	with	_	
93-15	14079-14086	respect	_	
93-16	14087-14089	to	_	
93-17	14090-14101	concomitant	_	
93-18	14102-14111	treatment	_	
93-19	14112-14116	with	_	
93-20	14117-14132	antidepressants	_	
93-21	14133-14134	(	_	
93-22	14134-14144	reboxetine	_	
93-23	14145-14148	and	_	
93-24	14149-14158	bupropion	_	
93-25	14158-14159	)	_	
93-26	14159-14160	.	_	

#Text=As previously reported, groups largely differed in frequency and severity of co-occurring OCS.
94-1	14161-14163	As	_	
94-2	14164-14174	previously	_	
94-3	14175-14183	reported	_	
94-4	14183-14184	,	_	
94-5	14185-14191	groups	_	
94-6	14192-14199	largely	_	
94-7	14200-14208	differed	_	
94-8	14209-14211	in	_	
94-9	14212-14221	frequency	_	
94-10	14222-14225	and	_	
94-11	14226-14234	severity	_	
94-12	14235-14237	of	_	
94-13	14238-14250	co-occurring	_	
94-14	14251-14254	OCS	_	
94-15	14254-14255	.	_	

#Text=Whereas only one patient in group II reported at least mild symptom severity (YBOCS ≥ 8) according to interpretation guidelines, 14 patients within group I fulfilled this criterion.
95-1	14256-14263	Whereas	_	
95-2	14264-14268	only	_	
95-3	14269-14272	one	_	
95-4	14273-14280	patient	_	
95-5	14281-14283	in	_	
95-6	14284-14289	group	_	
95-7	14290-14292	II	_	
95-8	14293-14301	reported	_	
95-9	14302-14304	at	_	
95-10	14305-14310	least	_	
95-11	14311-14315	mild	_	
95-12	14316-14323	symptom	_	
95-13	14324-14332	severity	_	
95-14	14333-14334	(	_	
95-15	14334-14339	YBOCS	_	
95-16	14340-14341	≥	_	
95-17	14342-14343	8	_	
95-18	14343-14344	)	_	
95-19	14345-14354	according	_	
95-20	14355-14357	to	_	
95-21	14358-14372	interpretation	_	
95-22	14373-14383	guidelines	_	
95-23	14383-14384	,	_	
95-24	14385-14387	14	_	
95-25	14388-14396	patients	_	
95-26	14397-14403	within	_	
95-27	14404-14409	group	_	
95-28	14410-14411	I	_	
95-29	14412-14421	fulfilled	_	
95-30	14422-14426	this	_	
95-31	14427-14436	criterion	_	
95-32	14436-14437	.	_	

#Text=Of these 14, only 3 reported OCS onset prior to initiation of clozapine or olanzapine medication.
96-1	14438-14440	Of	_	
96-2	14441-14446	these	_	
96-3	14447-14449	14	_	
96-4	14449-14450	,	_	
96-5	14451-14455	only	_	
96-6	14456-14457	3	_	
96-7	14458-14466	reported	_	
96-8	14467-14470	OCS	_	
96-9	14471-14476	onset	_	
96-10	14477-14482	prior	_	
96-11	14483-14485	to	_	
96-12	14486-14496	initiation	_	
96-13	14497-14499	of	_	
96-14	14500-14509	clozapine	_	
96-15	14510-14512	or	_	
96-16	14513-14523	olanzapine	_	
96-17	14524-14534	medication	_	
96-18	14534-14535	.	_	

#Text=Results of the HZI showed that compulsions mainly consisted of checking and counting behavior.
97-1	14536-14543	Results	_	
97-2	14544-14546	of	_	
97-3	14547-14550	the	_	
97-4	14551-14554	HZI	_	
97-5	14555-14561	showed	_	
97-6	14562-14566	that	_	
97-7	14567-14578	compulsions	_	
97-8	14579-14585	mainly	_	
97-9	14586-14595	consisted	_	
97-10	14596-14598	of	_	
97-11	14599-14607	checking	_	
97-12	14608-14611	and	_	
97-13	14612-14620	counting	_	
97-14	14621-14629	behavior	_	
97-15	14629-14630	.	_	

#Text=Groups did not differ in duration of illness before index treatment, the severity of positive symptoms, depressive symptoms, general psychopathology or the level of psychosocial functioning.
98-1	14631-14637	Groups	_	
98-2	14638-14641	did	_	
98-3	14642-14645	not	_	
98-4	14646-14652	differ	_	
98-5	14653-14655	in	_	
98-6	14656-14664	duration	_	
98-7	14665-14667	of	_	
98-8	14668-14675	illness	_	
98-9	14676-14682	before	_	
98-10	14683-14688	index	_	
98-11	14689-14698	treatment	_	
98-12	14698-14699	,	_	
98-13	14700-14703	the	_	
98-14	14704-14712	severity	_	
98-15	14713-14715	of	_	
98-16	14716-14724	positive	_	
98-17	14725-14733	symptoms	_	
98-18	14733-14734	,	_	
98-19	14735-14745	depressive	_	
98-20	14746-14754	symptoms	_	
98-21	14754-14755	,	_	
98-22	14756-14763	general	_	
98-23	14764-14779	psychopathology	_	
98-24	14780-14782	or	_	
98-25	14783-14786	the	_	
98-26	14787-14792	level	_	
98-27	14793-14795	of	_	
98-28	14796-14808	psychosocial	_	
98-29	14809-14820	functioning	_	
98-30	14820-14821	.	_	

#Text=Patients in group I tended to show higher overall severity of negative symptoms according to PANSS rating, however, no differences in specific negative symptom domains were found (see SANS in Table 1).
99-1	14822-14830	Patients	_	
99-2	14831-14833	in	_	
99-3	14834-14839	group	_	
99-4	14840-14841	I	_	
99-5	14842-14848	tended	_	
99-6	14849-14851	to	_	
99-7	14852-14856	show	_	
99-8	14857-14863	higher	_	
99-9	14864-14871	overall	_	
99-10	14872-14880	severity	_	
99-11	14881-14883	of	_	
99-12	14884-14892	negative	_	
99-13	14893-14901	symptoms	_	
99-14	14902-14911	according	_	
99-15	14912-14914	to	_	
99-16	14915-14920	PANSS	_	
99-17	14921-14927	rating	_	
99-18	14927-14928	,	_	
99-19	14929-14936	however	_	
99-20	14936-14937	,	_	
99-21	14938-14940	no	_	
99-22	14941-14952	differences	_	
99-23	14953-14955	in	_	
99-24	14956-14964	specific	_	
99-25	14965-14973	negative	_	
99-26	14974-14981	symptom	_	
99-27	14982-14989	domains	_	
99-28	14990-14994	were	_	
99-29	14995-15000	found	_	
99-30	15001-15002	(	_	
99-31	15002-15005	see	_	
99-32	15006-15010	SANS	_	
99-33	15011-15013	in	_	
99-34	15014-15019	Table	_	
99-35	15019-15020	 	_	
99-36	15020-15021	1	_	
99-37	15021-15022	)	_	
99-38	15022-15023	.	_	

#Text=No differences in CPZ dosage equivalents were found between the two groups, referring to the following mean (± SD) dosages (clozapine: 348.1 ± 144.5; olanzapine: 16.4 ± 4.8; amisulpride: 425.0 ± 190.9; aripiprazole: 17.5 ± 6.2).
100-1	15024-15026	No	_	
100-2	15027-15038	differences	_	
100-3	15039-15041	in	_	
100-4	15042-15045	CPZ	_	
100-5	15046-15052	dosage	_	
100-6	15053-15064	equivalents	_	
100-7	15065-15069	were	_	
100-8	15070-15075	found	_	
100-9	15076-15083	between	_	
100-10	15084-15087	the	_	
100-11	15088-15091	two	_	
100-12	15092-15098	groups	_	
100-13	15098-15099	,	_	
100-14	15100-15109	referring	_	
100-15	15110-15112	to	_	
100-16	15113-15116	the	_	
100-17	15117-15126	following	_	
100-18	15127-15131	mean	_	
100-19	15132-15133	(	_	
100-20	15133-15134	±	_	
100-21	15135-15137	SD	_	
100-22	15137-15138	)	_	
100-23	15139-15146	dosages	_	
100-24	15147-15148	(	_	
100-25	15148-15157	clozapine	_	
100-26	15157-15158	:	_	
100-27	15159-15164	348.1	_	
100-28	15165-15166	±	_	
100-29	15167-15172	144.5	_	
100-30	15172-15173	;	_	
100-31	15174-15184	olanzapine	_	
100-32	15184-15185	:	_	
100-33	15186-15190	16.4	_	
100-34	15191-15192	±	_	
100-35	15193-15196	4.8	_	
100-36	15196-15197	;	_	
100-37	15198-15209	amisulpride	_	
100-38	15209-15210	:	_	
100-39	15211-15216	425.0	_	
100-40	15217-15218	±	_	
100-41	15219-15224	190.9	_	
100-42	15224-15225	;	_	
100-43	15226-15238	aripiprazole	_	
100-44	15238-15239	:	_	
100-45	15240-15244	17.5	_	
100-46	15245-15246	±	_	
100-47	15247-15250	6.2	_	
100-48	15250-15251	)	_	
100-49	15251-15252	.	_	

#Text=Between-group differences in sociodemographic and clinical characteristics
#Text=\tGroup I (n = 20)Mean ± SD, 95% CI\tGroup II (n = 20)Mean ± SD, 95% CI\tBetween-group differences\tEffect size\t \tSociodemographics\t \t Age\t40.7 ± 9.8, (36.1, 45.3)\t38.9 ± 10.8, (33.8, 44.0)\tT = 0.551 p = 0.585\td = 0.17\t \t Male/female ratio\t18:2\t13:7\tχ2 = 3.584 p = 0.058\tOR 4.85\t \t Duration of illness before ‘index treatmenta’ (years)\t7.5 ± 8.8, (3.4, 11.6)\t5.5 ± 6.6, (2.3, 8.6)\tT = 0.805 p = 0.426\td = 0.26\t \t Education (years)\t11.5 ± 1.7, (10.7, 12.3)\t11.2 ± 1.8, (10.4, 12.0)\tT = 0.524 p = 0.594\td = 0.17\t \t Premorbid intelligence\t111.5 ± 16.6, (103.7, 119.2)\t110.4 ± 12.5, (104.7, 116.9)\tT = 0.212 p = 0.833\td = 0.07\t \tAntipsychotic medication\t \t Duration of index treatment (years)\t6.8 ± 4.9, (4.5, 9.1)\t1.7 ± 1.9, (0.8, 2.6)\tT = 4.326 p < 0.001\td = 1.37\t \t Dosage mg/day (CPZ)\t336.7 ± 122.8, (279.3, 394.2)\t321.8 ± 124.8, (248.0, 372.0)\tT = 0.376 p = 0.709\td = 0.12\t \tPsychopathology\t \t YBOCS\t \t  Obsessions\t6.4 ± 4.7, (4.1, 8.6)\t0.3 ± 1.3, (− 0.3, 0.9)\tZ = − 4.235 p < 0.001\tr = 0.67\t \t  Compulsions\t6.1 ± 5.4, (3.5, 8.6)\t1.4 ± 2.8, (0.0, 2.7)\tZ = − 2.966 p = 0.008\tr = 0.47\t \t  Total\t12.4 ± 9.2, (8.1, 16.7)\t1.6 ± 3.8, (− 0.2, 3.4)\tZ = − 3.892 p < 0.001\tr = 0.62\t \t HZI\t \t  Checking\t5.1 ± 3.0, (3.7, 6.5)\t2.3 ± 2.1, (1.3, 3.3)\tZ = − 3.040 p = 0.002\tr = 0.48\t \t  Washing\t1.5 ± 1.7, (0.7, 2.4)\t1.6 ± 1.6, (0.8, 2.4)\tZ = − 0.242 p = 0.817\tr = 0.04\t \t  Ordering\t2.6 ± 1.7, (1.8, 3.5)\t2.2 ± 1.5, (1.5, 2.9)\tZ = − 0.688 p = 0.506\tr = 0.11\t \t  Counting\t2.2 ± 2.4, (1.0, 3.4)\t0.5 ± 0.8, (0.5, 0.2)\tZ = − 2.662 p = 0.012\tr = 0.42\t \t  Obsessions\t2.3 ± 2.0, (1.3, 3.2)\t2.2 ± 1.5, (2.2, 1.4)\tZ = − 0.210 p = 0.840\tr = 0.03\t \t  Aggressive obsessions\t1.3 ± 1.9, (0.4, 2.2)\t0.3 ± 0.7, (− 0.1, 0.6)\tZ = − 1.953 p = 0.123\tr = 0.31\t \t PANSS\t \t  Positive Scale\t13.8 ± 3.1, (12.3, 15.2)\t13.0 ± 3.0, (11.6, 14.4)\tT = 0.780 p = 0.440\td = 0.26\t \t  Negative Scale\t16.7 ± 4.3, (14.7, 18.7)\t13.8 ± 4.4, (11.7, 15.8)\tT = 2.134 p = 0.039\td = 0.67\t \t  General psychopathology\t34.3 ± 4.7, (32.0, 36.5)\t32.0 ± 5.4, (29.4, 34.5)\tT = 1.436 p = 0.159\td = 0.54\t \tSANS\t \t Affective flattening\t1.6 ± 1.2, (1.0, 2.1)\t1.3 ± 1.2, (0.7, 1.8)\tT = 0.791 p = 0.434\td = 0.25\t \t  Alogia\t1.5 ± 1.2, (0.9, 2.1)\t1.0 ± 1.1, (0.4, 1.5)\tT = 1.488 p = 0.145\td = 0.43\t \t  Avolition–apathy\t2.0 ± 1.0, (1.6, 2.6)\t1.5 ± 1.3, (0.9, 2.1)\tT = 1.641 p = 0.109\td = 0.43\t \t  Anhedonia\t2.0 ± 1.0, (1.5, 2.5)\t1.5 ± 1.5, (0.7, 2.2)\tT = 1.351 p = 0.185\td = 0.39\t \t  Attention\t2.0 ± 1.3, (1.3, 2.6)\t1.5 ± 1.3, (0.9, 2.1)\tT = 1.219 p = 0.230\td = 0.38\t \tCDSS\t1.1 ± 1.5, (0.4, 1.8)\t1.8 ± 2.8, (0.5, 3.1)\tT = − 0.993 p = 0.327\td = 0.31\t \tPSP\t67.6 ± 6.5, (64.6, 70.6)\t71.1 ± 7.1, (67.7, 70.6)\tT = − 1.610 p = 0.116\td = 0.51\t \t
#Text=CDSS Calgary Depression Scale for Schizophrenia, CI confidence interval, CPZ chlorpromazine equivalents, HZI Hamburger Zwangsinventar, OR odds ratio, PANSS Positive and Negative Syndrome Scale, PSP Personal and Social Performance Scale, SD standard deviation, SANS Scale for the Assessment of Negative Symptoms, YBOCS Yale–Brown Obsessive–Compulsive Scale
#Text=aTreatment with clozapine, olanzapine, aripiprazole or amisulpride
#Text=Functional MRI
#Text=Behavioral data
#Text=The two groups did not significantly differ in their performance in the face-matching task, neither regarding percent of correct answers (ps > 0.31) (group I: faces: 95.83 ± 9.70; forms: 97.71 ± 3.70; group II faces: 98.12 ± 2.52; forms: 97.29 ± 3.39) nor regarding reaction times (ps > 0.77) (group I: faces: 1619.83 ± 443.30 ms; forms: 1243.08 ± 354.39 ms; group II: faces: 1583.79 ± 322.47 ms; forms: 1230.11 ± 260.61 ms).
101-1	15253-15266	Between-group	_	
101-2	15267-15278	differences	_	
101-3	15279-15281	in	_	
101-4	15282-15298	sociodemographic	_	
101-5	15299-15302	and	_	
101-6	15303-15311	clinical	_	
101-7	15312-15327	characteristics	_	
101-8	15329-15334	Group	_	
101-9	15335-15336	I	_	
101-10	15337-15338	(	_	
101-11	15338-15339	n	_	
101-12	15340-15341	=	_	
101-13	15342-15344	20	_	
101-14	15344-15345	)	_	
101-15	15345-15349	Mean	_	
101-16	15350-15351	±	_	
101-17	15352-15354	SD	_	
101-18	15354-15355	,	_	
101-19	15356-15359	95%	_	
101-20	15360-15362	CI	_	
101-21	15363-15368	Group	_	
101-22	15369-15371	II	_	
101-23	15372-15373	(	_	
101-24	15373-15374	n	_	
101-25	15375-15376	=	_	
101-26	15377-15379	20	_	
101-27	15379-15380	)	_	
101-28	15380-15384	Mean	_	
101-29	15385-15386	±	_	
101-30	15387-15389	SD	_	
101-31	15389-15390	,	_	
101-32	15391-15394	95%	_	
101-33	15395-15397	CI	_	
101-34	15398-15411	Between-group	_	
101-35	15412-15423	differences	_	
101-36	15424-15430	Effect	_	
101-37	15431-15435	size	_	
101-38	15438-15455	Sociodemographics	_	
101-39	15458-15459	 	_	
101-40	15459-15462	Age	_	
101-41	15463-15467	40.7	_	
101-42	15468-15469	±	_	
101-43	15470-15473	9.8	_	
101-44	15473-15474	,	_	
101-45	15475-15476	(	_	
101-46	15476-15480	36.1	_	
101-47	15480-15481	,	_	
101-48	15482-15486	45.3	_	
101-49	15486-15487	)	_	
101-50	15488-15492	38.9	_	
101-51	15493-15494	±	_	
101-52	15495-15499	10.8	_	
101-53	15499-15500	,	_	
101-54	15501-15502	(	_	
101-55	15502-15506	33.8	_	
101-56	15506-15507	,	_	
101-57	15508-15512	44.0	_	
101-58	15512-15513	)	_	
101-59	15514-15515	T	_	
101-60	15516-15517	=	_	
101-61	15518-15523	0.551	_	
101-62	15524-15525	p	_	
101-63	15526-15527	=	_	
101-64	15528-15533	0.585	_	
101-65	15534-15535	d	_	
101-66	15536-15537	=	_	
101-67	15538-15542	0.17	_	
101-68	15545-15546	 	_	
101-69	15546-15550	Male	_	
101-70	15550-15551	/	_	
101-71	15551-15557	female	_	
101-72	15558-15563	ratio	_	
101-73	15564-15566	18	_	
101-74	15566-15567	:	_	
101-75	15567-15568	2	_	
101-76	15569-15571	13	_	
101-77	15571-15572	:	_	
101-78	15572-15573	7	_	
101-79	15574-15576	χ2	_	
101-80	15577-15578	=	_	
101-81	15579-15584	3.584	_	
101-82	15585-15586	p	_	
101-83	15587-15588	=	_	
101-84	15589-15594	0.058	_	
101-85	15595-15597	OR	_	
101-86	15598-15602	4.85	_	
101-87	15605-15606	 	_	
101-88	15606-15614	Duration	_	
101-89	15615-15617	of	_	
101-90	15618-15625	illness	_	
101-91	15626-15632	before	_	
101-92	15633-15634	‘	_	
101-93	15634-15639	index	_	
101-94	15640-15650	treatmenta	_	
101-95	15650-15651	’	_	
101-96	15652-15653	(	_	
101-97	15653-15658	years	_	
101-98	15658-15659	)	_	
101-99	15660-15663	7.5	_	
101-100	15664-15665	±	_	
101-101	15666-15669	8.8	_	
101-102	15669-15670	,	_	
101-103	15671-15672	(	_	
101-104	15672-15675	3.4	_	
101-105	15675-15676	,	_	
101-106	15677-15681	11.6	_	
101-107	15681-15682	)	_	
101-108	15683-15686	5.5	_	
101-109	15687-15688	±	_	
101-110	15689-15692	6.6	_	
101-111	15692-15693	,	_	
101-112	15694-15695	(	_	
101-113	15695-15698	2.3	_	
101-114	15698-15699	,	_	
101-115	15700-15703	8.6	_	
101-116	15703-15704	)	_	
101-117	15705-15706	T	_	
101-118	15707-15708	=	_	
101-119	15709-15714	0.805	_	
101-120	15715-15716	p	_	
101-121	15717-15718	=	_	
101-122	15719-15724	0.426	_	
101-123	15725-15726	d	_	
101-124	15727-15728	=	_	
101-125	15729-15733	0.26	_	
101-126	15736-15737	 	_	
101-127	15737-15746	Education	_	
101-128	15747-15748	(	_	
101-129	15748-15753	years	_	
101-130	15753-15754	)	_	
101-131	15755-15759	11.5	_	
101-132	15760-15761	±	_	
101-133	15762-15765	1.7	_	
101-134	15765-15766	,	_	
101-135	15767-15768	(	_	
101-136	15768-15772	10.7	_	
101-137	15772-15773	,	_	
101-138	15774-15778	12.3	_	
101-139	15778-15779	)	_	
101-140	15780-15784	11.2	_	
101-141	15785-15786	±	_	
101-142	15787-15790	1.8	_	
101-143	15790-15791	,	_	
101-144	15792-15793	(	_	
101-145	15793-15797	10.4	_	
101-146	15797-15798	,	_	
101-147	15799-15803	12.0	_	
101-148	15803-15804	)	_	
101-149	15805-15806	T	_	
101-150	15807-15808	=	_	
101-151	15809-15814	0.524	_	
101-152	15815-15816	p	_	
101-153	15817-15818	=	_	
101-154	15819-15824	0.594	_	
101-155	15825-15826	d	_	
101-156	15827-15828	=	_	
101-157	15829-15833	0.17	_	
101-158	15836-15837	 	_	
101-159	15837-15846	Premorbid	_	
101-160	15847-15859	intelligence	_	
101-161	15860-15865	111.5	_	
101-162	15866-15867	±	_	
101-163	15868-15872	16.6	_	
101-164	15872-15873	,	_	
101-165	15874-15875	(	_	
101-166	15875-15880	103.7	_	
101-167	15880-15881	,	_	
101-168	15882-15887	119.2	_	
101-169	15887-15888	)	_	
101-170	15889-15894	110.4	_	
101-171	15895-15896	±	_	
101-172	15897-15901	12.5	_	
101-173	15901-15902	,	_	
101-174	15903-15904	(	_	
101-175	15904-15909	104.7	_	
101-176	15909-15910	,	_	
101-177	15911-15916	116.9	_	
101-178	15916-15917	)	_	
101-179	15918-15919	T	_	
101-180	15920-15921	=	_	
101-181	15922-15927	0.212	_	
101-182	15928-15929	p	_	
101-183	15930-15931	=	_	
101-184	15932-15937	0.833	_	
101-185	15938-15939	d	_	
101-186	15940-15941	=	_	
101-187	15942-15946	0.07	_	
101-188	15949-15962	Antipsychotic	_	
101-189	15963-15973	medication	_	
101-190	15976-15977	 	_	
101-191	15977-15985	Duration	_	
101-192	15986-15988	of	_	
101-193	15989-15994	index	_	
101-194	15995-16004	treatment	_	
101-195	16005-16006	(	_	
101-196	16006-16011	years	_	
101-197	16011-16012	)	_	
101-198	16013-16016	6.8	_	
101-199	16017-16018	±	_	
101-200	16019-16022	4.9	_	
101-201	16022-16023	,	_	
101-202	16024-16025	(	_	
101-203	16025-16028	4.5	_	
101-204	16028-16029	,	_	
101-205	16030-16033	9.1	_	
101-206	16033-16034	)	_	
101-207	16035-16038	1.7	_	
101-208	16039-16040	±	_	
101-209	16041-16044	1.9	_	
101-210	16044-16045	,	_	
101-211	16046-16047	(	_	
101-212	16047-16050	0.8	_	
101-213	16050-16051	,	_	
101-214	16052-16055	2.6	_	
101-215	16055-16056	)	_	
101-216	16057-16058	T	_	
101-217	16059-16060	=	_	
101-218	16061-16066	4.326	_	
101-219	16067-16068	p	_	
101-220	16069-16070	<	_	
101-221	16071-16076	0.001	_	
101-222	16077-16078	d	_	
101-223	16079-16080	=	_	
101-224	16081-16085	1.37	_	
101-225	16088-16089	 	_	
101-226	16089-16095	Dosage	_	
101-227	16096-16098	mg	_	
101-228	16098-16099	/	_	
101-229	16099-16102	day	_	
101-230	16103-16104	(	_	
101-231	16104-16107	CPZ	_	
101-232	16107-16108	)	_	
101-233	16109-16114	336.7	_	
101-234	16115-16116	±	_	
101-235	16117-16122	122.8	_	
101-236	16122-16123	,	_	
101-237	16124-16125	(	_	
101-238	16125-16130	279.3	_	
101-239	16130-16131	,	_	
101-240	16132-16137	394.2	_	
101-241	16137-16138	)	_	
101-242	16139-16144	321.8	_	
101-243	16145-16146	±	_	
101-244	16147-16152	124.8	_	
101-245	16152-16153	,	_	
101-246	16154-16155	(	_	
101-247	16155-16160	248.0	_	
101-248	16160-16161	,	_	
101-249	16162-16167	372.0	_	
101-250	16167-16168	)	_	
101-251	16169-16170	T	_	
101-252	16171-16172	=	_	
101-253	16173-16178	0.376	_	
101-254	16179-16180	p	_	
101-255	16181-16182	=	_	
101-256	16183-16188	0.709	_	
101-257	16189-16190	d	_	
101-258	16191-16192	=	_	
101-259	16193-16197	0.12	_	
101-260	16200-16215	Psychopathology	_	
101-261	16218-16219	 	_	
101-262	16219-16224	YBOCS	_	
101-263	16227-16229	  	_	
101-264	16229-16239	Obsessions	_	
101-265	16240-16243	6.4	_	
101-266	16244-16245	±	_	
101-267	16246-16249	4.7	_	
101-268	16249-16250	,	_	
101-269	16251-16252	(	_	
101-270	16252-16255	4.1	_	
101-271	16255-16256	,	_	
101-272	16257-16260	8.6	_	
101-273	16260-16261	)	_	
101-274	16262-16265	0.3	_	
101-275	16266-16267	±	_	
101-276	16268-16271	1.3	_	
101-277	16271-16272	,	_	
101-278	16273-16274	(	_	
101-279	16274-16275	−	_	
101-280	16276-16279	0.3	_	
101-281	16279-16280	,	_	
101-282	16281-16284	0.9	_	
101-283	16284-16285	)	_	
101-284	16286-16287	Z	_	
101-285	16288-16289	=	_	
101-286	16290-16291	−	_	
101-287	16292-16297	4.235	_	
101-288	16298-16299	p	_	
101-289	16300-16301	<	_	
101-290	16302-16307	0.001	_	
101-291	16308-16309	r	_	
101-292	16310-16311	=	_	
101-293	16312-16316	0.67	_	
101-294	16319-16321	  	_	
101-295	16321-16332	Compulsions	_	
101-296	16333-16336	6.1	_	
101-297	16337-16338	±	_	
101-298	16339-16342	5.4	_	
101-299	16342-16343	,	_	
101-300	16344-16345	(	_	
101-301	16345-16348	3.5	_	
101-302	16348-16349	,	_	
101-303	16350-16353	8.6	_	
101-304	16353-16354	)	_	
101-305	16355-16358	1.4	_	
101-306	16359-16360	±	_	
101-307	16361-16364	2.8	_	
101-308	16364-16365	,	_	
101-309	16366-16367	(	_	
101-310	16367-16370	0.0	_	
101-311	16370-16371	,	_	
101-312	16372-16375	2.7	_	
101-313	16375-16376	)	_	
101-314	16377-16378	Z	_	
101-315	16379-16380	=	_	
101-316	16381-16382	−	_	
101-317	16383-16388	2.966	_	
101-318	16389-16390	p	_	
101-319	16391-16392	=	_	
101-320	16393-16398	0.008	_	
101-321	16399-16400	r	_	
101-322	16401-16402	=	_	
101-323	16403-16407	0.47	_	
101-324	16410-16412	  	_	
101-325	16412-16417	Total	_	
101-326	16418-16422	12.4	_	
101-327	16423-16424	±	_	
101-328	16425-16428	9.2	_	
101-329	16428-16429	,	_	
101-330	16430-16431	(	_	
101-331	16431-16434	8.1	_	
101-332	16434-16435	,	_	
101-333	16436-16440	16.7	_	
101-334	16440-16441	)	_	
101-335	16442-16445	1.6	_	
101-336	16446-16447	±	_	
101-337	16448-16451	3.8	_	
101-338	16451-16452	,	_	
101-339	16453-16454	(	_	
101-340	16454-16455	−	_	
101-341	16456-16459	0.2	_	
101-342	16459-16460	,	_	
101-343	16461-16464	3.4	_	
101-344	16464-16465	)	_	
101-345	16466-16467	Z	_	
101-346	16468-16469	=	_	
101-347	16470-16471	−	_	
101-348	16472-16477	3.892	_	
101-349	16478-16479	p	_	
101-350	16480-16481	<	_	
101-351	16482-16487	0.001	_	
101-352	16488-16489	r	_	
101-353	16490-16491	=	_	
101-354	16492-16496	0.62	_	
101-355	16499-16500	 	_	
101-356	16500-16503	HZI	_	
101-357	16506-16508	  	_	
101-358	16508-16516	Checking	_	
101-359	16517-16520	5.1	_	
101-360	16521-16522	±	_	
101-361	16523-16526	3.0	_	
101-362	16526-16527	,	_	
101-363	16528-16529	(	_	
101-364	16529-16532	3.7	_	
101-365	16532-16533	,	_	
101-366	16534-16537	6.5	_	
101-367	16537-16538	)	_	
101-368	16539-16542	2.3	_	
101-369	16543-16544	±	_	
101-370	16545-16548	2.1	_	
101-371	16548-16549	,	_	
101-372	16550-16551	(	_	
101-373	16551-16554	1.3	_	
101-374	16554-16555	,	_	
101-375	16556-16559	3.3	_	
101-376	16559-16560	)	_	
101-377	16561-16562	Z	_	
101-378	16563-16564	=	_	
101-379	16565-16566	−	_	
101-380	16567-16572	3.040	_	
101-381	16573-16574	p	_	
101-382	16575-16576	=	_	
101-383	16577-16582	0.002	_	
101-384	16583-16584	r	_	
101-385	16585-16586	=	_	
101-386	16587-16591	0.48	_	
101-387	16594-16596	  	_	
101-388	16596-16603	Washing	_	
101-389	16604-16607	1.5	_	
101-390	16608-16609	±	_	
101-391	16610-16613	1.7	_	
101-392	16613-16614	,	_	
101-393	16615-16616	(	_	
101-394	16616-16619	0.7	_	
101-395	16619-16620	,	_	
101-396	16621-16624	2.4	_	
101-397	16624-16625	)	_	
101-398	16626-16629	1.6	_	
101-399	16630-16631	±	_	
101-400	16632-16635	1.6	_	
101-401	16635-16636	,	_	
101-402	16637-16638	(	_	
101-403	16638-16641	0.8	_	
101-404	16641-16642	,	_	
101-405	16643-16646	2.4	_	
101-406	16646-16647	)	_	
101-407	16648-16649	Z	_	
101-408	16650-16651	=	_	
101-409	16652-16653	−	_	
101-410	16654-16659	0.242	_	
101-411	16660-16661	p	_	
101-412	16662-16663	=	_	
101-413	16664-16669	0.817	_	
101-414	16670-16671	r	_	
101-415	16672-16673	=	_	
101-416	16674-16678	0.04	_	
101-417	16681-16683	  	_	
101-418	16683-16691	Ordering	_	
101-419	16692-16695	2.6	_	
101-420	16696-16697	±	_	
101-421	16698-16701	1.7	_	
101-422	16701-16702	,	_	
101-423	16703-16704	(	_	
101-424	16704-16707	1.8	_	
101-425	16707-16708	,	_	
101-426	16709-16712	3.5	_	
101-427	16712-16713	)	_	
101-428	16714-16717	2.2	_	
101-429	16718-16719	±	_	
101-430	16720-16723	1.5	_	
101-431	16723-16724	,	_	
101-432	16725-16726	(	_	
101-433	16726-16729	1.5	_	
101-434	16729-16730	,	_	
101-435	16731-16734	2.9	_	
101-436	16734-16735	)	_	
101-437	16736-16737	Z	_	
101-438	16738-16739	=	_	
101-439	16740-16741	−	_	
101-440	16742-16747	0.688	_	
101-441	16748-16749	p	_	
101-442	16750-16751	=	_	
101-443	16752-16757	0.506	_	
101-444	16758-16759	r	_	
101-445	16760-16761	=	_	
101-446	16762-16766	0.11	_	
101-447	16769-16771	  	_	
101-448	16771-16779	Counting	_	
101-449	16780-16783	2.2	_	
101-450	16784-16785	±	_	
101-451	16786-16789	2.4	_	
101-452	16789-16790	,	_	
101-453	16791-16792	(	_	
101-454	16792-16795	1.0	_	
101-455	16795-16796	,	_	
101-456	16797-16800	3.4	_	
101-457	16800-16801	)	_	
101-458	16802-16805	0.5	_	
101-459	16806-16807	±	_	
101-460	16808-16811	0.8	_	
101-461	16811-16812	,	_	
101-462	16813-16814	(	_	
101-463	16814-16817	0.5	_	
101-464	16817-16818	,	_	
101-465	16819-16822	0.2	_	
101-466	16822-16823	)	_	
101-467	16824-16825	Z	_	
101-468	16826-16827	=	_	
101-469	16828-16829	−	_	
101-470	16830-16835	2.662	_	
101-471	16836-16837	p	_	
101-472	16838-16839	=	_	
101-473	16840-16845	0.012	_	
101-474	16846-16847	r	_	
101-475	16848-16849	=	_	
101-476	16850-16854	0.42	_	
101-477	16857-16859	  	_	
101-478	16859-16869	Obsessions	_	
101-479	16870-16873	2.3	_	
101-480	16874-16875	±	_	
101-481	16876-16879	2.0	_	
101-482	16879-16880	,	_	
101-483	16881-16882	(	_	
101-484	16882-16885	1.3	_	
101-485	16885-16886	,	_	
101-486	16887-16890	3.2	_	
101-487	16890-16891	)	_	
101-488	16892-16895	2.2	_	
101-489	16896-16897	±	_	
101-490	16898-16901	1.5	_	
101-491	16901-16902	,	_	
101-492	16903-16904	(	_	
101-493	16904-16907	2.2	_	
101-494	16907-16908	,	_	
101-495	16909-16912	1.4	_	
101-496	16912-16913	)	_	
101-497	16914-16915	Z	_	
101-498	16916-16917	=	_	
101-499	16918-16919	−	_	
101-500	16920-16925	0.210	_	
101-501	16926-16927	p	_	
101-502	16928-16929	=	_	
101-503	16930-16935	0.840	_	
101-504	16936-16937	r	_	
101-505	16938-16939	=	_	
101-506	16940-16944	0.03	_	
101-507	16947-16949	  	_	
101-508	16949-16959	Aggressive	_	
101-509	16960-16970	obsessions	_	
101-510	16971-16974	1.3	_	
101-511	16975-16976	±	_	
101-512	16977-16980	1.9	_	
101-513	16980-16981	,	_	
101-514	16982-16983	(	_	
101-515	16983-16986	0.4	_	
101-516	16986-16987	,	_	
101-517	16988-16991	2.2	_	
101-518	16991-16992	)	_	
101-519	16993-16996	0.3	_	
101-520	16997-16998	±	_	
101-521	16999-17002	0.7	_	
101-522	17002-17003	,	_	
101-523	17004-17005	(	_	
101-524	17005-17006	−	_	
101-525	17007-17010	0.1	_	
101-526	17010-17011	,	_	
101-527	17012-17015	0.6	_	
101-528	17015-17016	)	_	
101-529	17017-17018	Z	_	
101-530	17019-17020	=	_	
101-531	17021-17022	−	_	
101-532	17023-17028	1.953	_	
101-533	17029-17030	p	_	
101-534	17031-17032	=	_	
101-535	17033-17038	0.123	_	
101-536	17039-17040	r	_	
101-537	17041-17042	=	_	
101-538	17043-17047	0.31	_	
101-539	17050-17051	 	_	
101-540	17051-17056	PANSS	_	
101-541	17059-17061	  	_	
101-542	17061-17069	Positive	_	
101-543	17070-17075	Scale	_	
101-544	17076-17080	13.8	_	
101-545	17081-17082	±	_	
101-546	17083-17086	3.1	_	
101-547	17086-17087	,	_	
101-548	17088-17089	(	_	
101-549	17089-17093	12.3	_	
101-550	17093-17094	,	_	
101-551	17095-17099	15.2	_	
101-552	17099-17100	)	_	
101-553	17101-17105	13.0	_	
101-554	17106-17107	±	_	
101-555	17108-17111	3.0	_	
101-556	17111-17112	,	_	
101-557	17113-17114	(	_	
101-558	17114-17118	11.6	_	
101-559	17118-17119	,	_	
101-560	17120-17124	14.4	_	
101-561	17124-17125	)	_	
101-562	17126-17127	T	_	
101-563	17128-17129	=	_	
101-564	17130-17135	0.780	_	
101-565	17136-17137	p	_	
101-566	17138-17139	=	_	
101-567	17140-17145	0.440	_	
101-568	17146-17147	d	_	
101-569	17148-17149	=	_	
101-570	17150-17154	0.26	_	
101-571	17157-17159	  	_	
101-572	17159-17167	Negative	_	
101-573	17168-17173	Scale	_	
101-574	17174-17178	16.7	_	
101-575	17179-17180	±	_	
101-576	17181-17184	4.3	_	
101-577	17184-17185	,	_	
101-578	17186-17187	(	_	
101-579	17187-17191	14.7	_	
101-580	17191-17192	,	_	
101-581	17193-17197	18.7	_	
101-582	17197-17198	)	_	
101-583	17199-17203	13.8	_	
101-584	17204-17205	±	_	
101-585	17206-17209	4.4	_	
101-586	17209-17210	,	_	
101-587	17211-17212	(	_	
101-588	17212-17216	11.7	_	
101-589	17216-17217	,	_	
101-590	17218-17222	15.8	_	
101-591	17222-17223	)	_	
101-592	17224-17225	T	_	
101-593	17226-17227	=	_	
101-594	17228-17233	2.134	_	
101-595	17234-17235	p	_	
101-596	17236-17237	=	_	
101-597	17238-17243	0.039	_	
101-598	17244-17245	d	_	
101-599	17246-17247	=	_	
101-600	17248-17252	0.67	_	
101-601	17255-17257	  	_	
101-602	17257-17264	General	_	
101-603	17265-17280	psychopathology	_	
101-604	17281-17285	34.3	_	
101-605	17286-17287	±	_	
101-606	17288-17291	4.7	_	
101-607	17291-17292	,	_	
101-608	17293-17294	(	_	
101-609	17294-17298	32.0	_	
101-610	17298-17299	,	_	
101-611	17300-17304	36.5	_	
101-612	17304-17305	)	_	
101-613	17306-17310	32.0	_	
101-614	17311-17312	±	_	
101-615	17313-17316	5.4	_	
101-616	17316-17317	,	_	
101-617	17318-17319	(	_	
101-618	17319-17323	29.4	_	
101-619	17323-17324	,	_	
101-620	17325-17329	34.5	_	
101-621	17329-17330	)	_	
101-622	17331-17332	T	_	
101-623	17333-17334	=	_	
101-624	17335-17340	1.436	_	
101-625	17341-17342	p	_	
101-626	17343-17344	=	_	
101-627	17345-17350	0.159	_	
101-628	17351-17352	d	_	
101-629	17353-17354	=	_	
101-630	17355-17359	0.54	_	
101-631	17362-17366	SANS	_	
101-632	17369-17370	 	_	
101-633	17370-17379	Affective	_	
101-634	17380-17390	flattening	_	
101-635	17391-17394	1.6	_	
101-636	17395-17396	±	_	
101-637	17397-17400	1.2	_	
101-638	17400-17401	,	_	
101-639	17402-17403	(	_	
101-640	17403-17406	1.0	_	
101-641	17406-17407	,	_	
101-642	17408-17411	2.1	_	
101-643	17411-17412	)	_	
101-644	17413-17416	1.3	_	
101-645	17417-17418	±	_	
101-646	17419-17422	1.2	_	
101-647	17422-17423	,	_	
101-648	17424-17425	(	_	
101-649	17425-17428	0.7	_	
101-650	17428-17429	,	_	
101-651	17430-17433	1.8	_	
101-652	17433-17434	)	_	
101-653	17435-17436	T	_	
101-654	17437-17438	=	_	
101-655	17439-17444	0.791	_	
101-656	17445-17446	p	_	
101-657	17447-17448	=	_	
101-658	17449-17454	0.434	_	
101-659	17455-17456	d	_	
101-660	17457-17458	=	_	
101-661	17459-17463	0.25	_	
101-662	17466-17468	  	_	
101-663	17468-17474	Alogia	_	
101-664	17475-17478	1.5	_	
101-665	17479-17480	±	_	
101-666	17481-17484	1.2	_	
101-667	17484-17485	,	_	
101-668	17486-17487	(	_	
101-669	17487-17490	0.9	_	
101-670	17490-17491	,	_	
101-671	17492-17495	2.1	_	
101-672	17495-17496	)	_	
101-673	17497-17500	1.0	_	
101-674	17501-17502	±	_	
101-675	17503-17506	1.1	_	
101-676	17506-17507	,	_	
101-677	17508-17509	(	_	
101-678	17509-17512	0.4	_	
101-679	17512-17513	,	_	
101-680	17514-17517	1.5	_	
101-681	17517-17518	)	_	
101-682	17519-17520	T	_	
101-683	17521-17522	=	_	
101-684	17523-17528	1.488	_	
101-685	17529-17530	p	_	
101-686	17531-17532	=	_	
101-687	17533-17538	0.145	_	
101-688	17539-17540	d	_	
101-689	17541-17542	=	_	
101-690	17543-17547	0.43	_	
101-691	17550-17552	  	_	
101-692	17552-17568	Avolition–apathy	_	
101-693	17569-17572	2.0	_	
101-694	17573-17574	±	_	
101-695	17575-17578	1.0	_	
101-696	17578-17579	,	_	
101-697	17580-17581	(	_	
101-698	17581-17584	1.6	_	
101-699	17584-17585	,	_	
101-700	17586-17589	2.6	_	
101-701	17589-17590	)	_	
101-702	17591-17594	1.5	_	
101-703	17595-17596	±	_	
101-704	17597-17600	1.3	_	
101-705	17600-17601	,	_	
101-706	17602-17603	(	_	
101-707	17603-17606	0.9	_	
101-708	17606-17607	,	_	
101-709	17608-17611	2.1	_	
101-710	17611-17612	)	_	
101-711	17613-17614	T	_	
101-712	17615-17616	=	_	
101-713	17617-17622	1.641	_	
101-714	17623-17624	p	_	
101-715	17625-17626	=	_	
101-716	17627-17632	0.109	_	
101-717	17633-17634	d	_	
101-718	17635-17636	=	_	
101-719	17637-17641	0.43	_	
101-720	17644-17646	  	_	
101-721	17646-17655	Anhedonia	_	
101-722	17656-17659	2.0	_	
101-723	17660-17661	±	_	
101-724	17662-17665	1.0	_	
101-725	17665-17666	,	_	
101-726	17667-17668	(	_	
101-727	17668-17671	1.5	_	
101-728	17671-17672	,	_	
101-729	17673-17676	2.5	_	
101-730	17676-17677	)	_	
101-731	17678-17681	1.5	_	
101-732	17682-17683	±	_	
101-733	17684-17687	1.5	_	
101-734	17687-17688	,	_	
101-735	17689-17690	(	_	
101-736	17690-17693	0.7	_	
101-737	17693-17694	,	_	
101-738	17695-17698	2.2	_	
101-739	17698-17699	)	_	
101-740	17700-17701	T	_	
101-741	17702-17703	=	_	
101-742	17704-17709	1.351	_	
101-743	17710-17711	p	_	
101-744	17712-17713	=	_	
101-745	17714-17719	0.185	_	
101-746	17720-17721	d	_	
101-747	17722-17723	=	_	
101-748	17724-17728	0.39	_	
101-749	17731-17733	  	_	
101-750	17733-17742	Attention	_	
101-751	17743-17746	2.0	_	
101-752	17747-17748	±	_	
101-753	17749-17752	1.3	_	
101-754	17752-17753	,	_	
101-755	17754-17755	(	_	
101-756	17755-17758	1.3	_	
101-757	17758-17759	,	_	
101-758	17760-17763	2.6	_	
101-759	17763-17764	)	_	
101-760	17765-17768	1.5	_	
101-761	17769-17770	±	_	
101-762	17771-17774	1.3	_	
101-763	17774-17775	,	_	
101-764	17776-17777	(	_	
101-765	17777-17780	0.9	_	
101-766	17780-17781	,	_	
101-767	17782-17785	2.1	_	
101-768	17785-17786	)	_	
101-769	17787-17788	T	_	
101-770	17789-17790	=	_	
101-771	17791-17796	1.219	_	
101-772	17797-17798	p	_	
101-773	17799-17800	=	_	
101-774	17801-17806	0.230	_	
101-775	17807-17808	d	_	
101-776	17809-17810	=	_	
101-777	17811-17815	0.38	_	
101-778	17818-17822	CDSS	_	
101-779	17823-17826	1.1	_	
101-780	17827-17828	±	_	
101-781	17829-17832	1.5	_	
101-782	17832-17833	,	_	
101-783	17834-17835	(	_	
101-784	17835-17838	0.4	_	
101-785	17838-17839	,	_	
101-786	17840-17843	1.8	_	
101-787	17843-17844	)	_	
101-788	17845-17848	1.8	_	
101-789	17849-17850	±	_	
101-790	17851-17854	2.8	_	
101-791	17854-17855	,	_	
101-792	17856-17857	(	_	
101-793	17857-17860	0.5	_	
101-794	17860-17861	,	_	
101-795	17862-17865	3.1	_	
101-796	17865-17866	)	_	
101-797	17867-17868	T	_	
101-798	17869-17870	=	_	
101-799	17871-17872	−	_	
101-800	17873-17878	0.993	_	
101-801	17879-17880	p	_	
101-802	17881-17882	=	_	
101-803	17883-17888	0.327	_	
101-804	17889-17890	d	_	
101-805	17891-17892	=	_	
101-806	17893-17897	0.31	_	
101-807	17900-17903	PSP	_	
101-808	17904-17908	67.6	_	
101-809	17909-17910	±	_	
101-810	17911-17914	6.5	_	
101-811	17914-17915	,	_	
101-812	17916-17917	(	_	
101-813	17917-17921	64.6	_	
101-814	17921-17922	,	_	
101-815	17923-17927	70.6	_	
101-816	17927-17928	)	_	
101-817	17929-17933	71.1	_	
101-818	17934-17935	±	_	
101-819	17936-17939	7.1	_	
101-820	17939-17940	,	_	
101-821	17941-17942	(	_	
101-822	17942-17946	67.7	_	
101-823	17946-17947	,	_	
101-824	17948-17952	70.6	_	
101-825	17952-17953	)	_	
101-826	17954-17955	T	_	
101-827	17956-17957	=	_	
101-828	17958-17959	−	_	
101-829	17960-17965	1.610	_	
101-830	17966-17967	p	_	
101-831	17968-17969	=	_	
101-832	17970-17975	0.116	_	
101-833	17976-17977	d	_	
101-834	17978-17979	=	_	
101-835	17980-17984	0.51	_	
101-836	17988-17992	CDSS	_	
101-837	17993-18000	Calgary	_	
101-838	18001-18011	Depression	_	
101-839	18012-18017	Scale	_	
101-840	18018-18021	for	_	
101-841	18022-18035	Schizophrenia	_	
101-842	18035-18036	,	_	
101-843	18037-18039	CI	_	
101-844	18040-18050	confidence	_	
101-845	18051-18059	interval	_	
101-846	18059-18060	,	_	
101-847	18061-18064	CPZ	_	
101-848	18065-18079	chlorpromazine	_	
101-849	18080-18091	equivalents	_	
101-850	18091-18092	,	_	
101-851	18093-18096	HZI	_	
101-852	18097-18106	Hamburger	_	
101-853	18107-18121	Zwangsinventar	_	
101-854	18121-18122	,	_	
101-855	18123-18125	OR	_	
101-856	18126-18130	odds	_	
101-857	18131-18136	ratio	_	
101-858	18136-18137	,	_	
101-859	18138-18143	PANSS	_	
101-860	18144-18152	Positive	_	
101-861	18153-18156	and	_	
101-862	18157-18165	Negative	_	
101-863	18166-18174	Syndrome	_	
101-864	18175-18180	Scale	_	
101-865	18180-18181	,	_	
101-866	18182-18185	PSP	_	
101-867	18186-18194	Personal	_	
101-868	18195-18198	and	_	
101-869	18199-18205	Social	_	
101-870	18206-18217	Performance	_	
101-871	18218-18223	Scale	_	
101-872	18223-18224	,	_	
101-873	18225-18227	SD	_	
101-874	18228-18236	standard	_	
101-875	18237-18246	deviation	_	
101-876	18246-18247	,	_	
101-877	18248-18252	SANS	_	
101-878	18253-18258	Scale	_	
101-879	18259-18262	for	_	
101-880	18263-18266	the	_	
101-881	18267-18277	Assessment	_	
101-882	18278-18280	of	_	
101-883	18281-18289	Negative	_	
101-884	18290-18298	Symptoms	_	
101-885	18298-18299	,	_	
101-886	18300-18305	YBOCS	_	
101-887	18306-18316	Yale–Brown	_	
101-888	18317-18337	Obsessive–Compulsive	_	
101-889	18338-18343	Scale	_	
101-890	18344-18354	aTreatment	_	
101-891	18355-18359	with	_	
101-892	18360-18369	clozapine	_	
101-893	18369-18370	,	_	
101-894	18371-18381	olanzapine	_	
101-895	18381-18382	,	_	
101-896	18383-18395	aripiprazole	_	
101-897	18396-18398	or	_	
101-898	18399-18410	amisulpride	_	
101-899	18411-18421	Functional	_	
101-900	18422-18425	MRI	_	
101-901	18426-18436	Behavioral	_	
101-902	18437-18441	data	_	
101-903	18442-18445	The	_	
101-904	18446-18449	two	_	
101-905	18450-18456	groups	_	
101-906	18457-18460	did	_	
101-907	18461-18464	not	_	
101-908	18465-18478	significantly	_	
101-909	18479-18485	differ	_	
101-910	18486-18488	in	_	
101-911	18489-18494	their	_	
101-912	18495-18506	performance	_	
101-913	18507-18509	in	_	
101-914	18510-18513	the	_	
101-915	18514-18527	face-matching	_	
101-916	18528-18532	task	_	
101-917	18532-18533	,	_	
101-918	18534-18541	neither	_	
101-919	18542-18551	regarding	_	
101-920	18552-18559	percent	_	
101-921	18560-18562	of	_	
101-922	18563-18570	correct	_	
101-923	18571-18578	answers	_	
101-924	18579-18580	(	_	
101-925	18580-18582	ps	_	
101-926	18583-18584	>	_	
101-927	18585-18589	0.31	_	
101-928	18589-18590	)	_	
101-929	18591-18592	(	_	
101-930	18592-18597	group	_	
101-931	18598-18599	I	_	
101-932	18599-18600	:	_	
101-933	18601-18606	faces	_	
101-934	18606-18607	:	_	
101-935	18608-18613	95.83	_	
101-936	18614-18615	±	_	
101-937	18616-18620	9.70	_	
101-938	18620-18621	;	_	
101-939	18622-18627	forms	_	
101-940	18627-18628	:	_	
101-941	18629-18634	97.71	_	
101-942	18635-18636	±	_	
101-943	18637-18641	3.70	_	
101-944	18641-18642	;	_	
101-945	18643-18648	group	_	
101-946	18649-18651	II	_	
101-947	18652-18657	faces	_	
101-948	18657-18658	:	_	
101-949	18659-18664	98.12	_	
101-950	18665-18666	±	_	
101-951	18667-18671	2.52	_	
101-952	18671-18672	;	_	
101-953	18673-18678	forms	_	
101-954	18678-18679	:	_	
101-955	18680-18685	97.29	_	
101-956	18686-18687	±	_	
101-957	18688-18692	3.39	_	
101-958	18692-18693	)	_	
101-959	18694-18697	nor	_	
101-960	18698-18707	regarding	_	
101-961	18708-18716	reaction	_	
101-962	18717-18722	times	_	
101-963	18723-18724	(	_	
101-964	18724-18726	ps	_	
101-965	18727-18728	>	_	
101-966	18729-18733	0.77	_	
101-967	18733-18734	)	_	
101-968	18735-18736	(	_	
101-969	18736-18741	group	_	
101-970	18742-18743	I	_	
101-971	18743-18744	:	_	
101-972	18745-18750	faces	_	
101-973	18750-18751	:	_	
101-974	18752-18759	1619.83	_	
101-975	18760-18761	±	_	
101-976	18762-18768	443.30	_	
101-977	18768-18769	 	_	
101-978	18769-18771	ms	_	
101-979	18771-18772	;	_	
101-980	18773-18778	forms	_	
101-981	18778-18779	:	_	
101-982	18780-18787	1243.08	_	
101-983	18788-18789	±	_	
101-984	18790-18796	354.39	_	
101-985	18796-18797	 	_	
101-986	18797-18799	ms	_	
101-987	18799-18800	;	_	
101-988	18801-18806	group	_	
101-989	18807-18809	II	_	
101-990	18809-18810	:	_	
101-991	18811-18816	faces	_	
101-992	18816-18817	:	_	
101-993	18818-18825	1583.79	_	
101-994	18826-18827	±	_	
101-995	18828-18834	322.47	_	
101-996	18834-18835	 	_	
101-997	18835-18837	ms	_	
101-998	18837-18838	;	_	
101-999	18839-18844	forms	_	
101-1000	18844-18845	:	_	
101-1001	18846-18853	1230.11	_	
101-1002	18854-18855	±	_	
101-1003	18856-18862	260.61	_	
101-1004	18862-18863	 	_	
101-1005	18863-18865	ms	_	
101-1006	18865-18866	)	_	
101-1007	18866-18867	.	_	

#Text=Brain activation data and connectivity
#Text=Regarding the main effect of condition in the implicit emotion recognition task, the comparison of faces with geometrical shapes revealed activation in occipital regions, inferior frontal gyrus, thalamus, insula and amygdala (Fig. 1; Table 2).
102-1	18868-18873	Brain	_	
102-2	18874-18884	activation	_	
102-3	18885-18889	data	_	
102-4	18890-18893	and	_	
102-5	18894-18906	connectivity	_	
102-6	18907-18916	Regarding	_	
102-7	18917-18920	the	_	
102-8	18921-18925	main	_	
102-9	18926-18932	effect	_	
102-10	18933-18935	of	_	
102-11	18936-18945	condition	_	
102-12	18946-18948	in	_	
102-13	18949-18952	the	_	
102-14	18953-18961	implicit	_	
102-15	18962-18969	emotion	_	
102-16	18970-18981	recognition	_	
102-17	18982-18986	task	_	
102-18	18986-18987	,	_	
102-19	18988-18991	the	_	
102-20	18992-19002	comparison	_	
102-21	19003-19005	of	_	
102-22	19006-19011	faces	_	
102-23	19012-19016	with	_	
102-24	19017-19028	geometrical	_	
102-25	19029-19035	shapes	_	
102-26	19036-19044	revealed	_	
102-27	19045-19055	activation	_	
102-28	19056-19058	in	_	
102-29	19059-19068	occipital	_	
102-30	19069-19076	regions	_	
102-31	19076-19077	,	_	
102-32	19078-19086	inferior	_	
102-33	19087-19094	frontal	_	
102-34	19095-19100	gyrus	_	
102-35	19100-19101	,	_	
102-36	19102-19110	thalamus	_	
102-37	19110-19111	,	_	
102-38	19112-19118	insula	_	
102-39	19119-19122	and	_	
102-40	19123-19131	amygdala	_	
102-41	19132-19133	(	_	
102-42	19133-19136	Fig	_	
102-43	19136-19137	.	_	
102-44	19137-19138	 	_	
102-45	19138-19139	1	_	
102-46	19139-19140	;	_	
102-47	19141-19146	Table	_	
102-48	19146-19147	 	_	
102-49	19147-19148	2	_	
102-50	19148-19149	)	_	
102-51	19149-19150	.	_	

#Text=The enhanced amygdala activation was also confirmed by ROI analyses (left coordinates: x = − 21, y = − 7, z = − 18; T = 8.13; p < 0.001 (svc); k = 45; right coordinates: x = 21, y = − 4, z = − 15; T = 7.31; p < 0.001 (svc); k = 43).
103-1	19151-19154	The	_	
103-2	19155-19163	enhanced	_	
103-3	19164-19172	amygdala	_	
103-4	19173-19183	activation	_	
103-5	19184-19187	was	_	
103-6	19188-19192	also	_	
103-7	19193-19202	confirmed	_	
103-8	19203-19205	by	_	
103-9	19206-19209	ROI	_	
103-10	19210-19218	analyses	_	
103-11	19219-19220	(	_	
103-12	19220-19224	left	_	
103-13	19225-19236	coordinates	_	
103-14	19236-19237	:	_	
103-15	19238-19239	x	_	
103-16	19240-19241	=	_	
103-17	19242-19243	−	_	
103-18	19244-19246	21	_	
103-19	19246-19247	,	_	
103-20	19248-19249	y	_	
103-21	19250-19251	=	_	
103-22	19252-19253	−	_	
103-23	19254-19255	7	_	
103-24	19255-19256	,	_	
103-25	19257-19258	z	_	
103-26	19259-19260	=	_	
103-27	19261-19262	−	_	
103-28	19263-19265	18	_	
103-29	19265-19266	;	_	
103-30	19267-19268	T	_	
103-31	19269-19270	=	_	
103-32	19271-19275	8.13	_	
103-33	19275-19276	;	_	
103-34	19277-19278	p	_	
103-35	19279-19280	<	_	
103-36	19281-19286	0.001	_	
103-37	19287-19288	(	_	
103-38	19288-19291	svc	_	
103-39	19291-19292	)	_	
103-40	19292-19293	;	_	
103-41	19294-19295	k	_	
103-42	19296-19297	=	_	
103-43	19298-19300	45	_	
103-44	19300-19301	;	_	
103-45	19302-19307	right	_	
103-46	19308-19319	coordinates	_	
103-47	19319-19320	:	_	
103-48	19321-19322	x	_	
103-49	19323-19324	=	_	
103-50	19325-19327	21	_	
103-51	19327-19328	,	_	
103-52	19329-19330	y	_	
103-53	19331-19332	=	_	
103-54	19333-19334	−	_	
103-55	19335-19336	4	_	
103-56	19336-19337	,	_	
103-57	19338-19339	z	_	
103-58	19340-19341	=	_	
103-59	19342-19343	−	_	
103-60	19344-19346	15	_	
103-61	19346-19347	;	_	
103-62	19348-19349	T	_	
103-63	19350-19351	=	_	
103-64	19352-19356	7.31	_	
103-65	19356-19357	;	_	
103-66	19358-19359	p	_	
103-67	19360-19361	<	_	
103-68	19362-19367	0.001	_	
103-69	19368-19369	(	_	
103-70	19369-19372	svc	_	
103-71	19372-19373	)	_	
103-72	19373-19374	;	_	
103-73	19375-19376	k	_	
103-74	19377-19378	=	_	
103-75	19379-19381	43	_	
103-76	19381-19382	)	_	
103-77	19382-19383	.	_	

#Text=Enhanced activity for faces > geometrical figures (displayed with: p < 0.05 FWE corrected, k = 10) across all participants
#Text=Activity across all participants during face matching (> matching of geometrical shapes; p < 0.05 FWE corrected, k = 10)
#Text=Main effect faces\tBA\tCluster\tMNI\tT value\t \tArea\tx\ty\tz\t \tMiddle occipital gyrus\t18\t5.312\t18\t− 100\t12\t20.06\t \tLingual gyrus\t18\t\t6\t− 88\t− 9\t19.68\t \tMiddle occipital gyrus\t18\t\t36\t− 82\t− 15\t17.28\t \tThalamus\t\t598\t24\t− 28\t− 3\t11.81\t \tThalamus\t\t\t− 21\t− 31\t0\t9.92\t \tAmygdala\t\t\t− 21\t− 10\t− 15\t8.57\t \tInsula\t13\t415\t42\t8\t27\t9.26\t \tInferior frontal gyrus\t46\t\t45\t26\t18\t8.87\t \tInferior frontal gyrus\t45\t\t54\t38\t9\t6.50\t \tInferior frontal gyrus\t47\t16\t33\t32\t− 15\t6.54\t \tInferior frontal gyrus\t9\t20\t− 45\t14\t24\t6.13\t \tInferior frontal gyrus\t45\t11\t− 57\t26\t21\t5.62\t \t
#Text=Whole brain group comparisons at the given significance threshold (p < 0.05 FWE corrected, k = 10) revealed no significant group differences.
104-1	19384-19392	Enhanced	_	
104-2	19393-19401	activity	_	
104-3	19402-19405	for	_	
104-4	19406-19411	faces	_	
104-5	19412-19413	>	_	
104-6	19414-19425	geometrical	_	
104-7	19426-19433	figures	_	
104-8	19434-19435	(	_	
104-9	19435-19444	displayed	_	
104-10	19445-19449	with	_	
104-11	19449-19450	:	_	
104-12	19451-19452	p	_	
104-13	19453-19454	<	_	
104-14	19455-19459	0.05	_	
104-15	19460-19463	FWE	_	
104-16	19464-19473	corrected	_	
104-17	19473-19474	,	_	
104-18	19475-19476	k	_	
104-19	19477-19478	=	_	
104-20	19479-19481	10	_	
104-21	19481-19482	)	_	
104-22	19483-19489	across	_	
104-23	19490-19493	all	_	
104-24	19494-19506	participants	_	
104-25	19507-19515	Activity	_	
104-26	19516-19522	across	_	
104-27	19523-19526	all	_	
104-28	19527-19539	participants	_	
104-29	19540-19546	during	_	
104-30	19547-19551	face	_	
104-31	19552-19560	matching	_	
104-32	19561-19562	(	_	
104-33	19562-19563	>	_	
104-34	19564-19572	matching	_	
104-35	19573-19575	of	_	
104-36	19576-19587	geometrical	_	
104-37	19588-19594	shapes	_	
104-38	19594-19595	;	_	
104-39	19596-19597	p	_	
104-40	19598-19599	<	_	
104-41	19600-19604	0.05	_	
104-42	19605-19608	FWE	_	
104-43	19609-19618	corrected	_	
104-44	19618-19619	,	_	
104-45	19620-19621	k	_	
104-46	19622-19623	=	_	
104-47	19624-19626	10	_	
104-48	19626-19627	)	_	
104-49	19628-19632	Main	_	
104-50	19633-19639	effect	_	
104-51	19640-19645	faces	_	
104-52	19646-19648	BA	_	
104-53	19649-19656	Cluster	_	
104-54	19657-19660	MNI	_	
104-55	19661-19662	T	_	
104-56	19663-19668	value	_	
104-57	19671-19675	Area	_	
104-58	19676-19677	x	_	
104-59	19678-19679	y	_	
104-60	19680-19681	z	_	
104-61	19684-19690	Middle	_	
104-62	19691-19700	occipital	_	
104-63	19701-19706	gyrus	_	
104-64	19707-19709	18	_	
104-65	19710-19715	5.312	_	
104-66	19716-19718	18	_	
104-67	19719-19720	−	_	
104-68	19721-19724	100	_	
104-69	19725-19727	12	_	
104-70	19728-19733	20.06	_	
104-71	19736-19743	Lingual	_	
104-72	19744-19749	gyrus	_	
104-73	19750-19752	18	_	
104-74	19754-19755	6	_	
104-75	19756-19757	−	_	
104-76	19758-19760	88	_	
104-77	19761-19762	−	_	
104-78	19763-19764	9	_	
104-79	19765-19770	19.68	_	
104-80	19773-19779	Middle	_	
104-81	19780-19789	occipital	_	
104-82	19790-19795	gyrus	_	
104-83	19796-19798	18	_	
104-84	19800-19802	36	_	
104-85	19803-19804	−	_	
104-86	19805-19807	82	_	
104-87	19808-19809	−	_	
104-88	19810-19812	15	_	
104-89	19813-19818	17.28	_	
104-90	19821-19829	Thalamus	_	
104-91	19831-19834	598	_	
104-92	19835-19837	24	_	
104-93	19838-19839	−	_	
104-94	19840-19842	28	_	
104-95	19843-19844	−	_	
104-96	19845-19846	3	_	
104-97	19847-19852	11.81	_	
104-98	19855-19863	Thalamus	_	
104-99	19866-19867	−	_	
104-100	19868-19870	21	_	
104-101	19871-19872	−	_	
104-102	19873-19875	31	_	
104-103	19876-19877	0	_	
104-104	19878-19882	9.92	_	
104-105	19885-19893	Amygdala	_	
104-106	19896-19897	−	_	
104-107	19898-19900	21	_	
104-108	19901-19902	−	_	
104-109	19903-19905	10	_	
104-110	19906-19907	−	_	
104-111	19908-19910	15	_	
104-112	19911-19915	8.57	_	
104-113	19918-19924	Insula	_	
104-114	19925-19927	13	_	
104-115	19928-19931	415	_	
104-116	19932-19934	42	_	
104-117	19935-19936	8	_	
104-118	19937-19939	27	_	
104-119	19940-19944	9.26	_	
104-120	19947-19955	Inferior	_	
104-121	19956-19963	frontal	_	
104-122	19964-19969	gyrus	_	
104-123	19970-19972	46	_	
104-124	19974-19976	45	_	
104-125	19977-19979	26	_	
104-126	19980-19982	18	_	
104-127	19983-19987	8.87	_	
104-128	19990-19998	Inferior	_	
104-129	19999-20006	frontal	_	
104-130	20007-20012	gyrus	_	
104-131	20013-20015	45	_	
104-132	20017-20019	54	_	
104-133	20020-20022	38	_	
104-134	20023-20024	9	_	
104-135	20025-20029	6.50	_	
104-136	20032-20040	Inferior	_	
104-137	20041-20048	frontal	_	
104-138	20049-20054	gyrus	_	
104-139	20055-20057	47	_	
104-140	20058-20060	16	_	
104-141	20061-20063	33	_	
104-142	20064-20066	32	_	
104-143	20067-20068	−	_	
104-144	20069-20071	15	_	
104-145	20072-20076	6.54	_	
104-146	20079-20087	Inferior	_	
104-147	20088-20095	frontal	_	
104-148	20096-20101	gyrus	_	
104-149	20102-20103	9	_	
104-150	20104-20106	20	_	
104-151	20107-20108	−	_	
104-152	20109-20111	45	_	
104-153	20112-20114	14	_	
104-154	20115-20117	24	_	
104-155	20118-20122	6.13	_	
104-156	20125-20133	Inferior	_	
104-157	20134-20141	frontal	_	
104-158	20142-20147	gyrus	_	
104-159	20148-20150	45	_	
104-160	20151-20153	11	_	
104-161	20154-20155	−	_	
104-162	20156-20158	57	_	
104-163	20159-20161	26	_	
104-164	20162-20164	21	_	
104-165	20165-20169	5.62	_	
104-166	20173-20178	Whole	_	
104-167	20179-20184	brain	_	
104-168	20185-20190	group	_	
104-169	20191-20202	comparisons	_	
104-170	20203-20205	at	_	
104-171	20206-20209	the	_	
104-172	20210-20215	given	_	
104-173	20216-20228	significance	_	
104-174	20229-20238	threshold	_	
104-175	20239-20240	(	_	
104-176	20240-20241	p	_	
104-177	20242-20243	<	_	
104-178	20244-20248	0.05	_	
104-179	20249-20252	FWE	_	
104-180	20253-20262	corrected	_	
104-181	20262-20263	,	_	
104-182	20264-20265	k	_	
104-183	20266-20267	=	_	
104-184	20268-20270	10	_	
104-185	20270-20271	)	_	
104-186	20272-20280	revealed	_	
104-187	20281-20283	no	_	
104-188	20284-20295	significant	_	
104-189	20296-20301	group	_	
104-190	20302-20313	differences	_	
104-191	20313-20314	.	_	

#Text=When applying a ROI analysis for the amygdala, we found decreased activity in left amygdala in group I (coordinates: x = − 18, y = − 4, z = − 25; T = 2.62; p = 0.047 (svc); k = 18; Fig. 2a) compared to group II.
105-1	20315-20319	When	_	
105-2	20320-20328	applying	_	
105-3	20329-20330	a	_	
105-4	20331-20334	ROI	_	
105-5	20335-20343	analysis	_	
105-6	20344-20347	for	_	
105-7	20348-20351	the	_	
105-8	20352-20360	amygdala	_	
105-9	20360-20361	,	_	
105-10	20362-20364	we	_	
105-11	20365-20370	found	_	
105-12	20371-20380	decreased	_	
105-13	20381-20389	activity	_	
105-14	20390-20392	in	_	
105-15	20393-20397	left	_	
105-16	20398-20406	amygdala	_	
105-17	20407-20409	in	_	
105-18	20410-20415	group	_	
105-19	20416-20417	I	_	
105-20	20418-20419	(	_	
105-21	20419-20430	coordinates	_	
105-22	20430-20431	:	_	
105-23	20432-20433	x	_	
105-24	20434-20435	=	_	
105-25	20436-20437	−	_	
105-26	20438-20440	18	_	
105-27	20440-20441	,	_	
105-28	20442-20443	y	_	
105-29	20444-20445	=	_	
105-30	20446-20447	−	_	
105-31	20448-20449	4	_	
105-32	20449-20450	,	_	
105-33	20451-20452	z	_	
105-34	20453-20454	=	_	
105-35	20455-20456	−	_	
105-36	20457-20459	25	_	
105-37	20459-20460	;	_	
105-38	20461-20462	T	_	
105-39	20463-20464	=	_	
105-40	20465-20469	2.62	_	
105-41	20469-20470	;	_	
105-42	20471-20472	p	_	
105-43	20473-20474	=	_	
105-44	20475-20480	0.047	_	
105-45	20481-20482	(	_	
105-46	20482-20485	svc	_	
105-47	20485-20486	)	_	
105-48	20486-20487	;	_	
105-49	20488-20489	k	_	
105-50	20490-20491	=	_	
105-51	20492-20494	18	_	
105-52	20494-20495	;	_	
105-53	20496-20499	Fig	_	
105-54	20499-20500	.	_	
105-55	20500-20501	 	_	
105-56	20501-20503	2a	_	
105-57	20503-20504	)	_	
105-58	20505-20513	compared	_	
105-59	20514-20516	to	_	
105-60	20517-20522	group	_	
105-61	20523-20525	II	_	
105-62	20525-20526	.	_	

#Text=Reduced activity and connectivity of left amygdala in group I (patients treated with clozapine or olanzapine) in comparison to group II (patients treated with aripiprazole or amisulpride). a Reduced activity of left amygdala for the contrast faces > geometrical figures. b Reduced connectivity of left amygdala to right ventral striatum.
106-1	20527-20534	Reduced	_	
106-2	20535-20543	activity	_	
106-3	20544-20547	and	_	
106-4	20548-20560	connectivity	_	
106-5	20561-20563	of	_	
106-6	20564-20568	left	_	
106-7	20569-20577	amygdala	_	
106-8	20578-20580	in	_	
106-9	20581-20586	group	_	
106-10	20587-20588	I	_	
106-11	20589-20590	(	_	
106-12	20590-20598	patients	_	
106-13	20599-20606	treated	_	
106-14	20607-20611	with	_	
106-15	20612-20621	clozapine	_	
106-16	20622-20624	or	_	
106-17	20625-20635	olanzapine	_	
106-18	20635-20636	)	_	
106-19	20637-20639	in	_	
106-20	20640-20650	comparison	_	
106-21	20651-20653	to	_	
106-22	20654-20659	group	_	
106-23	20660-20662	II	_	
106-24	20663-20664	(	_	
106-25	20664-20672	patients	_	
106-26	20673-20680	treated	_	
106-27	20681-20685	with	_	
106-28	20686-20698	aripiprazole	_	
106-29	20699-20701	or	_	
106-30	20702-20713	amisulpride	_	
106-31	20713-20714	)	_	
106-32	20714-20715	.	_	
106-33	20716-20717	a	_	
106-34	20718-20725	Reduced	_	
106-35	20726-20734	activity	_	
106-36	20735-20737	of	_	
106-37	20738-20742	left	_	
106-38	20743-20751	amygdala	_	
106-39	20752-20755	for	_	
106-40	20756-20759	the	_	
106-41	20760-20768	contrast	_	
106-42	20769-20774	faces	_	
106-43	20775-20776	>	_	
106-44	20777-20788	geometrical	_	
106-45	20789-20796	figures	_	
106-46	20796-20797	.	_	
106-47	20798-20799	b	_	
106-48	20800-20807	Reduced	_	
106-49	20808-20820	connectivity	_	
106-50	20821-20823	of	_	
106-51	20824-20828	left	_	
106-52	20829-20837	amygdala	_	
106-53	20838-20840	to	_	
106-54	20841-20846	right	_	
106-55	20847-20854	ventral	_	
106-56	20855-20863	striatum	_	
106-57	20863-20864	.	_	

#Text=Note, activity and connectivity differences between groups are presented unmasked and are displayed with: p < 0.005, k = 10
#Text=Regarding associations between amygdala activation and OCS, regression analyses were conducted.
107-1	20865-20869	Note	_	
107-2	20869-20870	,	_	
107-3	20871-20879	activity	_	
107-4	20880-20883	and	_	
107-5	20884-20896	connectivity	_	
107-6	20897-20908	differences	_	
107-7	20909-20916	between	_	
107-8	20917-20923	groups	_	
107-9	20924-20927	are	_	
107-10	20928-20937	presented	_	
107-11	20938-20946	unmasked	_	
107-12	20947-20950	and	_	
107-13	20951-20954	are	_	
107-14	20955-20964	displayed	_	
107-15	20965-20969	with	_	
107-16	20969-20970	:	_	
107-17	20971-20972	p	_	
107-18	20973-20974	<	_	
107-19	20975-20980	0.005	_	
107-20	20980-20981	,	_	
107-21	20982-20983	k	_	
107-22	20984-20985	=	_	
107-23	20986-20988	10	_	
107-24	20989-20998	Regarding	_	
107-25	20999-21011	associations	_	
107-26	21012-21019	between	_	
107-27	21020-21028	amygdala	_	
107-28	21029-21039	activation	_	
107-29	21040-21043	and	_	
107-30	21044-21047	OCS	_	
107-31	21047-21048	,	_	
107-32	21049-21059	regression	_	
107-33	21060-21068	analyses	_	
107-34	21069-21073	were	_	
107-35	21074-21083	conducted	_	
107-36	21083-21084	.	_	

#Text=Analyses revealed a significant negative association between obsessive–compulsive severity (YBOCS total score) and bilateral amygdala activation (left coordinates: x = − 18, y = − 7, z = − 17; T = 2.98; p = 0.023 (svc); k = 44; right coordinates: x = 18, y = − 4, z = − 21; T = 2.76; p = 0.035 (svc); k = 42) across groups, as well as within group I (left coordinates: x = − 27, y = − 7, z = − 15; T = 3.35; p = 0.018 (svc); k = 28; right coordinates: x = 24, y = − 7, z = − 15; T = 3.34; p = 0.020 (svc); k = 34).
108-1	21085-21093	Analyses	_	
108-2	21094-21102	revealed	_	
108-3	21103-21104	a	_	
108-4	21105-21116	significant	_	
108-5	21117-21125	negative	_	
108-6	21126-21137	association	_	
108-7	21138-21145	between	_	
108-8	21146-21166	obsessive–compulsive	_	
108-9	21167-21175	severity	_	
108-10	21176-21177	(	_	
108-11	21177-21182	YBOCS	_	
108-12	21183-21188	total	_	
108-13	21189-21194	score	_	
108-14	21194-21195	)	_	
108-15	21196-21199	and	_	
108-16	21200-21209	bilateral	_	
108-17	21210-21218	amygdala	_	
108-18	21219-21229	activation	_	
108-19	21230-21231	(	_	
108-20	21231-21235	left	_	
108-21	21236-21247	coordinates	_	
108-22	21247-21248	:	_	
108-23	21249-21250	x	_	
108-24	21251-21252	=	_	
108-25	21253-21254	−	_	
108-26	21255-21257	18	_	
108-27	21257-21258	,	_	
108-28	21259-21260	y	_	
108-29	21261-21262	=	_	
108-30	21263-21264	−	_	
108-31	21265-21266	7	_	
108-32	21266-21267	,	_	
108-33	21268-21269	z	_	
108-34	21270-21271	=	_	
108-35	21272-21273	−	_	
108-36	21274-21276	17	_	
108-37	21276-21277	;	_	
108-38	21278-21279	T	_	
108-39	21280-21281	=	_	
108-40	21282-21286	2.98	_	
108-41	21286-21287	;	_	
108-42	21288-21289	p	_	
108-43	21290-21291	=	_	
108-44	21292-21297	0.023	_	
108-45	21298-21299	(	_	
108-46	21299-21302	svc	_	
108-47	21302-21303	)	_	
108-48	21303-21304	;	_	
108-49	21305-21306	k	_	
108-50	21307-21308	=	_	
108-51	21309-21311	44	_	
108-52	21311-21312	;	_	
108-53	21313-21318	right	_	
108-54	21319-21330	coordinates	_	
108-55	21330-21331	:	_	
108-56	21332-21333	x	_	
108-57	21334-21335	=	_	
108-58	21336-21338	18	_	
108-59	21338-21339	,	_	
108-60	21340-21341	y	_	
108-61	21342-21343	=	_	
108-62	21344-21345	−	_	
108-63	21346-21347	4	_	
108-64	21347-21348	,	_	
108-65	21349-21350	z	_	
108-66	21351-21352	=	_	
108-67	21353-21354	−	_	
108-68	21355-21357	21	_	
108-69	21357-21358	;	_	
108-70	21359-21360	T	_	
108-71	21361-21362	=	_	
108-72	21363-21367	2.76	_	
108-73	21367-21368	;	_	
108-74	21369-21370	p	_	
108-75	21371-21372	=	_	
108-76	21373-21378	0.035	_	
108-77	21379-21380	(	_	
108-78	21380-21383	svc	_	
108-79	21383-21384	)	_	
108-80	21384-21385	;	_	
108-81	21386-21387	k	_	
108-82	21388-21389	=	_	
108-83	21390-21392	42	_	
108-84	21392-21393	)	_	
108-85	21394-21400	across	_	
108-86	21401-21407	groups	_	
108-87	21407-21408	,	_	
108-88	21409-21411	as	_	
108-89	21412-21416	well	_	
108-90	21417-21419	as	_	
108-91	21420-21426	within	_	
108-92	21427-21432	group	_	
108-93	21433-21434	I	_	
108-94	21435-21436	(	_	
108-95	21436-21440	left	_	
108-96	21441-21452	coordinates	_	
108-97	21452-21453	:	_	
108-98	21454-21455	x	_	
108-99	21456-21457	=	_	
108-100	21458-21459	−	_	
108-101	21460-21462	27	_	
108-102	21462-21463	,	_	
108-103	21464-21465	y	_	
108-104	21466-21467	=	_	
108-105	21468-21469	−	_	
108-106	21470-21471	7	_	
108-107	21471-21472	,	_	
108-108	21473-21474	z	_	
108-109	21475-21476	=	_	
108-110	21477-21478	−	_	
108-111	21479-21481	15	_	
108-112	21481-21482	;	_	
108-113	21483-21484	T	_	
108-114	21485-21486	=	_	
108-115	21487-21491	3.35	_	
108-116	21491-21492	;	_	
108-117	21493-21494	p	_	
108-118	21495-21496	=	_	
108-119	21497-21502	0.018	_	
108-120	21503-21504	(	_	
108-121	21504-21507	svc	_	
108-122	21507-21508	)	_	
108-123	21508-21509	;	_	
108-124	21510-21511	k	_	
108-125	21512-21513	=	_	
108-126	21514-21516	28	_	
108-127	21516-21517	;	_	
108-128	21518-21523	right	_	
108-129	21524-21535	coordinates	_	
108-130	21535-21536	:	_	
108-131	21537-21538	x	_	
108-132	21539-21540	=	_	
108-133	21541-21543	24	_	
108-134	21543-21544	,	_	
108-135	21545-21546	y	_	
108-136	21547-21548	=	_	
108-137	21549-21550	−	_	
108-138	21551-21552	7	_	
108-139	21552-21553	,	_	
108-140	21554-21555	z	_	
108-141	21556-21557	=	_	
108-142	21558-21559	−	_	
108-143	21560-21562	15	_	
108-144	21562-21563	;	_	
108-145	21564-21565	T	_	
108-146	21566-21567	=	_	
108-147	21568-21572	3.34	_	
108-148	21572-21573	;	_	
108-149	21574-21575	p	_	
108-150	21576-21577	=	_	
108-151	21578-21583	0.020	_	
108-152	21584-21585	(	_	
108-153	21585-21588	svc	_	
108-154	21588-21589	)	_	
108-155	21589-21590	;	_	
108-156	21591-21592	k	_	
108-157	21593-21594	=	_	
108-158	21595-21597	34	_	
108-159	21597-21598	)	_	
108-160	21598-21599	.	_	

#Text=Group comparison connectivity
#Text=Whole brain group comparisons at the given significance threshold (p < 0.05 FWE corrected, k = 10) revealed no significant group differences.
109-1	21600-21605	Group	_	
109-2	21606-21616	comparison	_	
109-3	21617-21629	connectivity	_	
109-4	21630-21635	Whole	_	
109-5	21636-21641	brain	_	
109-6	21642-21647	group	_	
109-7	21648-21659	comparisons	_	
109-8	21660-21662	at	_	
109-9	21663-21666	the	_	
109-10	21667-21672	given	_	
109-11	21673-21685	significance	_	
109-12	21686-21695	threshold	_	
109-13	21696-21697	(	_	
109-14	21697-21698	p	_	
109-15	21699-21700	<	_	
109-16	21701-21705	0.05	_	
109-17	21706-21709	FWE	_	
109-18	21710-21719	corrected	_	
109-19	21719-21720	,	_	
109-20	21721-21722	k	_	
109-21	21723-21724	=	_	
109-22	21725-21727	10	_	
109-23	21727-21728	)	_	
109-24	21729-21737	revealed	_	
109-25	21738-21740	no	_	
109-26	21741-21752	significant	_	
109-27	21753-21758	group	_	
109-28	21759-21770	differences	_	
109-29	21770-21771	.	_	

#Text=When applying ROI analysis, decreased connectivity from left amygdala to right ventral striatum (x = 15, y = 11, z = − 12; T = 3.38, p = 0.006 (svc); k = 25) in group I compared to group II became apparent (Fig. 2b).
110-1	21772-21776	When	_	
110-2	21777-21785	applying	_	
110-3	21786-21789	ROI	_	
110-4	21790-21798	analysis	_	
110-5	21798-21799	,	_	
110-6	21800-21809	decreased	_	
110-7	21810-21822	connectivity	_	
110-8	21823-21827	from	_	
110-9	21828-21832	left	_	
110-10	21833-21841	amygdala	_	
110-11	21842-21844	to	_	
110-12	21845-21850	right	_	
110-13	21851-21858	ventral	_	
110-14	21859-21867	striatum	_	
110-15	21868-21869	(	_	
110-16	21869-21870	x	_	
110-17	21871-21872	=	_	
110-18	21873-21875	15	_	
110-19	21875-21876	,	_	
110-20	21877-21878	y	_	
110-21	21879-21880	=	_	
110-22	21881-21883	11	_	
110-23	21883-21884	,	_	
110-24	21885-21886	z	_	
110-25	21887-21888	=	_	
110-26	21889-21890	−	_	
110-27	21891-21893	12	_	
110-28	21893-21894	;	_	
110-29	21895-21896	T	_	
110-30	21897-21898	=	_	
110-31	21899-21903	3.38	_	
110-32	21903-21904	,	_	
110-33	21905-21906	p	_	
110-34	21907-21908	=	_	
110-35	21909-21914	0.006	_	
110-36	21915-21916	(	_	
110-37	21916-21919	svc	_	
110-38	21919-21920	)	_	
110-39	21920-21921	;	_	
110-40	21922-21923	k	_	
110-41	21924-21925	=	_	
110-42	21926-21928	25	_	
110-43	21928-21929	)	_	
110-44	21930-21932	in	_	
110-45	21933-21938	group	_	
110-46	21939-21940	I	_	
110-47	21941-21949	compared	_	
110-48	21950-21952	to	_	
110-49	21953-21958	group	_	
110-50	21959-21961	II	_	
110-51	21962-21968	became	_	
110-52	21969-21977	apparent	_	
110-53	21978-21979	(	_	
110-54	21979-21982	Fig	_	
110-55	21982-21983	.	_	
110-56	21983-21984	 	_	
110-57	21984-21986	2b	_	
110-58	21986-21987	)	_	
110-59	21987-21988	.	_	

#Text=Discussion
#Text=Differential SGA effects on brain activation and connectivity
#Text=Analyses of brain activation during the face-matching task revealed attenuated activation in the amygdala in patients treated with clozapine or olanzapine, while no between-group differences were found in task performance on the behavioral level.
111-1	21989-21999	Discussion	_	
111-2	22000-22012	Differential	_	
111-3	22013-22016	SGA	_	
111-4	22017-22024	effects	_	
111-5	22025-22027	on	_	
111-6	22028-22033	brain	_	
111-7	22034-22044	activation	_	
111-8	22045-22048	and	_	
111-9	22049-22061	connectivity	_	
111-10	22062-22070	Analyses	_	
111-11	22071-22073	of	_	
111-12	22074-22079	brain	_	
111-13	22080-22090	activation	_	
111-14	22091-22097	during	_	
111-15	22098-22101	the	_	
111-16	22102-22115	face-matching	_	
111-17	22116-22120	task	_	
111-18	22121-22129	revealed	_	
111-19	22130-22140	attenuated	_	
111-20	22141-22151	activation	_	
111-21	22152-22154	in	_	
111-22	22155-22158	the	_	
111-23	22159-22167	amygdala	_	
111-24	22168-22170	in	_	
111-25	22171-22179	patients	_	
111-26	22180-22187	treated	_	
111-27	22188-22192	with	_	
111-28	22193-22202	clozapine	_	
111-29	22203-22205	or	_	
111-30	22206-22216	olanzapine	_	
111-31	22216-22217	,	_	
111-32	22218-22223	while	_	
111-33	22224-22226	no	_	
111-34	22227-22240	between-group	_	
111-35	22241-22252	differences	_	
111-36	22253-22257	were	_	
111-37	22258-22263	found	_	
111-38	22264-22266	in	_	
111-39	22267-22271	task	_	
111-40	22272-22283	performance	_	
111-41	22284-22286	on	_	
111-42	22287-22290	the	_	
111-43	22291-22301	behavioral	_	
111-44	22302-22307	level	_	
111-45	22307-22308	.	_	

#Text=Furthermore, this group showed decreased connectivity from left amygdala to right ventral striatum.
112-1	22309-22320	Furthermore	_	
112-2	22320-22321	,	_	
112-3	22322-22326	this	_	
112-4	22327-22332	group	_	
112-5	22333-22339	showed	_	
112-6	22340-22349	decreased	_	
112-7	22350-22362	connectivity	_	
112-8	22363-22367	from	_	
112-9	22368-22372	left	_	
112-10	22373-22381	amygdala	_	
112-11	22382-22384	to	_	
112-12	22385-22390	right	_	
112-13	22391-22398	ventral	_	
112-14	22399-22407	striatum	_	
112-15	22407-22408	.	_	

#Text=Reduced amygdala activation was associated with higher severity of OCS in the whole sample and within group I.
113-1	22409-22416	Reduced	_	
113-2	22417-22425	amygdala	_	
113-3	22426-22436	activation	_	
113-4	22437-22440	was	_	
113-5	22441-22451	associated	_	
113-6	22452-22456	with	_	
113-7	22457-22463	higher	_	
113-8	22464-22472	severity	_	
113-9	22473-22475	of	_	
113-10	22476-22479	OCS	_	
113-11	22480-22482	in	_	
113-12	22483-22486	the	_	
113-13	22487-22492	whole	_	
113-14	22493-22499	sample	_	
113-15	22500-22503	and	_	
113-16	22504-22510	within	_	
113-17	22511-22516	group	_	
113-18	22517-22518	I	_	
113-19	22518-22519	.	_	

#Text=So far, the number of studies investigating differential effects of antipsychotic substances on brain regions involved in emotional processing is limited.
114-1	22520-22522	So	_	
114-2	22523-22526	far	_	
114-3	22526-22527	,	_	
114-4	22528-22531	the	_	
114-5	22532-22538	number	_	
114-6	22539-22541	of	_	
114-7	22542-22549	studies	_	
114-8	22550-22563	investigating	_	
114-9	22564-22576	differential	_	
114-10	22577-22584	effects	_	
114-11	22585-22587	of	_	
114-12	22588-22601	antipsychotic	_	
114-13	22602-22612	substances	_	
114-14	22613-22615	on	_	
114-15	22616-22621	brain	_	
114-16	22622-22629	regions	_	
114-17	22630-22638	involved	_	
114-18	22639-22641	in	_	
114-19	22642-22651	emotional	_	
114-20	22652-22662	processing	_	
114-21	22663-22665	is	_	
114-22	22666-22673	limited	_	
114-23	22673-22674	.	_	

#Text=Results from animal studies showed attenuation of amygdala activation under clozapine and differential effects of aripiprazole and olanzapine on 5-HT1A serotonin receptor expression in the limbic system of the rat brain.
115-1	22675-22682	Results	_	
115-2	22683-22687	from	_	
115-3	22688-22694	animal	_	
115-4	22695-22702	studies	_	
115-5	22703-22709	showed	_	
115-6	22710-22721	attenuation	_	
115-7	22722-22724	of	_	
115-8	22725-22733	amygdala	_	
115-9	22734-22744	activation	_	
115-10	22745-22750	under	_	
115-11	22751-22760	clozapine	_	
115-12	22761-22764	and	_	
115-13	22765-22777	differential	_	
115-14	22778-22785	effects	_	
115-15	22786-22788	of	_	
115-16	22789-22801	aripiprazole	_	
115-17	22802-22805	and	_	
115-18	22806-22816	olanzapine	_	
115-19	22817-22819	on	_	
115-20	22820-22821	5	_	
115-21	22821-22822	-	_	
115-22	22822-22826	HT1A	_	
115-23	22827-22836	serotonin	_	
115-24	22837-22845	receptor	_	
115-25	22846-22856	expression	_	
115-26	22857-22859	in	_	
115-27	22860-22863	the	_	
115-28	22864-22870	limbic	_	
115-29	22871-22877	system	_	
115-30	22878-22880	of	_	
115-31	22881-22884	the	_	
115-32	22885-22888	rat	_	
115-33	22889-22894	brain	_	
115-34	22894-22895	.	_	

#Text=In humans, both quetiapine and risperidone have been described to increased BOLD-signal in brain regions involved in emotional processing.
116-1	22896-22898	In	_	
116-2	22899-22905	humans	_	
116-3	22905-22906	,	_	
116-4	22907-22911	both	_	
116-5	22912-22922	quetiapine	_	
116-6	22923-22926	and	_	
116-7	22927-22938	risperidone	_	
116-8	22939-22943	have	_	
116-9	22944-22948	been	_	
116-10	22949-22958	described	_	
116-11	22959-22961	to	_	
116-12	22962-22971	increased	_	
116-13	22972-22983	BOLD-signal	_	
116-14	22984-22986	in	_	
116-15	22987-22992	brain	_	
116-16	22993-23000	regions	_	
116-17	23001-23009	involved	_	
116-18	23010-23012	in	_	
116-19	23013-23022	emotional	_	
116-20	23023-23033	processing	_	
116-21	23033-23034	.	_	

#Text=Our results and these findings support the assumption that the pharmacodynamic fingerprints of SGAs might indeed influence neural activation during emotional processing.
117-1	23035-23038	Our	_	
117-2	23039-23046	results	_	
117-3	23047-23050	and	_	
117-4	23051-23056	these	_	
117-5	23057-23065	findings	_	
117-6	23066-23073	support	_	
117-7	23074-23077	the	_	
117-8	23078-23088	assumption	_	
117-9	23089-23093	that	_	
117-10	23094-23097	the	_	
117-11	23098-23113	pharmacodynamic	_	
117-12	23114-23126	fingerprints	_	
117-13	23127-23129	of	_	
117-14	23130-23134	SGAs	_	
117-15	23135-23140	might	_	
117-16	23141-23147	indeed	_	
117-17	23148-23157	influence	_	
117-18	23158-23164	neural	_	
117-19	23165-23175	activation	_	
117-20	23176-23182	during	_	
117-21	23183-23192	emotional	_	
117-22	23193-23203	processing	_	
117-23	23203-23204	.	_	

#Text=However, no previous study accounted for varying receptor profiles of different SGAs.
118-1	23205-23212	However	_	
118-2	23212-23213	,	_	
118-3	23214-23216	no	_	
118-4	23217-23225	previous	_	
118-5	23226-23231	study	_	
118-6	23232-23241	accounted	_	
118-7	23242-23245	for	_	
118-8	23246-23253	varying	_	
118-9	23254-23262	receptor	_	
118-10	23263-23271	profiles	_	
118-11	23272-23274	of	_	
118-12	23275-23284	different	_	
118-13	23285-23289	SGAs	_	
118-14	23289-23290	.	_	

#Text=Association between amygdala activation and connectivity and OCS
#Text=In general, the cortico–limbic interaction plays an important role in theories of emotional processing in OCD, in particular the activation and connectivity of the amygdala.
119-1	23291-23302	Association	_	
119-2	23303-23310	between	_	
119-3	23311-23319	amygdala	_	
119-4	23320-23330	activation	_	
119-5	23331-23334	and	_	
119-6	23335-23347	connectivity	_	
119-7	23348-23351	and	_	
119-8	23352-23355	OCS	_	
119-9	23356-23358	In	_	
119-10	23359-23366	general	_	
119-11	23366-23367	,	_	
119-12	23368-23371	the	_	
119-13	23372-23386	cortico–limbic	_	
119-14	23387-23398	interaction	_	
119-15	23399-23404	plays	_	
119-16	23405-23407	an	_	
119-17	23408-23417	important	_	
119-18	23418-23422	role	_	
119-19	23423-23425	in	_	
119-20	23426-23434	theories	_	
119-21	23435-23437	of	_	
119-22	23438-23447	emotional	_	
119-23	23448-23458	processing	_	
119-24	23459-23461	in	_	
119-25	23462-23465	OCD	_	
119-26	23465-23466	,	_	
119-27	23467-23469	in	_	
119-28	23470-23480	particular	_	
119-29	23481-23484	the	_	
119-30	23485-23495	activation	_	
119-31	23496-23499	and	_	
119-32	23500-23512	connectivity	_	
119-33	23513-23515	of	_	
119-34	23516-23519	the	_	
119-35	23520-23528	amygdala	_	
119-36	23528-23529	.	_	

#Text=Studies have been inconsistent with regard to hyper- vs hypoactivation of the amygdala in primary OCD patients.
120-1	23530-23537	Studies	_	
120-2	23538-23542	have	_	
120-3	23543-23547	been	_	
120-4	23548-23560	inconsistent	_	
120-5	23561-23565	with	_	
120-6	23566-23572	regard	_	
120-7	23573-23575	to	_	
120-8	23576-23581	hyper	_	
120-9	23581-23582	-	_	
120-10	23583-23585	vs	_	
120-11	23586-23600	hypoactivation	_	
120-12	23601-23603	of	_	
120-13	23604-23607	the	_	
120-14	23608-23616	amygdala	_	
120-15	23617-23619	in	_	
120-16	23620-23627	primary	_	
120-17	23628-23631	OCD	_	
120-18	23632-23640	patients	_	
120-19	23640-23641	.	_	

#Text=Increased amygdala activation and task-dependent functional connectivity have been reported during symptom provocation, response inhibition and emotional face processing.
121-1	23642-23651	Increased	_	
121-2	23652-23660	amygdala	_	
121-3	23661-23671	activation	_	
121-4	23672-23675	and	_	
121-5	23676-23690	task-dependent	_	
121-6	23691-23701	functional	_	
121-7	23702-23714	connectivity	_	
121-8	23715-23719	have	_	
121-9	23720-23724	been	_	
121-10	23725-23733	reported	_	
121-11	23734-23740	during	_	
121-12	23741-23748	symptom	_	
121-13	23749-23760	provocation	_	
121-14	23760-23761	,	_	
121-15	23762-23770	response	_	
121-16	23771-23781	inhibition	_	
121-17	23782-23785	and	_	
121-18	23786-23795	emotional	_	
121-19	23796-23800	face	_	
121-20	23801-23811	processing	_	
121-21	23811-23812	.	_	

#Text=In contrast, other studies reported less amygdala activation to general emotional stimuli or facial expressions in primary OCD.
122-1	23813-23815	In	_	
122-2	23816-23824	contrast	_	
122-3	23824-23825	,	_	
122-4	23826-23831	other	_	
122-5	23832-23839	studies	_	
122-6	23840-23848	reported	_	
122-7	23849-23853	less	_	
122-8	23854-23862	amygdala	_	
122-9	23863-23873	activation	_	
122-10	23874-23876	to	_	
122-11	23877-23884	general	_	
122-12	23885-23894	emotional	_	
122-13	23895-23902	stimuli	_	
122-14	23903-23905	or	_	
122-15	23906-23912	facial	_	
122-16	23913-23924	expressions	_	
122-17	23925-23927	in	_	
122-18	23928-23935	primary	_	
122-19	23936-23939	OCD	_	
122-20	23939-23940	.	_	

#Text=Beyond important experimental differences and perspectives of comparison, some authors explain the heterogeneity of the results with reciprocal functional relationships between the amygdala and the prefrontal cortex.
123-1	23941-23947	Beyond	_	
123-2	23948-23957	important	_	
123-3	23958-23970	experimental	_	
123-4	23971-23982	differences	_	
123-5	23983-23986	and	_	
123-6	23987-23999	perspectives	_	
123-7	24000-24002	of	_	
123-8	24003-24013	comparison	_	
123-9	24013-24014	,	_	
123-10	24015-24019	some	_	
123-11	24020-24027	authors	_	
123-12	24028-24035	explain	_	
123-13	24036-24039	the	_	
123-14	24040-24053	heterogeneity	_	
123-15	24054-24056	of	_	
123-16	24057-24060	the	_	
123-17	24061-24068	results	_	
123-18	24069-24073	with	_	
123-19	24074-24084	reciprocal	_	
123-20	24085-24095	functional	_	
123-21	24096-24109	relationships	_	
123-22	24110-24117	between	_	
123-23	24118-24121	the	_	
123-24	24122-24130	amygdala	_	
123-25	24131-24134	and	_	
123-26	24135-24138	the	_	
123-27	24139-24149	prefrontal	_	
123-28	24150-24156	cortex	_	
123-29	24156-24157	.	_	

#Text=They hypothesized that the commonly reported hyperactivity of the CSTC found in OCD may dampen amygdala activation to disorder-irrelevant stimuli, such as facial expression.
124-1	24158-24162	They	_	
124-2	24163-24175	hypothesized	_	
124-3	24176-24180	that	_	
124-4	24181-24184	the	_	
124-5	24185-24193	commonly	_	
124-6	24194-24202	reported	_	
124-7	24203-24216	hyperactivity	_	
124-8	24217-24219	of	_	
124-9	24220-24223	the	_	
124-10	24224-24228	CSTC	_	
124-11	24229-24234	found	_	
124-12	24235-24237	in	_	
124-13	24238-24241	OCD	_	
124-14	24242-24245	may	_	
124-15	24246-24252	dampen	_	
124-16	24253-24261	amygdala	_	
124-17	24262-24272	activation	_	
124-18	24273-24275	to	_	
124-19	24276-24295	disorder-irrelevant	_	
124-20	24296-24303	stimuli	_	
124-21	24303-24304	,	_	
124-22	24305-24309	such	_	
124-23	24310-24312	as	_	
124-24	24313-24319	facial	_	
124-25	24320-24330	expression	_	
124-26	24330-24331	.	_	

#Text=Reduced connectivity between the limbic system and cortico-striatal circuits has been described in antidepressant-free OCD patients at rest and during reward tasks.
125-1	24332-24339	Reduced	_	
125-2	24340-24352	connectivity	_	
125-3	24353-24360	between	_	
125-4	24361-24364	the	_	
125-5	24365-24371	limbic	_	
125-6	24372-24378	system	_	
125-7	24379-24382	and	_	
125-8	24383-24399	cortico-striatal	_	
125-9	24400-24408	circuits	_	
125-10	24409-24412	has	_	
125-11	24413-24417	been	_	
125-12	24418-24427	described	_	
125-13	24428-24430	in	_	
125-14	24431-24450	antidepressant-free	_	
125-15	24451-24454	OCD	_	
125-16	24455-24463	patients	_	
125-17	24464-24466	at	_	
125-18	24467-24471	rest	_	
125-19	24472-24475	and	_	
125-20	24476-24482	during	_	
125-21	24483-24489	reward	_	
125-22	24490-24495	tasks	_	
125-23	24495-24496	.	_	

#Text=In summary, existing fMRI studies suggest that OCD may be characterized by alterations in amygdala activation and in the interaction between the limbic and cortico-striatal system.
126-1	24497-24499	In	_	
126-2	24500-24507	summary	_	
126-3	24507-24508	,	_	
126-4	24509-24517	existing	_	
126-5	24518-24522	fMRI	_	
126-6	24523-24530	studies	_	
126-7	24531-24538	suggest	_	
126-8	24539-24543	that	_	
126-9	24544-24547	OCD	_	
126-10	24548-24551	may	_	
126-11	24552-24554	be	_	
126-12	24555-24568	characterized	_	
126-13	24569-24571	by	_	
126-14	24572-24583	alterations	_	
126-15	24584-24586	in	_	
126-16	24587-24595	amygdala	_	
126-17	24596-24606	activation	_	
126-18	24607-24610	and	_	
126-19	24611-24613	in	_	
126-20	24614-24617	the	_	
126-21	24618-24629	interaction	_	
126-22	24630-24637	between	_	
126-23	24638-24641	the	_	
126-24	24642-24648	limbic	_	
126-25	24649-24652	and	_	
126-26	24653-24669	cortico-striatal	_	
126-27	24670-24676	system	_	
126-28	24676-24677	.	_	

#Text=Inconsistent results on the direction of these alterations might dependent on the experimental setting and state of the OCD patient.
127-1	24678-24690	Inconsistent	_	
127-2	24691-24698	results	_	
127-3	24699-24701	on	_	
127-4	24702-24705	the	_	
127-5	24706-24715	direction	_	
127-6	24716-24718	of	_	
127-7	24719-24724	these	_	
127-8	24725-24736	alterations	_	
127-9	24737-24742	might	_	
127-10	24743-24752	dependent	_	
127-11	24753-24755	on	_	
127-12	24756-24759	the	_	
127-13	24760-24772	experimental	_	
127-14	24773-24780	setting	_	
127-15	24781-24784	and	_	
127-16	24785-24790	state	_	
127-17	24791-24793	of	_	
127-18	24794-24797	the	_	
127-19	24798-24801	OCD	_	
127-20	24802-24809	patient	_	
127-21	24809-24810	.	_	

#Text=These findings in primary OCD patients together with the negative association between amygdala activation and reported OCS severity in the current sample and specifically within group I suggest that the observed reduced amygdala activation and aberrant connectivity during treatment with mainly antiserotonergic SGAs might represent a neural mechanism involved in the de novo development and maintenance of comorbid OCS in patients with schizophrenia.
128-1	24811-24816	These	_	
128-2	24817-24825	findings	_	
128-3	24826-24828	in	_	
128-4	24829-24836	primary	_	
128-5	24837-24840	OCD	_	
128-6	24841-24849	patients	_	
128-7	24850-24858	together	_	
128-8	24859-24863	with	_	
128-9	24864-24867	the	_	
128-10	24868-24876	negative	_	
128-11	24877-24888	association	_	
128-12	24889-24896	between	_	
128-13	24897-24905	amygdala	_	
128-14	24906-24916	activation	_	
128-15	24917-24920	and	_	
128-16	24921-24929	reported	_	
128-17	24930-24933	OCS	_	
128-18	24934-24942	severity	_	
128-19	24943-24945	in	_	
128-20	24946-24949	the	_	
128-21	24950-24957	current	_	
128-22	24958-24964	sample	_	
128-23	24965-24968	and	_	
128-24	24969-24981	specifically	_	
128-25	24982-24988	within	_	
128-26	24989-24994	group	_	
128-27	24995-24996	I	_	
128-28	24997-25004	suggest	_	
128-29	25005-25009	that	_	
128-30	25010-25013	the	_	
128-31	25014-25022	observed	_	
128-32	25023-25030	reduced	_	
128-33	25031-25039	amygdala	_	
128-34	25040-25050	activation	_	
128-35	25051-25054	and	_	
128-36	25055-25063	aberrant	_	
128-37	25064-25076	connectivity	_	
128-38	25077-25083	during	_	
128-39	25084-25093	treatment	_	
128-40	25094-25098	with	_	
128-41	25099-25105	mainly	_	
128-42	25106-25122	antiserotonergic	_	
128-43	25123-25127	SGAs	_	
128-44	25128-25133	might	_	
128-45	25134-25143	represent	_	
128-46	25144-25145	a	_	
128-47	25146-25152	neural	_	
128-48	25153-25162	mechanism	_	
128-49	25163-25171	involved	_	
128-50	25172-25174	in	_	
128-51	25175-25178	the	_	
128-52	25179-25181	de	_	
128-53	25182-25186	novo	_	
128-54	25187-25198	development	_	
128-55	25199-25202	and	_	
128-56	25203-25214	maintenance	_	
128-57	25215-25217	of	_	
128-58	25218-25226	comorbid	_	
128-59	25227-25230	OCS	_	
128-60	25231-25233	in	_	
128-61	25234-25242	patients	_	
128-62	25243-25247	with	_	
128-63	25248-25261	schizophrenia	_	
128-64	25261-25262	.	_	

#Text=Limitations
#Text=This non-interventional study is confined by limitations due to its cross-sectional design and observational nature.
129-1	25263-25274	Limitations	_	
129-2	25275-25279	This	_	
129-3	25280-25298	non-interventional	_	
129-4	25299-25304	study	_	
129-5	25305-25307	is	_	
129-6	25308-25316	confined	_	
129-7	25317-25319	by	_	
129-8	25320-25331	limitations	_	
129-9	25332-25335	due	_	
129-10	25336-25338	to	_	
129-11	25339-25342	its	_	
129-12	25343-25358	cross-sectional	_	
129-13	25359-25365	design	_	
129-14	25366-25369	and	_	
129-15	25370-25383	observational	_	
129-16	25384-25390	nature	_	
129-17	25390-25391	.	_	

#Text=This impedes any causal assumptions between the type of antipsychotic medication, aberrations in brain functioning and clinical presentation of OCS.
130-1	25392-25396	This	_	
130-2	25397-25404	impedes	_	
130-3	25405-25408	any	_	
130-4	25409-25415	causal	_	
130-5	25416-25427	assumptions	_	
130-6	25428-25435	between	_	
130-7	25436-25439	the	_	
130-8	25440-25444	type	_	
130-9	25445-25447	of	_	
130-10	25448-25461	antipsychotic	_	
130-11	25462-25472	medication	_	
130-12	25472-25473	,	_	
130-13	25474-25485	aberrations	_	
130-14	25486-25488	in	_	
130-15	25489-25494	brain	_	
130-16	25495-25506	functioning	_	
130-17	25507-25510	and	_	
130-18	25511-25519	clinical	_	
130-19	25520-25532	presentation	_	
130-20	25533-25535	of	_	
130-21	25536-25539	OCS	_	
130-22	25539-25540	.	_	

#Text=Longitudinal studies with a randomized and blinded design would be necessary to further elucidate proposed causal interrelations.
131-1	25541-25553	Longitudinal	_	
131-2	25554-25561	studies	_	
131-3	25562-25566	with	_	
131-4	25567-25568	a	_	
131-5	25569-25579	randomized	_	
131-6	25580-25583	and	_	
131-7	25584-25591	blinded	_	
131-8	25592-25598	design	_	
131-9	25599-25604	would	_	
131-10	25605-25607	be	_	
131-11	25608-25617	necessary	_	
131-12	25618-25620	to	_	
131-13	25621-25628	further	_	
131-14	25629-25638	elucidate	_	
131-15	25639-25647	proposed	_	
131-16	25648-25654	causal	_	
131-17	25655-25669	interrelations	_	
131-18	25669-25670	.	_	

#Text=Longitudinal clinical observations of the here described groups showed progressive differences in OCS severity over a 1 year period, supporting the assumption of causal influences.
132-1	25671-25683	Longitudinal	_	
132-2	25684-25692	clinical	_	
132-3	25693-25705	observations	_	
132-4	25706-25708	of	_	
132-5	25709-25712	the	_	
132-6	25713-25717	here	_	
132-7	25718-25727	described	_	
132-8	25728-25734	groups	_	
132-9	25735-25741	showed	_	
132-10	25742-25753	progressive	_	
132-11	25754-25765	differences	_	
132-12	25766-25768	in	_	
132-13	25769-25772	OCS	_	
132-14	25773-25781	severity	_	
132-15	25782-25786	over	_	
132-16	25787-25788	a	_	
132-17	25789-25790	1	_	
132-18	25790-25791	 	_	
132-19	25791-25795	year	_	
132-20	25796-25802	period	_	
132-21	25802-25803	,	_	
132-22	25804-25814	supporting	_	
132-23	25815-25818	the	_	
132-24	25819-25829	assumption	_	
132-25	25830-25832	of	_	
132-26	25833-25839	causal	_	
132-27	25840-25850	influences	_	
132-28	25850-25851	.	_	

#Text=Unfortunately, imaging data were only collected cross-sectionally and sample sizes were relatively small.
133-1	25852-25865	Unfortunately	_	
133-2	25865-25866	,	_	
133-3	25867-25874	imaging	_	
133-4	25875-25879	data	_	
133-5	25880-25884	were	_	
133-6	25885-25889	only	_	
133-7	25890-25899	collected	_	
133-8	25900-25917	cross-sectionally	_	
133-9	25918-25921	and	_	
133-10	25922-25928	sample	_	
133-11	25929-25934	sizes	_	
133-12	25935-25939	were	_	
133-13	25940-25950	relatively	_	
133-14	25951-25956	small	_	
133-15	25956-25957	.	_	

#Text=The stratification of participants into four groups for comparisons of individual substances was therefore not possible due to lack of power.
134-1	25958-25961	The	_	
134-2	25962-25976	stratification	_	
134-3	25977-25979	of	_	
134-4	25980-25992	participants	_	
134-5	25993-25997	into	_	
134-6	25998-26002	four	_	
134-7	26003-26009	groups	_	
134-8	26010-26013	for	_	
134-9	26014-26025	comparisons	_	
134-10	26026-26028	of	_	
134-11	26029-26039	individual	_	
134-12	26040-26050	substances	_	
134-13	26051-26054	was	_	
134-14	26055-26064	therefore	_	
134-15	26065-26068	not	_	
134-16	26069-26077	possible	_	
134-17	26078-26081	due	_	
134-18	26082-26084	to	_	
134-19	26085-26089	lack	_	
134-20	26090-26092	of	_	
134-21	26093-26098	power	_	
134-22	26098-26099	.	_	

#Text=Furthermore, the proposed differential effect of antipsychotic medication is certainly not restricted to alterations within the serotonergic neurotransmission, but reciprocal interactions between serotonergic, dopaminergic and glutamatergic neurotransmission are most likely.
135-1	26100-26111	Furthermore	_	
135-2	26111-26112	,	_	
135-3	26113-26116	the	_	
135-4	26117-26125	proposed	_	
135-5	26126-26138	differential	_	
135-6	26139-26145	effect	_	
135-7	26146-26148	of	_	
135-8	26149-26162	antipsychotic	_	
135-9	26163-26173	medication	_	
135-10	26174-26176	is	_	
135-11	26177-26186	certainly	_	
135-12	26187-26190	not	_	
135-13	26191-26201	restricted	_	
135-14	26202-26204	to	_	
135-15	26205-26216	alterations	_	
135-16	26217-26223	within	_	
135-17	26224-26227	the	_	
135-18	26228-26240	serotonergic	_	
135-19	26241-26258	neurotransmission	_	
135-20	26258-26259	,	_	
135-21	26260-26263	but	_	
135-22	26264-26274	reciprocal	_	
135-23	26275-26287	interactions	_	
135-24	26288-26295	between	_	
135-25	26296-26308	serotonergic	_	
135-26	26308-26309	,	_	
135-27	26310-26322	dopaminergic	_	
135-28	26323-26326	and	_	
135-29	26327-26340	glutamatergic	_	
135-30	26341-26358	neurotransmission	_	
135-31	26359-26362	are	_	
135-32	26363-26367	most	_	
135-33	26368-26374	likely	_	
135-34	26374-26375	.	_	

#Text=Furthermore, groups differed in the duration of treatment.
136-1	26376-26387	Furthermore	_	
136-2	26387-26388	,	_	
136-3	26389-26395	groups	_	
136-4	26396-26404	differed	_	
136-5	26405-26407	in	_	
136-6	26408-26411	the	_	
136-7	26412-26420	duration	_	
136-8	26421-26423	of	_	
136-9	26424-26433	treatment	_	
136-10	26433-26434	.	_	

#Text=We assume that the longer treatment duration of index medication within group I might represent a component of the proposed causative pharmacodynamics property of SGA treatment.
137-1	26435-26437	We	_	
137-2	26438-26444	assume	_	
137-3	26445-26449	that	_	
137-4	26450-26453	the	_	
137-5	26454-26460	longer	_	
137-6	26461-26470	treatment	_	
137-7	26471-26479	duration	_	
137-8	26480-26482	of	_	
137-9	26483-26488	index	_	
137-10	26489-26499	medication	_	
137-11	26500-26506	within	_	
137-12	26507-26512	group	_	
137-13	26513-26514	I	_	
137-14	26515-26520	might	_	
137-15	26521-26530	represent	_	
137-16	26531-26532	a	_	
137-17	26533-26542	component	_	
137-18	26543-26545	of	_	
137-19	26546-26549	the	_	
137-20	26550-26558	proposed	_	
137-21	26559-26568	causative	_	
137-22	26569-26585	pharmacodynamics	_	
137-23	26586-26594	property	_	
137-24	26595-26597	of	_	
137-25	26598-26601	SGA	_	
137-26	26602-26611	treatment	_	
137-27	26611-26612	.	_	

#Text=Previous results suggest that especially clozapine aggravates or induces OCS in a dose- and time-dependent manner.
138-1	26613-26621	Previous	_	
138-2	26622-26629	results	_	
138-3	26630-26637	suggest	_	
138-4	26638-26642	that	_	
138-5	26643-26653	especially	_	
138-6	26654-26663	clozapine	_	
138-7	26664-26674	aggravates	_	
138-8	26675-26677	or	_	
138-9	26678-26685	induces	_	
138-10	26686-26689	OCS	_	
138-11	26690-26692	in	_	
138-12	26693-26694	a	_	
138-13	26695-26699	dose	_	
138-14	26699-26700	-	_	
138-15	26701-26704	and	_	
138-16	26705-26719	time-dependent	_	
138-17	26720-26726	manner	_	
138-18	26726-26727	.	_	

#Text=In contrast, there is no evidence that duration of other antipsychotic treatment is correlated with severity of OCS in schizophrenia.
139-1	26728-26730	In	_	
139-2	26731-26739	contrast	_	
139-3	26739-26740	,	_	
139-4	26741-26746	there	_	
139-5	26747-26749	is	_	
139-6	26750-26752	no	_	
139-7	26753-26761	evidence	_	
139-8	26762-26766	that	_	
139-9	26767-26775	duration	_	
139-10	26776-26778	of	_	
139-11	26779-26784	other	_	
139-12	26785-26798	antipsychotic	_	
139-13	26799-26808	treatment	_	
139-14	26809-26811	is	_	
139-15	26812-26822	correlated	_	
139-16	26823-26827	with	_	
139-17	26828-26836	severity	_	
139-18	26837-26839	of	_	
139-19	26840-26843	OCS	_	
139-20	26844-26846	in	_	
139-21	26847-26860	schizophrenia	_	
139-22	26860-26861	.	_	

#Text=Other relevant variables such as age, gender, estimated IQ, the severity of psychotic symptoms, general psychopathology and level of psychosocial functioning did not differ between groups.
140-1	26862-26867	Other	_	
140-2	26868-26876	relevant	_	
140-3	26877-26886	variables	_	
140-4	26887-26891	such	_	
140-5	26892-26894	as	_	
140-6	26895-26898	age	_	
140-7	26898-26899	,	_	
140-8	26900-26906	gender	_	
140-9	26906-26907	,	_	
140-10	26908-26917	estimated	_	
140-11	26918-26920	IQ	_	
140-12	26920-26921	,	_	
140-13	26922-26925	the	_	
140-14	26926-26934	severity	_	
140-15	26935-26937	of	_	
140-16	26938-26947	psychotic	_	
140-17	26948-26956	symptoms	_	
140-18	26956-26957	,	_	
140-19	26958-26965	general	_	
140-20	26966-26981	psychopathology	_	
140-21	26982-26985	and	_	
140-22	26986-26991	level	_	
140-23	26992-26994	of	_	
140-24	26995-27007	psychosocial	_	
140-25	27008-27019	functioning	_	
140-26	27020-27023	did	_	
140-27	27024-27027	not	_	
140-28	27028-27034	differ	_	
140-29	27035-27042	between	_	
140-30	27043-27049	groups	_	
140-31	27049-27050	.	_	

#Text=In addition, including a healthy control group for comparison would have strengthened the results.
141-1	27051-27053	In	_	
141-2	27054-27062	addition	_	
141-3	27062-27063	,	_	
141-4	27064-27073	including	_	
141-5	27074-27075	a	_	
141-6	27076-27083	healthy	_	
141-7	27084-27091	control	_	
141-8	27092-27097	group	_	
141-9	27098-27101	for	_	
141-10	27102-27112	comparison	_	
141-11	27113-27118	would	_	
141-12	27119-27123	have	_	
141-13	27124-27136	strengthened	_	
141-14	27137-27140	the	_	
141-15	27141-27148	results	_	
141-16	27148-27149	.	_	

#Text=Finally, the updated SPM12 version has several advantages over SPM8 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/), therefore the use of SPM8 for data analyses is a limitation that should be considered when interpreting the results.
142-1	27150-27157	Finally	_	
142-2	27157-27158	,	_	
142-3	27159-27162	the	_	
142-4	27163-27170	updated	_	
142-5	27171-27176	SPM12	_	
142-6	27177-27184	version	_	
142-7	27185-27188	has	_	
142-8	27189-27196	several	_	
142-9	27197-27207	advantages	_	
142-10	27208-27212	over	_	
142-11	27213-27217	SPM8	_	
142-12	27218-27219	(	_	
142-13	27219-27224	https	_	
142-14	27224-27225	:	_	
142-15	27225-27226	/	_	
142-16	27226-27227	/	_	
142-17	27227-27248	www.fil.ion.ucl.ac.uk	_	
142-18	27248-27249	/	_	
142-19	27249-27252	spm	_	
142-20	27252-27253	/	_	
142-21	27253-27261	software	_	
142-22	27261-27262	/	_	
142-23	27262-27267	spm12	_	
142-24	27267-27268	/	_	
142-25	27268-27269	)	_	
142-26	27269-27270	,	_	
142-27	27271-27280	therefore	_	
142-28	27281-27284	the	_	
142-29	27285-27288	use	_	
142-30	27289-27291	of	_	
142-31	27292-27296	SPM8	_	
142-32	27297-27300	for	_	
142-33	27301-27305	data	_	
142-34	27306-27314	analyses	_	
142-35	27315-27317	is	_	
142-36	27318-27319	a	_	
142-37	27320-27330	limitation	_	
142-38	27331-27335	that	_	
142-39	27336-27342	should	_	
142-40	27343-27345	be	_	
142-41	27346-27356	considered	_	
142-42	27357-27361	when	_	
142-43	27362-27374	interpreting	_	
142-44	27375-27378	the	_	
142-45	27379-27386	results	_	
142-46	27386-27387	.	_	

#Text=Conclusion
#Text=Aberrant amygdala activation and interaction between the amygdala and other limbic circuits during emotional processing was associated with the type of antipsychotic treatment and severity of co-occurring OCS in patients with schizophrenia.
143-1	27388-27398	Conclusion	_	
143-2	27399-27407	Aberrant	_	
143-3	27408-27416	amygdala	_	
143-4	27417-27427	activation	_	
143-5	27428-27431	and	_	
143-6	27432-27443	interaction	_	
143-7	27444-27451	between	_	
143-8	27452-27455	the	_	
143-9	27456-27464	amygdala	_	
143-10	27465-27468	and	_	
143-11	27469-27474	other	_	
143-12	27475-27481	limbic	_	
143-13	27482-27490	circuits	_	
143-14	27491-27497	during	_	
143-15	27498-27507	emotional	_	
143-16	27508-27518	processing	_	
143-17	27519-27522	was	_	
143-18	27523-27533	associated	_	
143-19	27534-27538	with	_	
143-20	27539-27542	the	_	
143-21	27543-27547	type	_	
143-22	27548-27550	of	_	
143-23	27551-27564	antipsychotic	_	
143-24	27565-27574	treatment	_	
143-25	27575-27578	and	_	
143-26	27579-27587	severity	_	
143-27	27588-27590	of	_	
143-28	27591-27603	co-occurring	_	
143-29	27604-27607	OCS	_	
143-30	27608-27610	in	_	
143-31	27611-27619	patients	_	
143-32	27620-27624	with	_	
143-33	27625-27638	schizophrenia	_	
143-34	27638-27639	.	_	

#Text=In line with previously reported differences in OFC activation during an inhibitory control task, this finding contributes to a neurobiological theory of SGA-induced or -aggravated OCS.
144-1	27640-27642	In	_	
144-2	27643-27647	line	_	
144-3	27648-27652	with	_	
144-4	27653-27663	previously	_	
144-5	27664-27672	reported	_	
144-6	27673-27684	differences	_	
144-7	27685-27687	in	_	
144-8	27688-27691	OFC	_	
144-9	27692-27702	activation	_	
144-10	27703-27709	during	_	
144-11	27710-27712	an	_	
144-12	27713-27723	inhibitory	_	
144-13	27724-27731	control	_	
144-14	27732-27736	task	_	
144-15	27736-27737	,	_	
144-16	27738-27742	this	_	
144-17	27743-27750	finding	_	
144-18	27751-27762	contributes	_	
144-19	27763-27765	to	_	
144-20	27766-27767	a	_	
144-21	27768-27783	neurobiological	_	
144-22	27784-27790	theory	_	
144-23	27791-27793	of	_	
144-24	27794-27805	SGA-induced	_	
144-25	27806-27808	or	_	
144-26	27809-27810	-	_	
144-27	27810-27820	aggravated	_	
144-28	27821-27824	OCS	_	
144-29	27824-27825	.	_	

#Text=Further studies are needed to investigate the proposed pathogenic pathways and might help to identify risk constellations and early detection of second-onset OCS and hopefully contribute to improved treatment options.
145-1	27826-27833	Further	_	
145-2	27834-27841	studies	_	
145-3	27842-27845	are	_	
145-4	27846-27852	needed	_	
145-5	27853-27855	to	_	
145-6	27856-27867	investigate	_	
145-7	27868-27871	the	_	
145-8	27872-27880	proposed	_	
145-9	27881-27891	pathogenic	_	
145-10	27892-27900	pathways	_	
145-11	27901-27904	and	_	
145-12	27905-27910	might	_	
145-13	27911-27915	help	_	
145-14	27916-27918	to	_	
145-15	27919-27927	identify	_	
145-16	27928-27932	risk	_	
145-17	27933-27947	constellations	_	
145-18	27948-27951	and	_	
145-19	27952-27957	early	_	
145-20	27958-27967	detection	_	
145-21	27968-27970	of	_	
145-22	27971-27983	second-onset	_	
145-23	27984-27987	OCS	_	
145-24	27988-27991	and	_	
145-25	27992-28001	hopefully	_	
145-26	28002-28012	contribute	_	
145-27	28013-28015	to	_	
145-28	28016-28024	improved	_	
145-29	28025-28034	treatment	_	
145-30	28035-28042	options	_	
145-31	28042-28043	.	_	

#Text=Daniela Mier and Frederike Schirmbeck contributed equally as first authors.
146-1	28044-28051	Daniela	_	
146-2	28052-28056	Mier	_	
146-3	28057-28060	and	_	
146-4	28061-28070	Frederike	_	
146-5	28071-28081	Schirmbeck	_	
146-6	28082-28093	contributed	_	
146-7	28094-28101	equally	_	
146-8	28102-28104	as	_	
146-9	28105-28110	first	_	
146-10	28111-28118	authors	_	
146-11	28118-28119	.	_	

#Text=Compliance with ethical standards
#Text=Ethical standards
#Text=Al participants provided written informed consent prior to their inclusion in the study.
147-1	28120-28130	Compliance	_	
147-2	28131-28135	with	_	
147-3	28136-28143	ethical	_	
147-4	28144-28153	standards	_	
147-5	28154-28161	Ethical	_	
147-6	28162-28171	standards	_	
147-7	28172-28174	Al	_	
147-8	28175-28187	participants	_	
147-9	28188-28196	provided	_	
147-10	28197-28204	written	_	
147-11	28205-28213	informed	_	
147-12	28214-28221	consent	_	
147-13	28222-28227	prior	_	
147-14	28228-28230	to	_	
147-15	28231-28236	their	_	
147-16	28237-28246	inclusion	_	
147-17	28247-28249	in	_	
147-18	28250-28253	the	_	
147-19	28254-28259	study	_	
147-20	28259-28260	.	_	

#Text=The study was approved by the accredited Medical Ethics Review Committee (METC) and has therefore been performed in accordance with the ethical standards laid down in the Declaration of Helsinki.
148-1	28261-28264	The	_	
148-2	28265-28270	study	_	
148-3	28271-28274	was	_	
148-4	28275-28283	approved	_	
148-5	28284-28286	by	_	
148-6	28287-28290	the	_	
148-7	28291-28301	accredited	_	
148-8	28302-28309	Medical	_	
148-9	28310-28316	Ethics	_	
148-10	28317-28323	Review	_	
148-11	28324-28333	Committee	_	
148-12	28334-28335	(	_	
148-13	28335-28339	METC	_	
148-14	28339-28340	)	_	
148-15	28341-28344	and	_	
148-16	28345-28348	has	_	
148-17	28349-28358	therefore	_	
148-18	28359-28363	been	_	
148-19	28364-28373	performed	_	
148-20	28374-28376	in	_	
148-21	28377-28387	accordance	_	
148-22	28388-28392	with	_	
148-23	28393-28396	the	_	
148-24	28397-28404	ethical	_	
148-25	28405-28414	standards	_	
148-26	28415-28419	laid	_	
148-27	28420-28424	down	_	
148-28	28425-28427	in	_	
148-29	28428-28431	the	_	
148-30	28432-28443	Declaration	_	
148-31	28444-28446	of	_	
148-32	28447-28455	Helsinki	_	
148-33	28455-28456	.	_	

#Text=Conflict of interest
#Text=F.
149-1	28457-28465	Conflict	_	
149-2	28466-28468	of	_	
149-3	28469-28477	interest	_	
149-4	28478-28479	F	_	
149-5	28479-28480	.	_	

#Text=Schirmbeck was supported by a PhD fellowship of the Evangelisches Studienwerk and by a fellowship within the Postdoc-Programme of the German Academic Exchange Service (DAAD).
150-1	28481-28491	Schirmbeck	_	
150-2	28492-28495	was	_	
150-3	28496-28505	supported	_	
150-4	28506-28508	by	_	
150-5	28509-28510	a	_	
150-6	28511-28514	PhD	_	
150-7	28515-28525	fellowship	_	
150-8	28526-28528	of	_	
150-9	28529-28532	the	_	
150-10	28533-28546	Evangelisches	_	
150-11	28547-28558	Studienwerk	_	
150-12	28559-28562	and	_	
150-13	28563-28565	by	_	
150-14	28566-28567	a	_	
150-15	28568-28578	fellowship	_	
150-16	28579-28585	within	_	
150-17	28586-28589	the	_	
150-18	28590-28607	Postdoc-Programme	_	
150-19	28608-28610	of	_	
150-20	28611-28614	the	_	
150-21	28615-28621	German	_	
150-22	28622-28630	Academic	_	
150-23	28631-28639	Exchange	_	
150-24	28640-28647	Service	_	
150-25	28648-28649	(	_	
150-26	28649-28653	DAAD	_	
150-27	28653-28654	)	_	
150-28	28654-28655	.	_	

#Text=D.
151-1	28656-28657	D	_	
151-2	28657-28658	.	_	

#Text=Mier was funded by the Olympia-Morata Program.
152-1	28659-28663	Mier	_	
152-2	28664-28667	was	_	
152-3	28668-28674	funded	_	
152-4	28675-28677	by	_	
152-5	28678-28681	the	_	
152-6	28682-28696	Olympia-Morata	_	
152-7	28697-28704	Program	_	
152-8	28704-28705	.	_	

#Text=S.
153-1	28706-28707	S	_	
153-2	28707-28708	.	_	

#Text=Eisenacher was supported by a research grant of the Landesgraduiertenförderung of the Heidelberg University.
154-1	28709-28719	Eisenacher	_	
154-2	28720-28723	was	_	
154-3	28724-28733	supported	_	
154-4	28734-28736	by	_	
154-5	28737-28738	a	_	
154-6	28739-28747	research	_	
154-7	28748-28753	grant	_	
154-8	28754-28756	of	_	
154-9	28757-28760	the	_	
154-10	28761-28787	Landesgraduiertenförderung	_	
154-11	28788-28790	of	_	
154-12	28791-28794	the	_	
154-13	28795-28805	Heidelberg	_	
154-14	28806-28816	University	_	
154-15	28816-28817	.	_	

#Text=S.
155-1	28818-28819	S	_	
155-2	28819-28820	.	_	

#Text=Englisch has received travel expenses and consultant fees from AstraZeneca, Bristol-Myers Squibb GmbH & CoKGaA, Eli-Lilly, Janssen Cilag, Otsuka Pharma, Pfizer Pharma and Servier.
156-1	28821-28829	Englisch	_	
156-2	28830-28833	has	_	
156-3	28834-28842	received	_	
156-4	28843-28849	travel	_	
156-5	28850-28858	expenses	_	
156-6	28859-28862	and	_	
156-7	28863-28873	consultant	_	
156-8	28874-28878	fees	_	
156-9	28879-28883	from	_	
156-10	28884-28895	AstraZeneca	_	
156-11	28895-28896	,	_	
156-12	28897-28910	Bristol-Myers	_	
156-13	28911-28917	Squibb	_	
156-14	28918-28922	GmbH	_	
156-15	28923-28924	&	_	
156-16	28925-28931	CoKGaA	_	
156-17	28931-28932	,	_	
156-18	28933-28942	Eli-Lilly	_	
156-19	28942-28943	,	_	
156-20	28944-28951	Janssen	_	
156-21	28952-28957	Cilag	_	
156-22	28957-28958	,	_	
156-23	28959-28965	Otsuka	_	
156-24	28966-28972	Pharma	_	
156-25	28972-28973	,	_	
156-26	28974-28980	Pfizer	_	
156-27	28981-28987	Pharma	_	
156-28	28988-28991	and	_	
156-29	28992-28999	Servier	_	
156-30	28999-29000	.	_	

#Text=A.
157-1	29001-29002	A	_	
157-2	29002-29003	.	_	

#Text=Meyer-Lindenberg received consultant fees and travel expenses from AstraZeneca, Hoffmann-La Roche and Lundbeck Foundation and speaker’s fees from Pfizer Pharma, Lilly Deutschland, Glaxo SmithKline, Janssen Cilag, Bristol-Myers Squibb, Lundbeck, Servier and AstraZeneca.
158-1	29004-29020	Meyer-Lindenberg	_	
158-2	29021-29029	received	_	
158-3	29030-29040	consultant	_	
158-4	29041-29045	fees	_	
158-5	29046-29049	and	_	
158-6	29050-29056	travel	_	
158-7	29057-29065	expenses	_	
158-8	29066-29070	from	_	
158-9	29071-29082	AstraZeneca	_	
158-10	29082-29083	,	_	
158-11	29084-29095	Hoffmann-La	_	
158-12	29096-29101	Roche	_	
158-13	29102-29105	and	_	
158-14	29106-29114	Lundbeck	_	
158-15	29115-29125	Foundation	_	
158-16	29126-29129	and	_	
158-17	29130-29137	speaker	_	
158-18	29137-29138	’	_	
158-19	29138-29139	s	_	
158-20	29140-29144	fees	_	
158-21	29145-29149	from	_	
158-22	29150-29156	Pfizer	_	
158-23	29157-29163	Pharma	_	
158-24	29163-29164	,	_	
158-25	29165-29170	Lilly	_	
158-26	29171-29182	Deutschland	_	
158-27	29182-29183	,	_	
158-28	29184-29189	Glaxo	_	
158-29	29190-29200	SmithKline	_	
158-30	29200-29201	,	_	
158-31	29202-29209	Janssen	_	
158-32	29210-29215	Cilag	_	
158-33	29215-29216	,	_	
158-34	29217-29230	Bristol-Myers	_	
158-35	29231-29237	Squibb	_	
158-36	29237-29238	,	_	
158-37	29239-29247	Lundbeck	_	
158-38	29247-29248	,	_	
158-39	29249-29256	Servier	_	
158-40	29257-29260	and	_	
158-41	29261-29272	AstraZeneca	_	
158-42	29272-29273	.	_	

#Text=M.
159-1	29274-29275	M	_	
159-2	29275-29276	.	_	

#Text=Zink received unrestricted scientifc grants of the European Research Advisory Board (ERAB), German Research Foundation (DFG), Pfizer Pharma GmbH, Servier and Bristol Myers Squibb Pharmaceuticals; further speaker and travel grants were provided from Astra Zeneca, Lilly, Pfizer Pharma GmbH, Bristol Myers Squibb Pharmaceuticals, Otsuka, Servier, Lundbeck and Janssen Cilag.
160-1	29277-29281	Zink	_	
160-2	29282-29290	received	_	
160-3	29291-29303	unrestricted	_	
160-4	29304-29313	scientifc	_	
160-5	29314-29320	grants	_	
160-6	29321-29323	of	_	
160-7	29324-29327	the	_	
160-8	29328-29336	European	_	
160-9	29337-29345	Research	_	
160-10	29346-29354	Advisory	_	
160-11	29355-29360	Board	_	
160-12	29361-29362	(	_	
160-13	29362-29366	ERAB	_	
160-14	29366-29367	)	_	
160-15	29367-29368	,	_	
160-16	29369-29375	German	_	
160-17	29376-29384	Research	_	
160-18	29385-29395	Foundation	_	
160-19	29396-29397	(	_	
160-20	29397-29400	DFG	_	
160-21	29400-29401	)	_	
160-22	29401-29402	,	_	
160-23	29403-29409	Pfizer	_	
160-24	29410-29416	Pharma	_	
160-25	29417-29421	GmbH	_	
160-26	29421-29422	,	_	
160-27	29423-29430	Servier	_	
160-28	29431-29434	and	_	
160-29	29435-29442	Bristol	_	
160-30	29443-29448	Myers	_	
160-31	29449-29455	Squibb	_	
160-32	29456-29471	Pharmaceuticals	_	
160-33	29471-29472	;	_	
160-34	29473-29480	further	_	
160-35	29481-29488	speaker	_	
160-36	29489-29492	and	_	
160-37	29493-29499	travel	_	
160-38	29500-29506	grants	_	
160-39	29507-29511	were	_	
160-40	29512-29520	provided	_	
160-41	29521-29525	from	_	
160-42	29526-29531	Astra	_	
160-43	29532-29538	Zeneca	_	
160-44	29538-29539	,	_	
160-45	29540-29545	Lilly	_	
160-46	29545-29546	,	_	
160-47	29547-29553	Pfizer	_	
160-48	29554-29560	Pharma	_	
160-49	29561-29565	GmbH	_	
160-50	29565-29566	,	_	
160-51	29567-29574	Bristol	_	
160-52	29575-29580	Myers	_	
160-53	29581-29587	Squibb	_	
160-54	29588-29603	Pharmaceuticals	_	
160-55	29603-29604	,	_	
160-56	29605-29611	Otsuka	_	
160-57	29611-29612	,	_	
160-58	29613-29620	Servier	_	
160-59	29620-29621	,	_	
160-60	29622-29630	Lundbeck	_	
160-61	29631-29634	and	_	
160-62	29635-29642	Janssen	_	
160-63	29643-29648	Cilag	_	
160-64	29648-29649	.	_	

#Text=M.
161-1	29650-29651	M	_	
161-2	29651-29652	.	_	

#Text=Zink, A.
162-1	29653-29657	Zink	_	
162-2	29657-29658	,	_	
162-3	29659-29660	A	_	
162-4	29660-29661	.	_	

#Text=Meyer-Lindenberg and P.
163-1	29662-29678	Meyer-Lindenberg	_	
163-2	29679-29682	and	_	
163-3	29683-29684	P	_	
163-4	29684-29685	.	_	

#Text=Kirsch were funded by the Deutsche Forschungsgesellschaft (DFG, http://www.dfg.de, projects ZI1253/3-1, ZI1253/3-2, KI 576/14-2, ME 1591/6-2).
164-1	29686-29692	Kirsch	_	
164-2	29693-29697	were	_	
164-3	29698-29704	funded	_	
164-4	29705-29707	by	_	
164-5	29708-29711	the	_	
164-6	29712-29720	Deutsche	_	
164-7	29721-29743	Forschungsgesellschaft	_	
164-8	29744-29745	(	_	
164-9	29745-29748	DFG	_	
164-10	29748-29749	,	_	
164-11	29750-29754	http	_	
164-12	29754-29755	:	_	
164-13	29755-29756	/	_	
164-14	29756-29757	/	_	
164-15	29757-29767	www.dfg.de	_	
164-16	29767-29768	,	_	
164-17	29769-29777	projects	_	
164-18	29778-29784	ZI1253	_	
164-19	29784-29785	/	_	
164-20	29785-29786	3	_	
164-21	29786-29787	-	_	
164-22	29787-29788	1	_	
164-23	29788-29789	,	_	
164-24	29790-29796	ZI1253	_	
164-25	29796-29797	/	_	
164-26	29797-29798	3	_	
164-27	29798-29799	-	_	
164-28	29799-29800	2	_	
164-29	29800-29801	,	_	
164-30	29802-29804	KI	_	
164-31	29805-29808	576	_	
164-32	29808-29809	/	_	
164-33	29809-29811	14	_	
164-34	29811-29812	-	_	
164-35	29812-29813	2	_	
164-36	29813-29814	,	_	
164-37	29815-29817	ME	_	
164-38	29818-29822	1591	_	
164-39	29822-29823	/	_	
164-40	29823-29824	6	_	
164-41	29824-29825	-	_	
164-42	29825-29826	2	_	
164-43	29826-29827	)	_	
164-44	29827-29828	.	_	

#Text=The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
165-1	29829-29832	The	_	
165-2	29833-29840	funders	_	
165-3	29841-29844	had	_	
165-4	29845-29847	no	_	
165-5	29848-29852	role	_	
165-6	29853-29855	in	_	
165-7	29856-29861	study	_	
165-8	29862-29868	design	_	
165-9	29868-29869	,	_	
165-10	29870-29874	data	_	
165-11	29875-29885	collection	_	
165-12	29886-29889	and	_	
165-13	29890-29898	analysis	_	
165-14	29898-29899	,	_	
165-15	29900-29908	decision	_	
165-16	29909-29911	to	_	
165-17	29912-29919	publish	_	
165-18	29920-29922	or	_	
165-19	29923-29934	preparation	_	
165-20	29935-29937	of	_	
165-21	29938-29941	the	_	
165-22	29942-29952	manuscript	_	
165-23	29952-29953	.	_	

#Text=References
#Text=How prevalent are anxiety disorders in schizophrenia?
166-1	29954-29964	References	_	
166-2	29965-29968	How	_	
166-3	29969-29978	prevalent	_	
166-4	29979-29982	are	_	
166-5	29983-29990	anxiety	_	
166-6	29991-30000	disorders	_	
166-7	30001-30003	in	_	
166-8	30004-30017	schizophrenia	_	
166-9	30017-30018	?	_	

#Text=A meta-analysis and critical review on a significant association
#Text=The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates
#Text=Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life
#Text=Associations of comorbid obsessive–compulsive symptoms with psychotic and affective symptoms and general functioning
#Text=Suicidality in schizophrenic patients with and without obsessive–compulsive disorder
#Text=Long-term outcome of obsessive–compulsive disorder with psychotic features
#Text=The 5-year course of obsessive–compulsive symptoms and obsessive–compulsive disorder in first-episode schizophrenia and related disorders
#Text=Epidemiology: prevalence and clinical characteristics of obsessive–compulsive disorder and obsessive–compulsive symptoms in patients with psychotic disorders
#Text=Induced Obsessive compulsive symptoms (OCS) in schizophrenia patients under Atypical 2 antipsychotics (AAPs): review and hypotheses
#Text=Effects of antipsychotic treatment on obsessive–compulsive symptoms
#Text=Obsessive–compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders
#Text=Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
#Text=In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
#Text=Amisulpride: from animal pharmacology to therapeutic action [review]
#Text=A systematic review of aripiprazole–dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring
#Text=The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients
#Text=Amisulpride improves obsessive–compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study
#Text=Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
#Text=Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia
#Text=Clozapine-induced obsessive compulsive syndromes improve in combination with aripiprazole
#Text=Neurobiology confirms psychopathology: on the antagonism of psychosis and obsessive–compulsive syndromes
#Text=World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision
#Text=Polypharmacy for obsessive–compulsive symptoms in schizophrenia: augmentation and combination strategies
#Text=Systematic review of the influence of antipsychotics on the blood oxygenation level-dependent signal of functional magnetic resonance imaging
#Text=Antiserotonergic antipsychotics are associated with obsessive–compulsive symptoms in schizophrenia
#Text=Differential effects of antipsychotic agents on obsessive–compulsive symptoms in schizophrenia: a longitudinal study
#Text=Increased orbitofrontal cortex activation associated with “pro-obsessive” antipsychotic treatment in patients with schizophrenia
#Text=Brain imaging in childhood- and adolescence-onset schizophrenia associated with obsessive–compulsive symptoms
#Text=Working memory dysfunction in schizophrenia patients with obsessive–compulsive symptoms: an fMRI study
#Text=Obsessive–compulsive disorder among schizophrenic patients: an exploratory study using functional magnetic resonance imaging data
#Text=Neuroimaging and the neurobiology of obsessive–compulsive disorder
#Text=Toward a neurobiology of obsessive–compulsive disorder
#Text=Aberrant spontaneous and task-dependent functional connections in the anxious brain
#Text=Brain circuitry of compulsivity
#Text=Obsessive–compulsive disorder: beyond segregated cortico-striatal pathways
#Text=Cortico–amygdala–striatal circuits are organized as hierarchical subsystems through the primate amygdala
#Text=A framework for understanding the emerging role of corticolimbic-ventral striatal networks in OCD-associated repetitive behaviors
#Text=Amygdala activation and symptom dimensions in obsessive–compulsive disorder
#Text=Enhanced brain responsiveness during active emotional face processing in obsessive compulsive disorder
#Text=Amygdala activation in response to facial expressions in pediatric obsessive–compulsive disorder
#Text=Amygdala responses to human faces in obsessive–compulsive disorder
#Text=Emotion effects on attention, amygdala activation, and functional connectivity in schizophrenia
#Text=Task-related functional connectivity analysis of emotion discrimination in a family study of schizophrenia
#Text=Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data
#Text=Evidence for altered amygdala activation in schizophrenia in an adaptive emotion recognition task
#Text=Neuronal correlates of affective theory of mind in schizophrenia out-patients: evidence for a baseline deficit
#Text=Understanding the impact of 5-HTTLPR, antidepressants, and acute tryptophan depletion on brain activation during facial emotion processing: a review of the imaging literature
#Text=Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings
#Text=Amisulpride: from animal pharmacology to therapeutic action
#Text=Reliability and validity of the Yale–Brown Obsessive–Compulsive Scale in schizophrenia patients
#Text=Factor structure of the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive–compulsive symptoms
#Text=The Yale–Brown obsessive compulsive scale: I.
167-1	30019-30020	A	_	
167-2	30021-30034	meta-analysis	_	
167-3	30035-30038	and	_	
167-4	30039-30047	critical	_	
167-5	30048-30054	review	_	
167-6	30055-30057	on	_	
167-7	30058-30059	a	_	
167-8	30060-30071	significant	_	
167-9	30072-30083	association	_	
167-10	30084-30087	The	_	
167-11	30088-30097	obsessive	_	
167-12	30098-30108	compulsive	_	
167-13	30109-30117	spectrum	_	
167-14	30118-30120	in	_	
167-15	30121-30134	schizophrenia	_	
167-16	30134-30135	,	_	
167-17	30136-30137	a	_	
167-18	30138-30151	meta-analysis	_	
167-19	30152-30155	and	_	
167-20	30156-30171	meta-regression	_	
167-21	30172-30181	exploring	_	
167-22	30182-30192	prevalence	_	
167-23	30193-30198	rates	_	
167-24	30199-30207	Presence	_	
167-25	30208-30210	of	_	
167-26	30211-30220	obsessive	_	
167-27	30221-30231	compulsive	_	
167-28	30232-30240	symptoms	_	
167-29	30241-30243	in	_	
167-30	30244-30257	first-episode	_	
167-31	30258-30271	schizophrenia	_	
167-32	30272-30274	or	_	
167-33	30275-30282	related	_	
167-34	30283-30292	disorders	_	
167-35	30293-30295	is	_	
167-36	30296-30306	associated	_	
167-37	30307-30311	with	_	
167-38	30312-30322	subjective	_	
167-39	30323-30333	well-being	_	
167-40	30334-30337	and	_	
167-41	30338-30345	quality	_	
167-42	30346-30348	of	_	
167-43	30349-30353	life	_	
167-44	30354-30366	Associations	_	
167-45	30367-30369	of	_	
167-46	30370-30378	comorbid	_	
167-47	30379-30399	obsessive–compulsive	_	
167-48	30400-30408	symptoms	_	
167-49	30409-30413	with	_	
167-50	30414-30423	psychotic	_	
167-51	30424-30427	and	_	
167-52	30428-30437	affective	_	
167-53	30438-30446	symptoms	_	
167-54	30447-30450	and	_	
167-55	30451-30458	general	_	
167-56	30459-30470	functioning	_	
167-57	30471-30482	Suicidality	_	
167-58	30483-30485	in	_	
167-59	30486-30499	schizophrenic	_	
167-60	30500-30508	patients	_	
167-61	30509-30513	with	_	
167-62	30514-30517	and	_	
167-63	30518-30525	without	_	
167-64	30526-30546	obsessive–compulsive	_	
167-65	30547-30555	disorder	_	
167-66	30556-30565	Long-term	_	
167-67	30566-30573	outcome	_	
167-68	30574-30576	of	_	
167-69	30577-30597	obsessive–compulsive	_	
167-70	30598-30606	disorder	_	
167-71	30607-30611	with	_	
167-72	30612-30621	psychotic	_	
167-73	30622-30630	features	_	
167-74	30631-30634	The	_	
167-75	30635-30636	5	_	
167-76	30636-30637	-	_	
167-77	30637-30641	year	_	
167-78	30642-30648	course	_	
167-79	30649-30651	of	_	
167-80	30652-30672	obsessive–compulsive	_	
167-81	30673-30681	symptoms	_	
167-82	30682-30685	and	_	
167-83	30686-30706	obsessive–compulsive	_	
167-84	30707-30715	disorder	_	
167-85	30716-30718	in	_	
167-86	30719-30732	first-episode	_	
167-87	30733-30746	schizophrenia	_	
167-88	30747-30750	and	_	
167-89	30751-30758	related	_	
167-90	30759-30768	disorders	_	
167-91	30769-30781	Epidemiology	_	
167-92	30781-30782	:	_	
167-93	30783-30793	prevalence	_	
167-94	30794-30797	and	_	
167-95	30798-30806	clinical	_	
167-96	30807-30822	characteristics	_	
167-97	30823-30825	of	_	
167-98	30826-30846	obsessive–compulsive	_	
167-99	30847-30855	disorder	_	
167-100	30856-30859	and	_	
167-101	30860-30880	obsessive–compulsive	_	
167-102	30881-30889	symptoms	_	
167-103	30890-30892	in	_	
167-104	30893-30901	patients	_	
167-105	30902-30906	with	_	
167-106	30907-30916	psychotic	_	
167-107	30917-30926	disorders	_	
167-108	30927-30934	Induced	_	
167-109	30935-30944	Obsessive	_	
167-110	30945-30955	compulsive	_	
167-111	30956-30964	symptoms	_	
167-112	30965-30966	(	_	
167-113	30966-30969	OCS	_	
167-114	30969-30970	)	_	
167-115	30971-30973	in	_	
167-116	30974-30987	schizophrenia	_	
167-117	30988-30996	patients	_	
167-118	30997-31002	under	_	
167-119	31003-31011	Atypical	_	
167-120	31012-31013	2	_	
167-121	31014-31028	antipsychotics	_	
167-122	31029-31030	(	_	
167-123	31030-31034	AAPs	_	
167-124	31034-31035	)	_	
167-125	31035-31036	:	_	
167-126	31037-31043	review	_	
167-127	31044-31047	and	_	
167-128	31048-31058	hypotheses	_	
167-129	31059-31066	Effects	_	
167-130	31067-31069	of	_	
167-131	31070-31083	antipsychotic	_	
167-132	31084-31093	treatment	_	
167-133	31094-31096	on	_	
167-134	31097-31117	obsessive–compulsive	_	
167-135	31118-31126	symptoms	_	
167-136	31127-31147	Obsessive–compulsive	_	
167-137	31148-31156	symptoms	_	
167-138	31157-31163	during	_	
167-139	31164-31173	treatment	_	
167-140	31174-31178	with	_	
167-141	31179-31189	olanzapine	_	
167-142	31190-31193	and	_	
167-143	31194-31205	risperidone	_	
167-144	31205-31206	:	_	
167-145	31207-31208	a	_	
167-146	31209-31220	prospective	_	
167-147	31221-31226	study	_	
167-148	31227-31229	of	_	
167-149	31230-31233	113	_	
167-150	31234-31242	patients	_	
167-151	31243-31247	with	_	
167-152	31248-31260	recent-onset	_	
167-153	31261-31274	schizophrenia	_	
167-154	31275-31277	or	_	
167-155	31278-31285	related	_	
167-156	31286-31295	disorders	_	
167-157	31296-31313	Neuropharmacology	_	
167-158	31314-31316	of	_	
167-159	31317-31334	second-generation	_	
167-160	31335-31348	antipsychotic	_	
167-161	31349-31354	drugs	_	
167-162	31354-31355	:	_	
167-163	31356-31357	a	_	
167-164	31358-31366	validity	_	
167-165	31367-31369	of	_	
167-166	31370-31373	the	_	
167-167	31374-31392	serotonin-dopamine	_	
167-168	31393-31403	hypothesis	_	
167-169	31404-31406	In	_	
167-170	31407-31411	vivo	_	
167-171	31412-31419	actions	_	
167-172	31420-31422	of	_	
167-173	31423-31431	atypical	_	
167-174	31432-31445	antipsychotic	_	
167-175	31446-31450	drug	_	
167-176	31451-31453	on	_	
167-177	31454-31466	serotonergic	_	
167-178	31467-31470	and	_	
167-179	31471-31483	dopaminergic	_	
167-180	31484-31491	systems	_	
167-181	31492-31503	Amisulpride	_	
167-182	31503-31504	:	_	
167-183	31505-31509	from	_	
167-184	31510-31516	animal	_	
167-185	31517-31529	pharmacology	_	
167-186	31530-31532	to	_	
167-187	31533-31544	therapeutic	_	
167-188	31545-31551	action	_	
167-189	31552-31553	[	_	
167-190	31553-31559	review	_	
167-191	31559-31560	]	_	
167-192	31561-31562	A	_	
167-193	31563-31573	systematic	_	
167-194	31574-31580	review	_	
167-195	31581-31583	of	_	
167-196	31584-31601	aripiprazole–dose	_	
167-197	31601-31602	,	_	
167-198	31603-31609	plasma	_	
167-199	31610-31623	concentration	_	
167-200	31623-31624	,	_	
167-201	31625-31633	receptor	_	
167-202	31634-31643	occupancy	_	
167-203	31643-31644	,	_	
167-204	31645-31648	and	_	
167-205	31649-31657	response	_	
167-206	31657-31658	:	_	
167-207	31659-31671	implications	_	
167-208	31672-31675	for	_	
167-209	31676-31687	therapeutic	_	
167-210	31688-31692	drug	_	
167-211	31693-31703	monitoring	_	
167-212	31704-31707	The	_	
167-213	31708-31711	use	_	
167-214	31712-31714	of	_	
167-215	31715-31727	aripiprazole	_	
167-216	31728-31730	in	_	
167-217	31731-31751	obsessive–compulsive	_	
167-218	31752-31760	disorder	_	
167-219	31760-31761	:	_	
167-220	31762-31773	preliminary	_	
167-221	31774-31786	observations	_	
167-222	31787-31789	in	_	
167-223	31790-31791	8	_	
167-224	31792-31800	patients	_	
167-225	31801-31812	Amisulpride	_	
167-226	31813-31821	improves	_	
167-227	31822-31842	obsessive–compulsive	_	
167-228	31843-31851	symptoms	_	
167-229	31852-31854	in	_	
167-230	31855-31868	schizophrenia	_	
167-231	31869-31877	patients	_	
167-232	31878-31884	taking	_	
167-233	31885-31893	atypical	_	
167-234	31894-31908	antipsychotics	_	
167-235	31908-31909	:	_	
167-236	31910-31912	an	_	
167-237	31913-31923	open-label	_	
167-238	31924-31930	switch	_	
167-239	31931-31936	study	_	
167-240	31937-31943	Effect	_	
167-241	31944-31946	of	_	
167-242	31947-31959	aripiprazole	_	
167-243	31960-31972	augmentation	_	
167-244	31973-31975	of	_	
167-245	31976-31985	serotonin	_	
167-246	31986-31994	reuptake	_	
167-247	31995-32005	inhibitors	_	
167-248	32006-32008	or	_	
167-249	32009-32021	clomipramine	_	
167-250	32022-32024	in	_	
167-251	32025-32044	treatment-resistant	_	
167-252	32045-32065	obsessive–compulsive	_	
167-253	32066-32074	disorder	_	
167-254	32074-32075	:	_	
167-255	32076-32077	a	_	
167-256	32078-32090	double-blind	_	
167-257	32090-32091	,	_	
167-258	32092-32110	placebo-controlled	_	
167-259	32111-32116	study	_	
167-260	32117-32127	Management	_	
167-261	32128-32130	of	_	
167-262	32131-32148	clozapine-induced	_	
167-263	32149-32158	obsessive	_	
167-264	32159-32169	compulsive	_	
167-265	32170-32178	symptoms	_	
167-266	32179-32181	in	_	
167-267	32182-32183	a	_	
167-268	32184-32187	man	_	
167-269	32188-32192	with	_	
167-270	32193-32206	schizophrenia	_	
167-271	32207-32224	Clozapine-induced	_	
167-272	32225-32234	obsessive	_	
167-273	32235-32245	compulsive	_	
167-274	32246-32255	syndromes	_	
167-275	32256-32263	improve	_	
167-276	32264-32266	in	_	
167-277	32267-32278	combination	_	
167-278	32279-32283	with	_	
167-279	32284-32296	aripiprazole	_	
167-280	32297-32309	Neurobiology	_	
167-281	32310-32318	confirms	_	
167-282	32319-32334	psychopathology	_	
167-283	32334-32335	:	_	
167-284	32336-32338	on	_	
167-285	32339-32342	the	_	
167-286	32343-32353	antagonism	_	
167-287	32354-32356	of	_	
167-288	32357-32366	psychosis	_	
167-289	32367-32370	and	_	
167-290	32371-32391	obsessive–compulsive	_	
167-291	32392-32401	syndromes	_	
167-292	32402-32407	World	_	
167-293	32408-32418	Federation	_	
167-294	32419-32421	of	_	
167-295	32422-32431	Societies	_	
167-296	32432-32434	of	_	
167-297	32435-32445	Biological	_	
167-298	32446-32456	Psychiatry	_	
167-299	32457-32458	(	_	
167-300	32458-32463	WFSBP	_	
167-301	32463-32464	)	_	
167-302	32465-32475	guidelines	_	
167-303	32476-32479	for	_	
167-304	32480-32483	the	_	
167-305	32484-32499	pharmacological	_	
167-306	32500-32509	treatment	_	
167-307	32510-32512	of	_	
167-308	32513-32520	anxiety	_	
167-309	32520-32521	,	_	
167-310	32522-32542	obsessive–compulsive	_	
167-311	32543-32546	and	_	
167-312	32547-32561	post-traumatic	_	
167-313	32562-32568	stress	_	
167-314	32569-32584	disorders—first	_	
167-315	32585-32593	revision	_	
167-316	32594-32606	Polypharmacy	_	
167-317	32607-32610	for	_	
167-318	32611-32631	obsessive–compulsive	_	
167-319	32632-32640	symptoms	_	
167-320	32641-32643	in	_	
167-321	32644-32657	schizophrenia	_	
167-322	32657-32658	:	_	
167-323	32659-32671	augmentation	_	
167-324	32672-32675	and	_	
167-325	32676-32687	combination	_	
167-326	32688-32698	strategies	_	
167-327	32699-32709	Systematic	_	
167-328	32710-32716	review	_	
167-329	32717-32719	of	_	
167-330	32720-32723	the	_	
167-331	32724-32733	influence	_	
167-332	32734-32736	of	_	
167-333	32737-32751	antipsychotics	_	
167-334	32752-32754	on	_	
167-335	32755-32758	the	_	
167-336	32759-32764	blood	_	
167-337	32765-32776	oxygenation	_	
167-338	32777-32792	level-dependent	_	
167-339	32793-32799	signal	_	
167-340	32800-32802	of	_	
167-341	32803-32813	functional	_	
167-342	32814-32822	magnetic	_	
167-343	32823-32832	resonance	_	
167-344	32833-32840	imaging	_	
167-345	32841-32857	Antiserotonergic	_	
167-346	32858-32872	antipsychotics	_	
167-347	32873-32876	are	_	
167-348	32877-32887	associated	_	
167-349	32888-32892	with	_	
167-350	32893-32913	obsessive–compulsive	_	
167-351	32914-32922	symptoms	_	
167-352	32923-32925	in	_	
167-353	32926-32939	schizophrenia	_	
167-354	32940-32952	Differential	_	
167-355	32953-32960	effects	_	
167-356	32961-32963	of	_	
167-357	32964-32977	antipsychotic	_	
167-358	32978-32984	agents	_	
167-359	32985-32987	on	_	
167-360	32988-33008	obsessive–compulsive	_	
167-361	33009-33017	symptoms	_	
167-362	33018-33020	in	_	
167-363	33021-33034	schizophrenia	_	
167-364	33034-33035	:	_	
167-365	33036-33037	a	_	
167-366	33038-33050	longitudinal	_	
167-367	33051-33056	study	_	
167-368	33057-33066	Increased	_	
167-369	33067-33080	orbitofrontal	_	
167-370	33081-33087	cortex	_	
167-371	33088-33098	activation	_	
167-372	33099-33109	associated	_	
167-373	33110-33114	with	_	
167-374	33115-33116	“	_	
167-375	33116-33129	pro-obsessive	_	
167-376	33129-33130	”	_	
167-377	33131-33144	antipsychotic	_	
167-378	33145-33154	treatment	_	
167-379	33155-33157	in	_	
167-380	33158-33166	patients	_	
167-381	33167-33171	with	_	
167-382	33172-33185	schizophrenia	_	
167-383	33186-33191	Brain	_	
167-384	33192-33199	imaging	_	
167-385	33200-33202	in	_	
167-386	33203-33212	childhood	_	
167-387	33212-33213	-	_	
167-388	33214-33217	and	_	
167-389	33218-33235	adolescence-onset	_	
167-390	33236-33249	schizophrenia	_	
167-391	33250-33260	associated	_	
167-392	33261-33265	with	_	
167-393	33266-33286	obsessive–compulsive	_	
167-394	33287-33295	symptoms	_	
167-395	33296-33303	Working	_	
167-396	33304-33310	memory	_	
167-397	33311-33322	dysfunction	_	
167-398	33323-33325	in	_	
167-399	33326-33339	schizophrenia	_	
167-400	33340-33348	patients	_	
167-401	33349-33353	with	_	
167-402	33354-33374	obsessive–compulsive	_	
167-403	33375-33383	symptoms	_	
167-404	33383-33384	:	_	
167-405	33385-33387	an	_	
167-406	33388-33392	fMRI	_	
167-407	33393-33398	study	_	
167-408	33399-33419	Obsessive–compulsive	_	
167-409	33420-33428	disorder	_	
167-410	33429-33434	among	_	
167-411	33435-33448	schizophrenic	_	
167-412	33449-33457	patients	_	
167-413	33457-33458	:	_	
167-414	33459-33461	an	_	
167-415	33462-33473	exploratory	_	
167-416	33474-33479	study	_	
167-417	33480-33485	using	_	
167-418	33486-33496	functional	_	
167-419	33497-33505	magnetic	_	
167-420	33506-33515	resonance	_	
167-421	33516-33523	imaging	_	
167-422	33524-33528	data	_	
167-423	33529-33541	Neuroimaging	_	
167-424	33542-33545	and	_	
167-425	33546-33549	the	_	
167-426	33550-33562	neurobiology	_	
167-427	33563-33565	of	_	
167-428	33566-33586	obsessive–compulsive	_	
167-429	33587-33595	disorder	_	
167-430	33596-33602	Toward	_	
167-431	33603-33604	a	_	
167-432	33605-33617	neurobiology	_	
167-433	33618-33620	of	_	
167-434	33621-33641	obsessive–compulsive	_	
167-435	33642-33650	disorder	_	
167-436	33651-33659	Aberrant	_	
167-437	33660-33671	spontaneous	_	
167-438	33672-33675	and	_	
167-439	33676-33690	task-dependent	_	
167-440	33691-33701	functional	_	
167-441	33702-33713	connections	_	
167-442	33714-33716	in	_	
167-443	33717-33720	the	_	
167-444	33721-33728	anxious	_	
167-445	33729-33734	brain	_	
167-446	33735-33740	Brain	_	
167-447	33741-33750	circuitry	_	
167-448	33751-33753	of	_	
167-449	33754-33766	compulsivity	_	
167-450	33767-33787	Obsessive–compulsive	_	
167-451	33788-33796	disorder	_	
167-452	33796-33797	:	_	
167-453	33798-33804	beyond	_	
167-454	33805-33815	segregated	_	
167-455	33816-33832	cortico-striatal	_	
167-456	33833-33841	pathways	_	
167-457	33842-33867	Cortico–amygdala–striatal	_	
167-458	33868-33876	circuits	_	
167-459	33877-33880	are	_	
167-460	33881-33890	organized	_	
167-461	33891-33893	as	_	
167-462	33894-33906	hierarchical	_	
167-463	33907-33917	subsystems	_	
167-464	33918-33925	through	_	
167-465	33926-33929	the	_	
167-466	33930-33937	primate	_	
167-467	33938-33946	amygdala	_	
167-468	33947-33948	A	_	
167-469	33949-33958	framework	_	
167-470	33959-33962	for	_	
167-471	33963-33976	understanding	_	
167-472	33977-33980	the	_	
167-473	33981-33989	emerging	_	
167-474	33990-33994	role	_	
167-475	33995-33997	of	_	
167-476	33998-34019	corticolimbic-ventral	_	
167-477	34020-34028	striatal	_	
167-478	34029-34037	networks	_	
167-479	34038-34040	in	_	
167-480	34041-34055	OCD-associated	_	
167-481	34056-34066	repetitive	_	
167-482	34067-34076	behaviors	_	
167-483	34077-34085	Amygdala	_	
167-484	34086-34096	activation	_	
167-485	34097-34100	and	_	
167-486	34101-34108	symptom	_	
167-487	34109-34119	dimensions	_	
167-488	34120-34122	in	_	
167-489	34123-34143	obsessive–compulsive	_	
167-490	34144-34152	disorder	_	
167-491	34153-34161	Enhanced	_	
167-492	34162-34167	brain	_	
167-493	34168-34182	responsiveness	_	
167-494	34183-34189	during	_	
167-495	34190-34196	active	_	
167-496	34197-34206	emotional	_	
167-497	34207-34211	face	_	
167-498	34212-34222	processing	_	
167-499	34223-34225	in	_	
167-500	34226-34235	obsessive	_	
167-501	34236-34246	compulsive	_	
167-502	34247-34255	disorder	_	
167-503	34256-34264	Amygdala	_	
167-504	34265-34275	activation	_	
167-505	34276-34278	in	_	
167-506	34279-34287	response	_	
167-507	34288-34290	to	_	
167-508	34291-34297	facial	_	
167-509	34298-34309	expressions	_	
167-510	34310-34312	in	_	
167-511	34313-34322	pediatric	_	
167-512	34323-34343	obsessive–compulsive	_	
167-513	34344-34352	disorder	_	
167-514	34353-34361	Amygdala	_	
167-515	34362-34371	responses	_	
167-516	34372-34374	to	_	
167-517	34375-34380	human	_	
167-518	34381-34386	faces	_	
167-519	34387-34389	in	_	
167-520	34390-34410	obsessive–compulsive	_	
167-521	34411-34419	disorder	_	
167-522	34420-34427	Emotion	_	
167-523	34428-34435	effects	_	
167-524	34436-34438	on	_	
167-525	34439-34448	attention	_	
167-526	34448-34449	,	_	
167-527	34450-34458	amygdala	_	
167-528	34459-34469	activation	_	
167-529	34469-34470	,	_	
167-530	34471-34474	and	_	
167-531	34475-34485	functional	_	
167-532	34486-34498	connectivity	_	
167-533	34499-34501	in	_	
167-534	34502-34515	schizophrenia	_	
167-535	34516-34528	Task-related	_	
167-536	34529-34539	functional	_	
167-537	34540-34552	connectivity	_	
167-538	34553-34561	analysis	_	
167-539	34562-34564	of	_	
167-540	34565-34572	emotion	_	
167-541	34573-34587	discrimination	_	
167-542	34588-34590	in	_	
167-543	34591-34592	a	_	
167-544	34593-34599	family	_	
167-545	34600-34605	study	_	
167-546	34606-34608	of	_	
167-547	34609-34622	schizophrenia	_	
167-548	34623-34629	Facial	_	
167-549	34630-34637	emotion	_	
167-550	34638-34648	processing	_	
167-551	34649-34651	in	_	
167-552	34652-34665	schizophrenia	_	
167-553	34665-34666	:	_	
167-554	34667-34668	a	_	
167-555	34669-34682	meta-analysis	_	
167-556	34683-34685	of	_	
167-557	34686-34696	functional	_	
167-558	34697-34709	neuroimaging	_	
167-559	34710-34714	data	_	
167-560	34715-34723	Evidence	_	
167-561	34724-34727	for	_	
167-562	34728-34735	altered	_	
167-563	34736-34744	amygdala	_	
167-564	34745-34755	activation	_	
167-565	34756-34758	in	_	
167-566	34759-34772	schizophrenia	_	
167-567	34773-34775	in	_	
167-568	34776-34778	an	_	
167-569	34779-34787	adaptive	_	
167-570	34788-34795	emotion	_	
167-571	34796-34807	recognition	_	
167-572	34808-34812	task	_	
167-573	34813-34821	Neuronal	_	
167-574	34822-34832	correlates	_	
167-575	34833-34835	of	_	
167-576	34836-34845	affective	_	
167-577	34846-34852	theory	_	
167-578	34853-34855	of	_	
167-579	34856-34860	mind	_	
167-580	34861-34863	in	_	
167-581	34864-34877	schizophrenia	_	
167-582	34878-34890	out-patients	_	
167-583	34890-34891	:	_	
167-584	34892-34900	evidence	_	
167-585	34901-34904	for	_	
167-586	34905-34906	a	_	
167-587	34907-34915	baseline	_	
167-588	34916-34923	deficit	_	
167-589	34924-34937	Understanding	_	
167-590	34938-34941	the	_	
167-591	34942-34948	impact	_	
167-592	34949-34951	of	_	
167-593	34952-34953	5	_	
167-594	34953-34954	-	_	
167-595	34954-34960	HTTLPR	_	
167-596	34960-34961	,	_	
167-597	34962-34977	antidepressants	_	
167-598	34977-34978	,	_	
167-599	34979-34982	and	_	
167-600	34983-34988	acute	_	
167-601	34989-34999	tryptophan	_	
167-602	35000-35009	depletion	_	
167-603	35010-35012	on	_	
167-604	35013-35018	brain	_	
167-605	35019-35029	activation	_	
167-606	35030-35036	during	_	
167-607	35037-35043	facial	_	
167-608	35044-35051	emotion	_	
167-609	35052-35062	processing	_	
167-610	35062-35063	:	_	
167-611	35064-35065	a	_	
167-612	35066-35072	review	_	
167-613	35073-35075	of	_	
167-614	35076-35079	the	_	
167-615	35080-35087	imaging	_	
167-616	35088-35098	literature	_	
167-617	35099-35112	Antipsychotic	_	
167-618	35113-35123	medication	_	
167-619	35124-35127	and	_	
167-620	35128-35138	prefrontal	_	
167-621	35139-35145	cortex	_	
167-622	35146-35156	activation	_	
167-623	35156-35157	:	_	
167-624	35158-35159	a	_	
167-625	35160-35166	review	_	
167-626	35167-35169	of	_	
167-627	35170-35182	neuroimaging	_	
167-628	35183-35191	findings	_	
167-629	35192-35203	Amisulpride	_	
167-630	35203-35204	:	_	
167-631	35205-35209	from	_	
167-632	35210-35216	animal	_	
167-633	35217-35229	pharmacology	_	
167-634	35230-35232	to	_	
167-635	35233-35244	therapeutic	_	
167-636	35245-35251	action	_	
167-637	35252-35263	Reliability	_	
167-638	35264-35267	and	_	
167-639	35268-35276	validity	_	
167-640	35277-35279	of	_	
167-641	35280-35283	the	_	
167-642	35284-35294	Yale–Brown	_	
167-643	35295-35315	Obsessive–Compulsive	_	
167-644	35316-35321	Scale	_	
167-645	35322-35324	in	_	
167-646	35325-35338	schizophrenia	_	
167-647	35339-35347	patients	_	
167-648	35348-35354	Factor	_	
167-649	35355-35364	structure	_	
167-650	35365-35367	of	_	
167-651	35368-35371	the	_	
167-652	35372-35382	Yale–Brown	_	
167-653	35383-35403	Obsessive–Compulsive	_	
167-654	35404-35409	Scale	_	
167-655	35410-35411	(	_	
167-656	35411-35417	Y-BOCS	_	
167-657	35417-35418	)	_	
167-658	35419-35421	in	_	
167-659	35422-35423	a	_	
167-660	35424-35429	large	_	
167-661	35430-35436	sample	_	
167-662	35437-35439	of	_	
167-663	35440-35448	patients	_	
167-664	35449-35453	with	_	
167-665	35454-35467	schizophrenia	_	
167-666	35468-35470	or	_	
167-667	35471-35478	related	_	
167-668	35479-35488	disorders	_	
167-669	35489-35492	and	_	
167-670	35493-35501	comorbid	_	
167-671	35502-35522	obsessive–compulsive	_	
167-672	35523-35531	symptoms	_	
167-673	35532-35535	The	_	
167-674	35536-35546	Yale–Brown	_	
167-675	35547-35556	obsessive	_	
167-676	35557-35567	compulsive	_	
167-677	35568-35573	scale	_	
167-678	35573-35574	:	_	
167-679	35575-35576	I	_	
167-680	35576-35577	.	_	

#Text=Development, use, and reliability
#Text=The amygdala response to emotional stimuli: a comparison of faces and scenes
#Text=Dopamine dynamics during emotional cognitive processing: implications of the specific actions of clozapine compared with haloperidol
#Text=The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain
#Text=Amygdala hyperactivation during symptom provocation in obsessive–compulsive disorder and its modulation by distraction
#Text=Functional and structural connectivity of the amygdala in obsessive–compulsive disorder
#Text=Altered inhibition-related frontolimbic connectivity in obsessive–compulsive disorder
#Text=Decreased limbic and increased fronto-parietal connectivity in unmedicated patients with obsessive–compulsive disorder
#Text=Reduced functional connectivity within the limbic cortico-striato-thalamo-cortical loop in unmedicated adults with obsessive–compulsive disorder
#Text=Brain corticostriatal systems and the major clinical symptom dimensions of obsessive–compulsive disorder
#Text=Functional and structural neural indices of risk aversion in obsessive–compulsive disorder (OCD)
#Text=Abnormal corticostriatal-limbic functional connectivity in obsessive–compulsive disorder during reward processing and resting-state
#Text=Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
#Text=Clozapine-induced obsessive–compulsive symptoms in schizophrenia: a critical review
168-1	35578-35589	Development	_	
168-2	35589-35590	,	_	
168-3	35591-35594	use	_	
168-4	35594-35595	,	_	
168-5	35596-35599	and	_	
168-6	35600-35611	reliability	_	
168-7	35612-35615	The	_	
168-8	35616-35624	amygdala	_	
168-9	35625-35633	response	_	
168-10	35634-35636	to	_	
168-11	35637-35646	emotional	_	
168-12	35647-35654	stimuli	_	
168-13	35654-35655	:	_	
168-14	35656-35657	a	_	
168-15	35658-35668	comparison	_	
168-16	35669-35671	of	_	
168-17	35672-35677	faces	_	
168-18	35678-35681	and	_	
168-19	35682-35688	scenes	_	
168-20	35689-35697	Dopamine	_	
168-21	35698-35706	dynamics	_	
168-22	35707-35713	during	_	
168-23	35714-35723	emotional	_	
168-24	35724-35733	cognitive	_	
168-25	35734-35744	processing	_	
168-26	35744-35745	:	_	
168-27	35746-35758	implications	_	
168-28	35759-35761	of	_	
168-29	35762-35765	the	_	
168-30	35766-35774	specific	_	
168-31	35775-35782	actions	_	
168-32	35783-35785	of	_	
168-33	35786-35795	clozapine	_	
168-34	35796-35804	compared	_	
168-35	35805-35809	with	_	
168-36	35810-35821	haloperidol	_	
168-37	35822-35825	The	_	
168-38	35826-35833	effects	_	
168-39	35834-35836	of	_	
168-40	35837-35850	antipsychotic	_	
168-41	35851-35856	drugs	_	
168-42	35857-35871	administration	_	
168-43	35872-35874	on	_	
168-44	35875-35876	5	_	
168-45	35876-35877	-	_	
168-46	35877-35881	HT1A	_	
168-47	35882-35890	receptor	_	
168-48	35891-35901	expression	_	
168-49	35902-35904	in	_	
168-50	35905-35908	the	_	
168-51	35909-35915	limbic	_	
168-52	35916-35922	system	_	
168-53	35923-35925	of	_	
168-54	35926-35929	the	_	
168-55	35930-35933	rat	_	
168-56	35934-35939	brain	_	
168-57	35940-35948	Amygdala	_	
168-58	35949-35964	hyperactivation	_	
168-59	35965-35971	during	_	
168-60	35972-35979	symptom	_	
168-61	35980-35991	provocation	_	
168-62	35992-35994	in	_	
168-63	35995-36015	obsessive–compulsive	_	
168-64	36016-36024	disorder	_	
168-65	36025-36028	and	_	
168-66	36029-36032	its	_	
168-67	36033-36043	modulation	_	
168-68	36044-36046	by	_	
168-69	36047-36058	distraction	_	
168-70	36059-36069	Functional	_	
168-71	36070-36073	and	_	
168-72	36074-36084	structural	_	
168-73	36085-36097	connectivity	_	
168-74	36098-36100	of	_	
168-75	36101-36104	the	_	
168-76	36105-36113	amygdala	_	
168-77	36114-36116	in	_	
168-78	36117-36137	obsessive–compulsive	_	
168-79	36138-36146	disorder	_	
168-80	36147-36154	Altered	_	
168-81	36155-36173	inhibition-related	_	
168-82	36174-36186	frontolimbic	_	
168-83	36187-36199	connectivity	_	
168-84	36200-36202	in	_	
168-85	36203-36223	obsessive–compulsive	_	
168-86	36224-36232	disorder	_	
168-87	36233-36242	Decreased	_	
168-88	36243-36249	limbic	_	
168-89	36250-36253	and	_	
168-90	36254-36263	increased	_	
168-91	36264-36279	fronto-parietal	_	
168-92	36280-36292	connectivity	_	
168-93	36293-36295	in	_	
168-94	36296-36307	unmedicated	_	
168-95	36308-36316	patients	_	
168-96	36317-36321	with	_	
168-97	36322-36342	obsessive–compulsive	_	
168-98	36343-36351	disorder	_	
168-99	36352-36359	Reduced	_	
168-100	36360-36370	functional	_	
168-101	36371-36383	connectivity	_	
168-102	36384-36390	within	_	
168-103	36391-36394	the	_	
168-104	36395-36401	limbic	_	
168-105	36402-36434	cortico-striato-thalamo-cortical	_	
168-106	36435-36439	loop	_	
168-107	36440-36442	in	_	
168-108	36443-36454	unmedicated	_	
168-109	36455-36461	adults	_	
168-110	36462-36466	with	_	
168-111	36467-36487	obsessive–compulsive	_	
168-112	36488-36496	disorder	_	
168-113	36497-36502	Brain	_	
168-114	36503-36518	corticostriatal	_	
168-115	36519-36526	systems	_	
168-116	36527-36530	and	_	
168-117	36531-36534	the	_	
168-118	36535-36540	major	_	
168-119	36541-36549	clinical	_	
168-120	36550-36557	symptom	_	
168-121	36558-36568	dimensions	_	
168-122	36569-36571	of	_	
168-123	36572-36592	obsessive–compulsive	_	
168-124	36593-36601	disorder	_	
168-125	36602-36612	Functional	_	
168-126	36613-36616	and	_	
168-127	36617-36627	structural	_	
168-128	36628-36634	neural	_	
168-129	36635-36642	indices	_	
168-130	36643-36645	of	_	
168-131	36646-36650	risk	_	
168-132	36651-36659	aversion	_	
168-133	36660-36662	in	_	
168-134	36663-36683	obsessive–compulsive	_	
168-135	36684-36692	disorder	_	
168-136	36693-36694	(	_	
168-137	36694-36697	OCD	_	
168-138	36697-36698	)	_	
168-139	36699-36707	Abnormal	_	
168-140	36708-36730	corticostriatal-limbic	_	
168-141	36731-36741	functional	_	
168-142	36742-36754	connectivity	_	
168-143	36755-36757	in	_	
168-144	36758-36778	obsessive–compulsive	_	
168-145	36779-36787	disorder	_	
168-146	36788-36794	during	_	
168-147	36795-36801	reward	_	
168-148	36802-36812	processing	_	
168-149	36813-36816	and	_	
168-150	36817-36830	resting-state	_	
168-151	36831-36840	Glutamate	_	
168-152	36841-36846	drugs	_	
168-153	36847-36850	and	_	
168-154	36851-36867	pharmacogenetics	_	
168-155	36868-36870	of	_	
168-156	36871-36874	OCD	_	
168-157	36874-36875	:	_	
168-158	36876-36877	a	_	
168-159	36878-36891	pathway-based	_	
168-160	36892-36903	exploratory	_	
168-161	36904-36912	approach	_	
168-162	36913-36930	Clozapine-induced	_	
168-163	36931-36951	obsessive–compulsive	_	
168-164	36952-36960	symptoms	_	
168-165	36961-36963	in	_	
168-166	36964-36977	schizophrenia	_	
168-167	36977-36978	:	_	
168-168	36979-36980	a	_	
168-169	36981-36989	critical	_	
168-170	36990-36996	review	_	
